<?xml version="1.0" encoding="utf-8"?><soap:Envelope xmlns:soap="http://www.w3.org/2003/05/soap-envelope" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><soap:Body><EDRN_ProtocolResponse xmlns="http://perdy.fhcrc.org/edrn_ws/ws_newcompass.asmx"><EDRN_ProtocolResult>&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;84&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;84&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;A. SPECIFIC AIMS
   1. To develop and prospectively follow a large cohort at high-risk for lung cancer.   Individuals are recruited to one of two different study groups: The Screening Cohort includes people with and without increased risk for lung cancer. The Rule-Out Lung Cancer Patient Group is recruited from patients referred for evaluation of suspicious nodules.  All individuals answer a questionnaire, obtain PFTs, chest CT scan, sputum induction and phlebotomy.  For patients undergoing lung resections or biopsies, tissue samples are collected and banked.  Individuals are recruited for research bronchoscopy.  All participants are then followed prospectively.   The specimens obtained are banked and used for biomarker discovery and validation studies. 
   2. To identify and validate biomarkers for the early detection of lung cancer, and to describe preneoplastic cellular changes and lesions. Biomarker studies include DNA adducts, DNA methylation, protein markers, and other collaborations.  Preneoplasia studies include: fluorescence and Superdimension bronchoscopies to obtain biopsies of preneoplastic lesions and biomarker studies in individuals with preneoplasias.  
&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;n/a&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2015 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;May  8 2000 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;NYU Lung Cancer Biomarker Center&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;1519 total enrollment&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Screen Detection of Mismatch Repair Deficient Colorectal Neoplasias&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;To maintain and expand our High Risk Registry of carriers of cancer genetic syndromes who are willing to participate in biomarker studies.  &lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174, 153, 155, 183, 157, 154                                                                        &lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Registry&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;EDRN Registry for Hereditary Cancer&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt; The EDRN High Risk Registry (HRR)recruits individuals that carry germline mutations for hereditary cancer syndromes, who are willing to participate in biomarker studies.  Recruitment is pursued through distribution of recruitment packets.  The recruitment packet includes a cover letter, EDRN HRR brochure, consent form, HIPAA authorization, and baseline questionnaire.  Upon completion of enrollment materials, each Registry member is provided a Certificate of Confidentiality, which has been issued by the NCI for the EDRN HRR. The EDRN HRR has a website (http://medicine2.creighton.edu/EDRN-Registry). It provides eligibilty, enrollment educational information for individuals who are at high risk of developing hereditary cancer.  The EDRN HRR newsletter is published twice each year.  These are distributed to EDRN HRR members on an annual basis.

Follow-up questionnaires are sent to Registry participants each year. An EDRN HRR database has been established to store demographic data, personal and family history of cancer diagnoses, personal smoking history, female specific history, as well as cancer prevention, detection and treatment information collected on questionnaires.  All EDRN HRR questionnaires and database use the EDRN CDEs. &lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;67&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;67&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Samples are shared blinded&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;EDRN standard&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;May  1 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;May 30 2014 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep  1 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3, 4, 6, 7&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Preliminary Clinical Characterization of Serum Biomarkers for Colorectal Neoplasms&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;173 Colon Cancers
235 Adenomas
188 Hyperplastic polyps
59 IBD (UC)
487 Normal colon&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;1. Men 35 or older
2. Men w/o prior history of prostate cancer if no increased risk for developing prostate cancer
3. Recommended 50 years of age, if no increased risk for developing prostate cancer
4. Recommended 40 years of age if they are either African-American or have a positive family history of prostate cancer (1st or 2nd degree relative), if increase risk of developing prostate cancer
5. Willing to allow samples to be collected and entered into SABOR Biorepository
6. Able to provide informed consent&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;88&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;88&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;We will expand and enhance our cohort of men at risk for prostate cancer by increasing enrollment of men at greater risk of prostate cancer and at a higher risk of high-grade prostate cancer.
a. We will maintain follow-up and accrual of multi-ethnic, multi-racial cohort of men in the current SABOR cohort for prostate cancer outcomes
b. Maintain collection of wide range of biologic samples for this cohort and perform validation studies as new biomarkers are identified. Biologics gathered on patient visits are serum (at enrollment, annually and cancer dx.), whole blood, buffy coat (enrollment and cancer dx.) and PSA (enrollment, annually, and cancer dx.).
c. Maintain collection of extensive demographic and other risk factor data. Data elements gathered on cohort are date of birth, race, ethnicity, family history of PCA and other cancers, medical history, surgical history, current medications, AUA score, diabetes status, NSAID usage, prostate-related procedures and treatments
d. Additional biologics will be collected for prospective biomarker studies. Examples may include post-DRE urine collections or blood specimens with specific processing requirements.
&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;N/A&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Sep  1 2015 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb 28 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan  1 2000 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;SABOR&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;To determine if there are ways to predict which men will get prostate cancer, if there are ways to predict how a prostate cancer will develop (for example, slow or rapid growth) and why there are differences in prostate cancer among men from different ethnic backgrounds.&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;Multi-ethnic, multi-racial cohort of men approx. 9,000&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;9000 healthy men&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;76&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;76&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Proteomics Biomarker Development Laboratory&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;63, 85&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;85&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Validation of the Mutagen Sensitivity and Chromosomal Hotspot Assays&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;81&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;81, 92&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;81&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Detection of Serum Markers of Breast Cancer by SELDI&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;71&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 68, 71, 74, 85&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;71&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;188                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Early Detection of Urinary Bladder Cancer&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;EPCA-2, GSTPi, PSA, % free PSA, 2proPSA, BPSA, PBOV-1, JM-27, TSG, IL18, Endoglin (CD105), PCAM-1&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;83&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;83&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;1) Collection and archiving of matched serum and urine specimens for biomarker research.  Collected from men who are in the early detection, diagnosis, treatment and monitoring stages for prostate cancer.  All specimens are available for collaborative research through proper EDRN/NCI- Investigator approval processes for EDRN purposes.

2)Participation in prospective EDRN coordinated pre-Validation and validation studies of several biomarkers for prostate cancer.  

3)Explore analyses of novel tumor marker technologies and multi-variable model development.&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Various assay techniques&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All shared data is de-identified.&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Participation in ERNE- 
The overall goal of the EDRN Informatics Project, named the EDRN Resource Network Exchange (ERNE), is to develop network interfaces among databases for the purpose of sharing data of interest amongst EDRN investigators.  Our site was the first to go live across the internet and real time availability to our repository resources has been available for an entire year.  Through a secure network, EDRN investigators, via the DMCC, can query EDRN CDEs on all 4500 specimens collected at our CEVC.&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb 28 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Apr  1 2000 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;1, 3&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Development and Evaluation of a Tumor Marker for Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The primary objective is to work with the EDRN steering committee, the NCI administration, EDRN co-investigators, industrial partners and other biomarker scientists to further facilitate the rapid vertical evaluation and implementation of useful biomarkers into clinical practice.&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;1000 serum samples per year from healthy men&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;89&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;89&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Registry&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Pilot Project Supplement To BEDLAM&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;77&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;77&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174, 162, 172                                                                                       &lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research, Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;CLUE Studies: Evaluating Biomarkers of Carcinogenesis&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;91&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;67, 91&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;91&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;180                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Aug 13 2004 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug 12 1999 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Clinical Validation of Molecular Signatures of Cervical Neoplasia&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;89&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 74, 85, 86, 89&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;89&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Registry&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Protocol for Comparing Promoter Hypermethylation Methods in NSCLC&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;150&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;150&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;150&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;183                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;National Ovarian Cancer Early Detection Program Blood and Genetics&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;73&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;73&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;73&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;New Biomarkers &amp; Dysplastic Respiratory Epithelium&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Registry&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Hereditary Cancer Institute family study specimen bank&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;65&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;65&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;                                                                                                    &lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt; &lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;EDRN Informatics Pilot Project&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;m/z pattern&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 92&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;The specific aims are elaborated in the Validation protocol submitted earlier.&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;SELDI-TOF, MALDI-TOF/TOF, SELDI-QStar&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;There is a blinding protocol in place.&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;The three article that emerged from this study have been well referenced and represent the new standard for validation of high-throughput proteomics data.  The last two mansucripts were published back to back in Clinical Chemistry with three invited editorials to comment on the research.&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;All data is housed with the DMCC.  Pending approval by the PI (Semmes) and DMCC (Ziding) the data is made available to requestors as raw or processed format.&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Jan  1 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Body Fluids as a Source of Diagnostic Biomarkers: Prostate&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Collection of bodu fluids for the purpose of early validation of the SELDI-TOF based assay for detection of PCa.  The fluids were also utilized for determining analytical reproducibility for several MS platforms.&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;1056, 1055, 540, 539, 548, 525, 1053, 524, 708&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Highly reproducible technique.
Unable to detect PCa in the new cohort.&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;750&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 92&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Body Fluids as a Source of Diagnostic Biomarkers: Breast&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 74&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;74&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Dec  1 2002 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Convenience&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Presence of simian virus 40 DNA sequences in human&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;749&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;81&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;81&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct  1 2001 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Expression based markers for breast cancer detection&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;68&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;68&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Breast tissue array&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;89&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;89&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Registry&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Biomarker Dev Lab At Moffitt Supplement&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Other specify&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;90&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;90&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;90&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Detecting Breast Cancer Signatures in Body Fluids&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;74&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;74&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Convenience&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Research Depository of Normal and Neoplastic Human Tissues&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174, 185                                                                                            &lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Oct  1 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Nov  1 1999 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Body Fluids as a Source of Diagnostic Biomarkers&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;1200 prostate cancer cases; 750 benign or other urologic malignancies
50-60 breast cancer cases and 50-60 benign controls per year.&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;71&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;71&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;188                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Molecular Genetics of Urinary Bladder Carcinoma&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;88&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;88&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Identification of protein and genetic biomarkers of prostate cancer&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;MMR protein expression in HNPCC&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Convenience&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Methylation tumor markers in HNPCC&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Ki-ras&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;69, 80&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;157                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Jun  1 2004 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;MLDA in pancreatic cancer&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;1256&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Certain p16 mutation carriers showed mutation elevations in the specific Ki-ras and p53 alleles significantly higher than normal, similar to controls with pancreatitis.  Two individuals from separate families started out with &amp;quot;low risk&amp;quot; readings subsequently converted to &amp;quot;high risk&amp;quot; categorization and remained there in each sequential exam.&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;17 pancreatic juice samples&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;CA125&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;70, 80&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;To bring EDRN participation into the CGN study of early detection of ovarian cancer in high risk women using serum and plasma markers.   This is a project with Stephen Skates, Ph.D. (Massachusetts General Hospital, MGH Biostatistics Center) “Ovarian cancer screening pilot trial in high risk women”.   We will recruit 30 women for this trial.&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;183                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;May 26 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Ovarian Cancer Screening Pilot Trial In High Risk Women&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;This screening study includes women with high quantified risk of having a BRCA1/2 mutation, as well as women with a confirmed BRCA1/2 mutation.  This trial permits initial estimation of the incidence of ovarian cancer by age and menopausal status.  Subjects were screened for a minimum of one year and followed for up to one year.  Estimates of CA-125 values over time would provide the basis for refining the &amp;quot;risk of ovarian cancer algorithm&amp;quot; (ROCA) more accurately to high risk women and provide guidance for clinical interpretation of CA-125 tests in sub-groups (pre/post menopausal status, estrogen replacement therapy Y/N, and prophylactic oophorecomty Y/N).  &lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;2,343 high risk women enrolled, with 6,284 women years of screening and 19,549 CA125s obtained.  There were 628 (10%/yr)referrals to ultrasound (US) with 414 US performed.  38 women underwent study indicated surgeries. 9 OCs were identified during screening, 3 were prevalent (1 early, 2 late stage),and 6 were incident (5/6 = 83% early, 1 late).  3 of the 6 incident cases were found on prophylctic oophorectomy in early stage.  ROCA deteted 2 in early stage of remaining 3 incident cases, and 3 of 3 prevalent cases.  The PPV was 5/38 = 13% (95% CI 4.4%, 28%) and sensitivity was 5/6 = 83%, CI (36%, 99%). There was high compliance with CA125 testing throughout the study, with 84%, 85%, 85%, 82% subjects returning within 1 month of schedule for 4 tests.  CONCLUSION: Frequent CA125 testing using ROCA results in an acceptable PPV and high compliance in a cohort of women at increased risk for OC.  A definitive screening study (&amp;#062; or = 30 incident cases) using ROCA with serial CA125 and possibly additional markers is required to define sensitivity for early stage OC.&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;From Creighton University:
247 serum samples for CA-125 testing
247 serum samples and purple top tubes for biorepository for retrospective evaluation of other promising biomarkers.&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80, 92&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;HNPCC colon cancer-associated SELDI mass spectrometry protein profiles in serum&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;71, 74&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;71&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;188                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Early Molecular Detection of Invasive Bladder Cancer by Urine Examination&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;63, 92&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174, 185                                                                                            &lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research, Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Apr 28 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Establishment of a serum standard for use in high-throughput proteomic&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;79, 90, 92&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Detecting breast cancer protein signatures in body fluid&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80, 90, 92&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Aug 31 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Aug 31 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep  1 2005 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Protein profiling for detection of high risk breast cancer&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;66, 92&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;SELDI and LC-MS/MS discovery and profiling study of hepatocarcinomas&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;65, 92&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;SELDI biomarker discovery and serum protein profiling of lung cancers&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;88, 92&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;188                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;SELDI Profiling of serum and urine (bladder cancer studies)&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;65, 75, 80, 92&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;The samples were analyzed using serum protein profiling approaches but nothing striking was observed.&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Aug 30 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Aug 30 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep  1 2005 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Proteomic Profiling of Serum and Other Body Fluids for the Early Detection of Colon Cancers&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;93&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;93&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;183, 185                                                                                            &lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research, Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Biomarker Development Laboratory&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;91&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;91&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;180                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Identification of New Markers in Normal and Abnormal Pap Smears&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;66&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;66&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;66&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Early detection of liver cancer and hepatitis&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;81, 91&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;91&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;180                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Development of FISH-based assay for early detection of high grade cervical dysplasia&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;66, 67&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;66&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153, 154                                                                                            &lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Detection of cancer DNA markers in urine&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;77&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;77&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Ornithine decarboxylase (ODC) Polymorphism and Breast and Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;90&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;90&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Breast Ductal  Lavage Fluid Specimen Bank&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;88&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;88&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Inflammation as a Potential Marker of Risk ad Progression for Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;77&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;77&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;77&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174, 162, 172                                                                                       &lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research, Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Assessment of Clinical Potential of Digital SNP Analysis&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;85&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;85&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Apr 30 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep 30 1991 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Ecogenetic Study of Lung Cancer&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;70&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;70&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;180, 183                                                                                            &lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;pre-operative plevic mass study&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;FISH
&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;ELIGIBILITY CRITERIA 

3.1.    Inclusion Criteria.
3.1.1.&amp;nbsp;&amp;nbsp;&amp;nbsp;Adults (&amp;#062; 18 years old)
3.1.2.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with active or suspected Barrett’s esophagus including:
a.&amp;nbsp;&amp;nbsp;&amp;nbsp;Intestinal metaplasia without dysplasia, long and short segments
b.&amp;nbsp;&amp;nbsp;&amp;nbsp;Intestinal metaplasia with low-grade dysplasia
c.&amp;nbsp;&amp;nbsp;&amp;nbsp;Intestinal metaplasia with high-grade dysplasia
d.&amp;nbsp;&amp;nbsp;&amp;nbsp;Adenocarcinoma of the esophagus, primary diagnosis.
3.1.3.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients without Barrett’s after esophagoscopy.
3.1.4.&amp;nbsp;&amp;nbsp;&amp;nbsp;Able to physically tolerate removal of 30 – 60 ml of blood
3.1.5.&amp;nbsp;&amp;nbsp;&amp;nbsp;Tolerate extra research related biopsies
3.1.6.&amp;nbsp;&amp;nbsp;&amp;nbsp;Willing to permit extra blood/biopsies at endoscopic procedure 
3.1.7.&amp;nbsp;&amp;nbsp;&amp;nbsp;Ability and willingness to complete questionnaires
3.1.8.&amp;nbsp;&amp;nbsp;&amp;nbsp;Willing to sign informed consent.

3.2    Exclusion Criteria.
3.2.1.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with active gastrointestinal bleeding.
3.2.2.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with serious infections requiring IV antibiotics.
3.2.3.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with coagulopathies or on anticoagulant treatment.
3.2.4.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with known HIV or chronic viral hepatitis.
3.2.5.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients on active chemotherapy or radiation treatment.
3.2.6.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients who have had an esophagectomy.
3.2.7.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with an active malignancy diagnosed or treated within 5 years except for squamous cell carcinoma of the skin, basal cell carcinoma of the skin; Carcinoma in situ, Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery and/or radiation therapy; Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery.
&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;67, 68, 69&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;67&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Establish the feasibility of measuring the biomarkers in a multi-center clinical trial.

1.2&amp;nbsp;&amp;nbsp;&amp;nbsp;Estimate the variance of the biomarkers in cohorts defined by sex, race, age and histologic diagnosis (Barrett&amp;#39;s intestinal metaplasia, Barrett&amp;#39;s intestinal dysplasia [low-grade or high-grade], Adenocarcinoma, and non-Barrett’s controls).

1.3&amp;nbsp;&amp;nbsp;&amp;nbsp;Determine if the distributions of the biomarkers differ significantly among patients with different histologic diagnoses.

&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Blinded to outcome when shared&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;150                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;EDRN standard regarding data and sample sharing.&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Jan 15 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3, 4, 6, 7&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;GLNE 003: Preliminary Validation of Biomarkers Predictive of Barrett’s Esophagus Progression to Dysp&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;Recognizing that novel potential biomarkers are continually being identified and will need to be validated in a rapid, efficient, and scientifically rigorous manner, the NCI has made an enormous commitment to the development of a network that will facilitate biomarker development and validation in multiple organ sites. As part of the National Cancer Institute-funded Early Detection Research Network (EDRN), the Great Lakes-New England Clinical Epidemiological Center (GLNE CEC) proposes a research program that provides the structure for validating and discovering potential surrogate endpoint biomarkers (“biomarkers”). Although examples of such biomarkers are currently in clinical use (i.e. CEA, CA-125), there are limitations to all of them. Our consortium focuses specifically on gastrointestinal neoplasia.  
&amp;nbsp;&amp;nbsp;&amp;nbsp;There are three goals for this phase of the proposed research. 1. Establish the feasibility of measuring the biomarkers in a multi-center clinical trial.   2. Estimate the variance of the biomarkers in cohorts defined by sex, race, age and histologic diagnosis (non-Barrett’s controls, Barrett’s intestinal metaplasia, Barrett’s intestinal dysplasia [low and high-grade] and adenocarcinoma). 3. Determine if the distributions of the biomarkers differ significantly among patients with different histologic diagnoses.
&amp;nbsp;&amp;nbsp;&amp;nbsp;In this protocol, biological samples will consist of serum, plasma, urine, and biopsies from Barrett’s esophagus (metaplasia, low and high-grade dysplasia) patients, from patients with esophageal adenocarcinoma, and from non-Barrett’s controls. Samples will be assayed for villin, p53, Hsp27, cyclooxygenase-2, and Cyclin D1.  Samples will also be used for two biomarker discovery projects, one exploring genetic expression using genomic microarrays and a second using two-dimensional gene arrays to discover and characterize amplified proteins associated with esophageal carcinogenesis.  Fifty subjects will be studied in each stratum with an estimated total &lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;Esophageal Cancer 143
Normal (no barretts on endoscopy) 86
Barrett&amp;#39;s IM 192
Low Grade Barrett&amp;#39;s 68
High Grade Barrett&amp;#39;s 106
&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;D4S243, D21S1245, FGA, D17S695, D16S476, D9S171, IFN-A, D20S48, D17S654, D16S310, THO1, D9SS162, D9S747, MBP and MBPA&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See MSA protocol&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 110, 111, 112, 114, 115, 116, 117, 118, 119, 120, 121, 122, 124, 125, 131, 136, 201, 221, 222, 223, 226, 227, 228, 280, 287, 288, 298, 299, 310&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;121&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;2&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim 1: This study will test the specificity of MSA in two groups of participants without bladder cancer&amp;#9472;both healthy, normal controls as well as participants without bladder cancer who have conditions known to confound the performance of previous urinary tests for bladder cancer.
Aim 2: This study will test the sensitivity of MSA in the presence of clinically evident, pathologically confirmed bladder cancer.
Aim 3: This study will test the sensitivity and specificity of MSA for the detection of bladder cancer among participants undergoing surveillance for bladder cancer.
Aim 4: This study will test the value of MSA to predict subsequent development of bladder cancer among participants with a history of bladder cancer.
&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;The “gold standard” in diagnosis and surveillance of bladder cancer is the macroscopic identification of disease during cystoscopy.  Suspicious lesions are biopsied during cystoscopy, especially in participants with transitional cell carcinoma (TCC).  The ideal test to replace cystoscopy or decrease the frequency of the surveillance cystoscopy in the management of bladder cancer would be technologically driven, highly sensitive, and rapid.
Microsatellites are tandem repeat DNA sequences that are common, highly polymorphic genetic elements within the eukaryotic genome.  Alterations, either expansion or deletions, of microsatellites were used as clonal markers for the detection of human cancer, including bladder cancer (Mao, Lee, Tockman, Erozan, Askin, &amp; Sidransky, 1994).16 In preliminary studies, Mao et al., (1996)7 and Mourah et al., (1998)10 showed that microsatellite markers had high sensitivity and specificity in detecting bladder cancer in the voided urine specimens (Mao, Schoenberg, Scicchitano et al., 1996;7 Mourah, Cussenot, Vimont, et al., 1998).10 Further development of microsatellite testing to improve specificity, speed of testing, and operator efficiency may improve bladder cancer management.
The microsatellite analysis described herein is based on Short Tandem Repeats (STR).  The assay has been derived employing the STR technology.  The STR allele designations and peak heights from the participant control sample (blood) are compared to the allele designations and peak heights from the participant urine sample.  The purpose of the analysis is to identify loss of heterozygosity (LOH) and instability present in the urine sample. 
&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Analysis Labs only have specimen IDs with no relationship to study group&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;188                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Data will be shared after Cangen submits to FDA and receives response from FDA.&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Apr 12 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Oct  1 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct  1 2003 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;MSA&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Goal 1: To determine sensitivity and specificity of microsatellite analysis (MSA) of urine sediment, using a panel of 15 microsatellite markers, in detecting bladder cancer in participants requiring cystoscopy.  This technique will be compared to the diagnostic standard of cystoscopy, as well as to urine cytology.
Goal 2: To determine the temporal performance characteristics of microsatellite analysis of urine sediment.
Goal 3: To determine which of the 15 individual markers or combination of markers that make up the MSA test are most predictive of the presence of bladder cancer.
&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;The primary analysis for phase 1 was completed in 2009.  For the pre-specified panel decision rule in which the panel is assessed to be positive for bladder cancer presence if any of the fifteen individual markers are positive, the sensitivity of the panel was 38% and the specificity was 86% among the healthy controls and 78% among the controls with potentially confounding conditions.  This combination of sensitivity and specificity did not reach the minimum performance characteristics of at least 80% sensitivity and 90% specificity for the panel to be considered sufficient in itself to alter clinical practice.  Additional analyses included examining alternative rules for declaring the panel positive; identifying and dropping a subset of poorly performing markers from the panel; assessing whether the panel’s performance was affected by deviations from the sample collection and processing procedures; re-examination of controls with outlier values (particularly the foreign body controls); testing a two-stage panel incorporating amount of DNA in the urine with the MSA panel; and assessing the sensitivity of the panel as a function of the malignant potential of the underlying disease.  None of those analyses altered the conclusion that the panel, while having information distinguishing individuals with cancer from those without, did not have sufficient performance to act as a sole test for bladder cancer.
Between phases 1 and 2 of the analysis the laboratory methods for declaring a marker positive were changed at the instigation of the Commonwealth Biotechnologies Inc. (CBI) laboratory, based on their experience during the blinded analysis of the samples in the phase 1 analysis.  Their altered criteria for declaring a marker positive addressed issues of variability in the measurement of the degree of loss of heterozygosity that arose when the amount of DNA was low, and resulted in better consistency in marker measurement between the CBI laboratory and the quality control laboratory at the University of Maryland.  The modified definitions, developed blinded to disease status of MSA participants, resulted in more individual markers being declared positive among both those with and without cancer.  With the modified definition, the panel combination rule that maximized the sum of sensitivity and specificity was to declare the panel positive if three or more individual markers were positive.  The modified rule was used in the phase 2 analysis because it provded better consistency in cross-laboratory comparisons, but its performance in the phase 1 analysis did not differ from the original rule.
Laboratory assays of the follow-up samples were completed in 2010 and the phase 2 statistical analysis was completed and presented to the EDRN Steering Committee in March 2011.  To account for non-independence in the data since the same individual could contribute up to nine observations, the primary analysis used generalized estimating equations with a logistic link function and independence working correlation to test the association between the independent variable of the panel’s prediction and &lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;The MSA study tested a panel of 15 microsatellite markers for its sensitivity and specificity for detecting bladder cancer.  The analysis was performed in two phases:
1.   A cross-sectional analysis of 266 individuals with a superficial urothelial bladder cancer, 83 healthy controls, and 93 individuals with potentially confounding conditions (benign prostatic hypertrophy, hematuria, infections in the genitor-urinary system, or the presence of foreign bodies such as urinary stones or stents).
2.   A longitudinal analysis of the 266 individuals after their bladder tumors were excised, during two years of surveillance for tumor recurrence.
&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;300 incident or recurrent superficial bladder cancer cases, 100 healthy controls, 25 BPH controls, 25 foreign body controls, 25 GU infection controls and 25 hematuria controls.&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;protein&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 65, 75, 83, 87, 88, 92, 93, 108, 127&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Specific Aim IA/Phase IA - The EDRN-Prostate-SELDI Investigational Collaboration (EPSIC) will implement a process to synchronize SELDI output at the seven participating institutions using a single source of pooled normal sera (QC).

Specific Aim IB/Phase IB - The EPSIC will synchronize SELDI output at the seven participating institutions using prostate cancer/control samples with verified presence of optimized diagnostic peaks. The reproducibility of QSTAR&amp;#61668; will also be determined using the same samples and compared to that of the PBS-II data.

Specific Aim IC/Phase IC - The EPSIC will implement a seven-center collaboration to synchronize SELDI output using a new and expanded cohort of prostate cancer cases and controls obtained from all sites. The reproducibility of QSTAR&amp;#61668; will also be determined using the same samples and compared to that of the PBS-II data.

&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;The criteria for agreement among labs is based on the agreement in mass location and agreement in protein intensity. Since the true protein mass is unknown at each protein mass measured from the machine (there is always some measurement error, no matter how small it is), the mass location agreement is determined by the agreement of the locations of peaks between each lab and the reference lab (EVMS) and between each lab and other four labs combined. More specifically, after peak identification and alignment are performed by each lab, the coefficient of variation (CV) and intra-class correlation coefficient (ICC) for peak location measures and for peak intensity measures will be calculated for each peak location.  The between-lab variation will be compared to the between-sample variation. &lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;n/a pooled serum&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Data to be shared upon publication.&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Feb  1 2005 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 23 2003 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Dec 23 2002 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;9&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;SELDI -I&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;It is then the goal of this collaborative project – EDRN-Prostate-SELDI Investigational Collaboration (EPSIC) - to use state-of-the-art protein profiling technology to develop and validate such screening methods&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;524&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;The EDRN-Prostate-SELDI Investigational Collaboration (EPSIC) will implement a process to synchronize SELDI output at the seven participating institutions using a single source of pooled normal sera (QC).  The target was to recruit 100 healthy males and 100 healthy females to donate two tubes of blood.  Pregnant women and subjects less than 110 pounds were excluded from the blood collection.  An IRB protocol was submitted two months in advance of the project.  After IRB approval, fliers were generated and posted at many locations (e.g., EVMS, hospitals, doctor’s offices).  The blood was collected on November 6, 2002 from 7:30 am to 2:00 pm. A total of 360 healthy people (154 male and 206 female) donated two tubes of blood each to make quality control (QC) serum&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;proteomics pattern&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 65, 75, 83, 87, 88, 92, 108, 131, 142&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;2&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;The overall goal of Phase II is to develop and evaluate an algorithm for classifying cases and controls using protein profiles produced from SELDI-TOF-MS using serum collected from prostate cancer cases and non-cancer controls.
Objective 1 - Identification of biorepositories
Objective 2 - Generate protein profiles
Objective 3 - Construction of classifiers and development of algorithm.
Objective 4 – Validate the classifier constructed in Objective 3.  If Objective 3, Aim 1, is successfully met&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;The DMCC will apply the boosting decision tree,11 the boosting logistic regression13, and other classification methods to identify a classification algorithm that has minimum Cross-Validation error. The performance of this classifier will be assessed with the following the intended clinical uses in mind: 1)For men with PSA &amp;#062; 4, the population by current practice undergone biopsies with 25% Positive Predicted Value (PPV) for positive biopsies, we could judge that the new test has clinical potential if on this population sensitivity is significantly better than 85% and specificity is significantly better than 50% (null hypothesis corresponding to PPV=36%). This question is answered by comparing the biopsy-negative non-cancer controls with each of two cancer groups (Gleason Score &amp;#060; 7, and 7 or greater), and combined. In order for the Phase II validation study has adequate power (85%), the target observed specificity for this classifier in training sample should be at least 65% at sensitivity fixed at 95% on ROC curve for all prostate cancers (Aim 1: two case groups combined and compared to controls). Aim 2 (Gleason 7 or greater prostate cancers compared to control and low grade prostate cancer groups combined) is considered as secondary because using Gleason Score 7 or greater as the cutoff point for high grade is more for feasibility rather reason (there are not enough prostate cancers with Gleason Score 8 or 9). 2) If the criterion for Aim 1 is satisfied, validation part of Phase II will proceed. If the observed sensitivity and specificity are significantly better than the values specified by null hypotheses but less than the target values, the study group will evaluate whether the observed performance still has potential clinical benefit, and if it does, whether to increase sample size for the validation part of Phase II.&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All samples were blinded at EVMS.&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Data will be shared upon completion of publication&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Feb  1 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep 29 2005 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Apr 19 2004 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;SELDI-2&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;This project –A Comprehensive Program for the Validation of Prostate Cancer Early Detection with Novel Protein Identification Techniques -- is divided into three phases.  The goal of Phase I was to assess the reproducibility and portability of Surface-Enhanced Laser Desorption and Ionization time-of-flight mass spectrometry (SELDI-TOF-MS) using protein profiles generated from serum.  Phase I was recently successfully completed at six institutions using a single source of pooled sera.   &lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;1056&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;A number of challenges arose during the validation study. One was the time required to collect the needed samples. Although at the study onset, it was anticipated that 6 months would be required for samples collection, due to (a) dissimilar rates of each sample type (e.g., cancer, biopsy negative control, inflammation, etc.), (b) sample-matching challenges, (c) requirements for adequate numbers of high-grade and lower grade tumors, and (d) the rigorous requirements for a range of samples across PSA levels, the sample acquisition ultimately required two years. Another challenge was a broken source on the SELDI-TOF-MS at UAB. This occurred concomitant with the destruction and shearing of the fan that spread metal fragments through the system, leading to unstable spectral patterns, it required several months to identify that the SELDI-TOF-MS source was the cause of the instability. Ultimately, daily QC procedures using a reference pooled serum sample allowed the team to recognize these issues and correct them prior to the initiation of the analysis stage. The final challenge occurring during the analysis of samples was a defective peptide calibration standard used for the first week of the study at EVMS. This calibration sample was derived from a defective manufacturer lot such that only 5 of the 7 peaks could be identified. This suboptimal standard was used for about 1/3 of the samples run at EVMS. Subsequently, this lack of uniform 7 peak standard data was solved by extrapolation of data across the study and was unnecessary when the wavelet analytical approach was employed.&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;500 prostate cancer cases (250 with aggressive/advanced disease and 250 with intermediate- or low-risk disease) as well as 250 prostate cancer controls (biopsy-negative with a range of PSA values).  An additional group of 50 patients with other cancers but no evidence of prostate cancer and 50 patients with various inflammatory diseases will also be examined.&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;des-gamma carboxyprothrombin (DCP), alpha-fetoprotein (AFP)and AFP-L3&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 67, 68, 87, 131, 143, 144, 145, 146, 147, 148, 196, 197, 198, 275, 276&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;143&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;2&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;The aims of this proposal are: (a) to determine the sensitivity and specificity of DCP for the detection of early HCC, (b) to compare the accuracy of DCP and AFP for the detection of early HCC, and (c) to determine whether demographic or etiology of underlying liver disease alter the expression of DCP or AFP. In order to achieve the aims of the study, we will enroll patients at 7 liver centers to perform a case control study of those with cirrhosis and those with early HCC. We will obtain the demographics, medical history, history of liver disease, social history (attention to lifetime smoking and alcohol), etiology of liver disease, family history, and clinical and laboratory data of patients with cirrhosis and early HCC. In addition, we will obtain serum, plasma and DNA for the evaluation of markers for HCC. All the data obtained will be maintained in a web-based database. We plan to enroll 450 HCC patients and 450 cirrhosis controls in order to target 190 early-stage HCC cases to achieve 90% power.  If 260 late-stage HCC cases are recruited before the target 190 early-stage HCC cases, then additional enrollment of late-stage HCC cases will be stopped. This is an important validation study of DCP, which may lead to the development of a clinically needed marker for HCC.&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;The primary goal is to compare the sensitivity and specificity of DCP to AFP for early stage HCC. We will test the null hypothesis that the ratio, TPF(DCP)/TPF(AFP) is larger than one, and similarly the null hypothesis FPF(DCP)/FPF(AFP) is less than one (Aim 2). 95% confidence interval for these two ratios, as well as that for differences between the two markers in TPF and FPF will be calculated. If both null hypotheses are rejected, we will conclude that DCP is superior to AFP in both TPF and FPF. If one null hypothesis is rejected (most likely for TPF) and another is inconclusive, the conclusion is that DCP is superior to AFP in TPF but inconclusive in FPF. A subsequent study will be required with a larger number of non-HCC cirrhosis patients to estimate the magnitude and direction of the difference in FPF. If neither null hypothesis is rejected, we will conclude that DCP is not superior to AFP in TPF or FPF. In that case, it is still of interest to see if the combination of two will improve the performance of either test. A joint confidence region of (TPF, FPF) for DCP (Aim 1), as well as that for AFP will be constructed. This will provide the performance measure of each biomarker for early stage HCC. To examine whether the performance of DCP depends on demographic or etiology of underlying liver disease (Aim 3), we will use logistic regression model. Taking ethnicity as an example, the logistic regression will have disease status as the dependent variable and independent variables will include the value of DCP, ethnicity indicator, and DCP by ethnicity interaction. The effect of clinical variables, e.g., etiology (no Hepatitis, HCV, HBV), and their interaction with DCP in predicting disease status will be examined in similar way. Of particular interest is to compare Hepatitis C-related HCC versus Hepatitis C-related controls and Hepatitis C negative HCC versus Hepatitis C negative controls due to the fact that Hepatitis C is the most common cause of cirrhosis and HCC in the USA.  To examine whether the combination of DCP and AFP will perform better than either test alone, we will use logistic regression with DCP or AFP alone, or a model with DCP, AFP, and their interaction term in the model, and compare their performance. If the combination does improve the classification, we will look at the linear combination of regression coefficients to find out the optimal combination as a classification rule. AFP-L3 was added to this study as an ancillary study. The data analysis of AFP-L3, as compared to AFP, is similar to that for DCP described above. We will also use a logistic regression entering DCP, AFP, and AFP-L3 into the model in different order to assess each marker’s independent additional contribution to ROC curve in addition to other marker(s).
The primary goal is to compare the sensitivity and specificity of DCP to AFP for early stage HCC. We will test the null hypothesis that the ratio, TPF(DCP)/TPF(AFP) is larger than one, and similarly&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;The DMCC provides each site with de-identified specimen labels for all serum, plasma and DNA aliquots.  Case/Control status can not be determined by any analysis lab.&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Upon publication data will be shared outside of EDRN.  Upon accrual completion and statistical analysis data will be shared within EDRN&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Feb 28 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb 14 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb 14 2005 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;DCP&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Using the guidelines for cancer biomarker validation suggested by Pepe et al. (23), we propose to perform a Phase 2 study of DCP for the detection of early stage HCC.  In this proposal, we plan to perform a larger case-control study to compare the sensitivity and specificity of DCP and AFP alone and in combination in differentiating patients with all stages of HCC and more importantly those with early HCC from patients with cirrhosis. We plan to enroll consecutive patients with HCC seen at 7 centers in the United States. Controls are frequency matched to cases (all center combined) using the following criteria:  age (±10 years), gender (+10%) and etiology of liver disease (viral vs non-viral (+5%). Within each participating institution, there will be an equal number (+20%) of cases and controls.&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Not yet published&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;422 HCC Cases (208 Early Stage and 214 Late Stage). 419 Cirrhosis Controls.  5 Cirrhosis Controls who progressed to HCC.&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;450 HCC Liver Cancer Cases, 450 Cirrhosis Controls&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;189&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;189&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Proteomics/SNPs&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;189&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;189&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Expression-based profiling&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;CD90, AGR2, CEACAM5&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;192&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;192&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;192&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Sort cancer cells from tumor specimens

Determine gene expression (transcriptome) by Affymetrix DNA arrays

Dataset analysis to identify cancer up-regulated genes encoding secreted or extracellular proteins

Proteomic analysis (mass spectrometry, Western blotting) to validate increased cancer expression&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Genomics and proteomics. DNA microarray analysis of sorted cell types to identify cancer-specific genes encoding secreted/extracellular proteins. Mass spectrometry-based proteomics to measure protin levels in case vs. control urine samples. &lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;n/a&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;Data analysis was done to evaluate data quality of Affymetrix arrays (mRNA expression correlation to protein expression by immunohistochemistry), to compare other publicly available prostate cancer datasets.  &lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;All data are available for query and download from our public database, UESC.&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;May 18 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;May 19 2004 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;1, 3&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Prostate &amp; Bladder Cancer Biomarkers&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;To identify potential cancer-specific protein biomarkers via genomic analysis of differential gene expression between cancer cells and their normal counterpart. 
To use proteomic analysis for quantitative detection of these proteins in urine.&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;518&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;CD90, AGR2, CEACAM5 are all up-regulated in prostate cancer&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;N=100 (tumor samples, urine samples)&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;No specific sample size listed in protocol.  Researcher will utilize prostate tumor tissue, prostate normal tissue, bladder tumor tissue, bladder normal tissue, and urine.&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;REFERENCE SETS A and C:

5.1 Clinical setting: Diagnosis of lung cancer

5.2 Cases eligibility Set A:

- All lung cancers discovered on CXR or on CT

- Pathology: confirmation of malignancy, all histological groups, primary lung cancer
- &amp;#8805;50% Stage I (Stage 1A = T1, N0, M0 and Stage 1B = T2, N0, M0)

   - No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last    5 years

   - Blood collected prior to treatment (chemo/radiation)

5.3 Controls eligibility Set A
- High risk individuals as defined by &amp;#062;50 YO, &amp;#062; 30 PKYs of smoking (prevalence of cancer ~1% based on (3-7)) with a lung lesions on CXR or on CT suspicious for lung cancer but proven not to be cancer at 1 year follow up.  If at 1 year follow up participant has been diagnosed with a type of cancer other than lung then the participant will be considered an “other cancer” control.

- 75 patients with pathology proven primary cancers from other organ sites (25 breast, 25 colon, 25 prostate)

- No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last 5 years

Cases and controls will be matched for prevalence according to age, sex, race, smoking status,    and PKY history of smoking

5.4 Sample sizes Set A
(1) Rapid single biomarker pre-validation:    87 cases and 50 controls, 25 other cancer controls
   (2) Panel of biomarkers pre-validation:   150 cases and 150 controls
(3) Phase II validation:         180 cases and 180 controls, 75 other cancer controls

5.5 Institution provider candidates Set A   
Pittsburgh
Vanderbilt
MDACC
UCLA
   UCHSC
   NYU
   JHU
 
REFERENCE SET B:

5.6 Clinical setting Set B
CT screening trial for the early detection of lung cancer

5.7 Cases eligib&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 65, 73, 84, 85, 87, 89, 131, 151, 239, 240, 241, 247, 248&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;65&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Our specific goals include:
1.   Develop reference case/control serum/plasma sets held in a NCI repository and make these samples available to the research community.
2.   Define, refine and validate blood-based biomarkers for lung cancer.
3.   Test reproducibility of biomarkers within and across institutions.
4.   Test reproducibility of biomarkers within and across analytical platforms.
&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;recipients of the specimens will sign a data sharing agreement&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Sep 30 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Mar 18 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Mar 18 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;LUNG REF&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The NCI/EDRN/SPORE Lung Cancer Biomarkers Group (LCBG) began its activities back in November 2004 and developed clear objectives and strategies on how to begin validating a series of candidate biomarkers for the early detection of lung cancer. The initial goal of the LCBG is to develop the requisite sample resources to validate serum/plasma biomarkers for the early diagnosis of lung cancer.  Researchers may use these resources and process for continued biomarker refinement but this is not the primary activity of the LCBG.  

&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;Set A:  180 Cases, 180 High Risk Controls &amp; 75 Other Cancers.
Set B: 170 Cases, 250 High Risk Controls and 75 Other Cancers.
Set C:  179 Cases, 181 High Risk Controls and 37 Other Cancers.&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Set A:  180 cases, 180 controls, 75 other cancers
Set B:  170 cases, 250 controls
Set C:  180 cases, 180 controls, 75 other cancers&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 65, 67, 70, 73, 80, 81, 83, 84, 87, 88, 89, 91, 128, 189, 202, 203, 411&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;87&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;ERNE&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;82&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;74, 82&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;82&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153, 154                                                                                            &lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep  1 1999 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Polyp Prediction Study&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;N/A&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See BRSCW description&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 70, 87, 131&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;70&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;50 pre- and 50 post-menopausal healthy women who have no personal nor any strong family history of cancer will be recruited through the Research Blood Components and have between 225 -250 ml of blood drawn yielding sufficient sera for 350 0.3mL aliquots on each individual subject plus sufficient residual sera which will be pooled to construct 350 sets of 8 replicate serum specimens. At the same time, pooled sets of ovarian cancer cases stratified by menopausal status and histologic type will also be created providing 4 sets of 250 0.3ml aliquots from case recruited through an existing IRB protocol (Preoperative Predictors of Findings at Pelvic Surgery #2000p001678).  Ca-125, CEA, and Ca 15-3 will be measured as standard markers in all subjects including the individual cases and controls as well as in the set of pooled specimens.  The reference sets will be assembled and stored in barcoded capillary tubes in liquid nitrogen.  Investigators requesting specimens to evaluate a new marker would receive a “blinded” test control panel of 200 individual controls, 8(replicate) pooled control specimens (to yield a co-efficient of variation on the assay), and a set of 4 pooled case specimens.  Investigator would report the results of their assay to the EDRN data coordinating center which would  provide statistical output including the means and standard errors for the marker in all controls and the pre-and post-menopausal groups, the coefficient of variation for the marker, estimates of the marker in the pooled specimens in relation to the control distribution, and performance relative to standard markers.  Markers, whose levels in the case pools are more extreme than the best standard marker relative to the distribution in controls, would be promising candidates to move to the next level of validation.  &lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;N/A&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;The pooled case specimens and replicate control specimens cannot be associated with any individual subject. The identity of the control subjects has been retained by the commercial blood bank and is unknown to Partner’s Investigators. Thus, the ability to link the specimen to a specific individual is impossible for the investigator receiving the specimen.&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174, 182, 183                                                                                       &lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Follow EDRN guidelines&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;May 27 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep  1 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jun 22 2005 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;1, 2, 3, 4, 6, 7, 9&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BRSCW&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The purpose of this study is to develop a standard reference set of specimens for use by investigators participating in the National Cancer Institutes Early Detection Research Network (EDRN) in defining false positive rates for new cancer biomarkers in women. &lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;N/A&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;N/A&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;95 healthy women with no personal or strong family history of cancer and 20 identical replicates to measure assay variation.  275 serum aliquots of 0.3ml for all controls and an additional serum pool for creating the replicates.&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;FHCRC: CA125, HE4, Mesothelin (SMRP), SLPI , Spondin, Cadherin-6, B7-H4, CD-24, IGF2, CHI3L1, DcR3, CA15-3, CA72-4, CA19-9.  MD Anderson: Hepcidin, ITIH4, CTAPIII, B2-microglobulin, Transferring, Transthyretin, apolipoprotein A1.  Pittsburgh: CA125, Prolactin, MIF, TSH, IGF-BP1, CYFRA21.1, Eotaxin, sVCAM-1, MMP-2, IL-6, IL-2R, IL-8, EGFR, GH, Leptin.  MGH: CA125, CA72.4, CA19.9, CA15.3, CEA, HE4, SMRP, B7-H4, DcR3, Spondin-2, IGF-2, CHI3L1.&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 70, 87, 167, 231, 235, 236, 237, 238, 246, 531&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;70&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;2&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;1. Retest all of the biomarkers that have performed well in preliminary studies in a newly-assembled test set of 160 cases with pre-operative bloods representing major histologic types and including 80 early-staged and 80 late-staged cases, 160 controls with benign disease, 480 general population controls, and a small set of serial Samples collected either at least 3 months apart, but not more than 6 months apart OR between 10 months apart and no more than 14 months apart in 40 healthy controls. 
2. Evaluate the reproducibility, concordance with standard ELISA, and performance of the bead-based (Luminex) assays. 
3. Identify a consensus panel comprising the biomarkers that are most informative on their own as well as those that are most complementary when used together, and that can be evaluated in no more than .3 ml of serum using the Luminex platform, and up to 5 additional markers that can be measured adequately only by standard ELISA.  &lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Based upon comprehensive reviews of ovarian cancer biomarkers and preliminary studies in which multiple biomarkers have been compared simultaneously, investigators representing Ovarian Cancer SPORES, EDRN and the PLCO trial are working towards defining a consensus panel of biomarkers appropriate for ovarian cancer screening.  Towards this goal, SPORE and EDRN investigators proposed to assemble a new set of phase II specimens (160 ovarian cancer cases with pre-operative bloods over-sampled for early-stage disease, 160 benign disease controls, 480 general population controls, and serial samples collected one year apart from 40 healthy women).  The top 5 markers identified in preliminary work by Boston-NW and FHCRC investigators, plus an expanded panel of Luminex markers, were evaluated to identify a final consensus panel of 5 to 15 biomarkers.  CA125 and the top 5 new markers were measured by standard ELISA using an automated platform, or kit, at BWH.  CA125 and the top 5 new markers, as well as additional candidate markers unique to each institution, were measured using Luminex at FHCRC and Pittsburgh. Results from ELISA were compared to results obtained from Luminex to evaluate the consistency of CA125 and the top 5 new markers across platforms and institutions.  Markers were selected for inclusion in the panel based on their individual performance, their contribution to a panel, and their stability over time, where the last predicts the improvement in performance expected from their use in a longitudinal algorithm. 
For markers that could be measured adequately on Luminex, to preserve specimen volume, the Luminex platform was used to evaluate the final consensus panel in the requested PLCO specimens; standard ELISA were used only if necessary due to inadequate measurement by Luminex.  &lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All samples were blinded at FCCC&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;183                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Study results will become available upon publication completion.&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Oct 23 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Aug  1 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug 15 2005 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3, 7&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;OVAR-VAL-PRE-PLCO&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Create a new set of phase II specimens (160 cases with pre-operative bloods representing major histologic types and including 80 early-staged and 80 late-staged cases, 160 controls with benign disease, 480 general population controls, and a small set of serial Samples collected either at least 3 months apart, but not more than 6 months apart OR between 10 months apart and no more than 14 months apart in 40 healthy controls) will be used to evaluate markers identified in preliminary work. The top 5-10 markers, plus an expanded panel of Luminex markers, will comprise a “working consensus panel” for subsequent analysis in PLCO specimens. &lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Results will be posted after publication.&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;Results will be posted after publication.&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;160 cases, 160 benign disease controls, 480 general population controls&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;160 Ovarian Cases (80 early stage &amp; 80 late stage); 160 benign disease controls; 480 general population controls;  40 serial samples&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 83, 87, 88, 131, 203, 510&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;203&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All samples will be sent to NCI-Frederick for blinding and set assembly.&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Application for specimen use in place.  Authorized labs will release their results to the DMCC.  Upon publication, data will be shared.&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;May 31 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb 28 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;9&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;PROS-REF&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;To collect biologic samples on men prior to prostate biopsy, in association with clinical information and common data elements appropriate for evaluation of risk and prognosis of prostate cancer&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;165 Prostate Cancer Cases
210 Bx Benign Controls&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;3 Subject Selection
3.1 Eligibility Criteria
3.1.1 Cases (n=300 invasive cancer and 100 DCIS: Up to 100 LCIS and 100 Pagets may
be included but are not the targeted population) and Benign Disease Controls (n=100 benign
non-proliferative conditions and 100 benign proliferative conditions)
a. Female
b. At least 18 years of age
c. Mammographic finding or palpable breast mass
d. Undergoing initial diagnosis to determine if breast cancer is present
3.1.2 Normal Controls (n=100):
a. Female
b. At least 18 years of age
c. Undergoing routine mammographic screening (with or without clinical breast
exam)
d. BIRADS score less than or equal to 2
3.2 Exclusion Criteria
3.2.1 Cases and Benign Disease Controls
a. Already diagnosed by biopsy for current presentation of breast cancer or benign
disease
b. History of invasive breast or other cancers (except basal or squamous cell
carcinoma of the skin)
c. Recurrence of previous breast cancer
d. Pregnant or nursing
The consenting process and blood draw will be carried out before primary pathology results
are obtained. This may occur either before or after the diagnostic biopsy, but will be limited
to the same day that the biopsy is performed or up to 2 weeks prior to biopsy. There are two
reasons for this restriction: 1) It will ensure that the cancer (or benign) mass is present at the
time of blood sampling and 2) It will reduce potential biases that might result from subjects
knowing their diagnosis with certainty to be malignant or benign. No exclusion will be
made based upon age, race, extent of disease, drug usage, family history, prior biopsies, prior
benign diseases or prior DCIS.
3.2.2 Normal Controls
a. Current evidence of breast abnormality (prior benign disease or DCIS
acceptable)
b. History of invasive breast or other cancers (except basal or squamous cell
carcinoma of the skin)
c. Pregnant or nursing
d. BIRADS score greater than 2 or palpable mass
For the purpose of this study, we defin&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 81, 87, 131, 189, 202, 230&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;81&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;all samples are blinded at NCI-Frederick&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;recipients of the reference set sign a data sharing agreement&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Aug  3 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun  2 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jun  2 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BREAST-REF&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The primary objective of this study is to assemble a well-characterized set of blood specimens to
test biomarkers that, in conjunction with mammography, can detect and discriminate breast
cancer. These samples will be divided to provide “sets” of specimens that can be tested in a
number of different laboratories. Since tests will be performed on the same sets of samples, the
data will be directly comparable and decisions regarding which biomarker or set of biomarkers
have value in breast cancer detection can be made. These sets will reside at a National Cancer
Institute facility at Frederick, MD.&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;Normals: 276
Benign Disease Atypia: 63
Benign Disease Non-Atypia: 231
DCIS: 48
LCIS: 7
Invasive:  190
Normal-Later Cancer:  15
Benign-Later Cancer: 2
&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Cases (n=300 invasive cancer and n=100 DCIS) and Benign Disease Controls (n=100 benign non-proliferative conditions and 100 benign proliferative conditions)and 100 normal&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;To develop a longitudinal serum biorepository with annual serial samples collected from mutation carriers within the Hereditary Cancer Institute and High Risk Registry for retrospective evaluation of  promising biomarkers.&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174, 153, 155, 183, 157, 154                                                                        &lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;LSB&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Four percent of EDRN Registry mutation carriers developed cancer within a year after beginning follow-up in this registry; within 2 years, 10% had developed cancer.  Within 2 years, 17% had developed either a cancer or a pre-malignant lesion (e.g. adenoma).

Our goal is to recruit 265 mutation carriers from the EDRN High Risk Registry and Hereditary Cancer Center for the Longitudinal Serum Biorepository (LSB). Based on the cancer rates observed to date in the EDRN Registry, four years of follow-up in a group of this size would be expected to yield 53 invasive and in situ cancers and 37 benign premalignant lesions.

All subjects in the serum biorepository (1)have signed consent (2) are counseled carriers (APC, BRCA1, BRCA2, CDH1, CDKN2A, MLH1, MSH2, MSH6) and (3) are enrolled in family studies through CU&amp;#39;s Department of Preventive Medicine and/or are enrolled in the EDRN High Risk Registry.  Post specimen medical history is collected annually.

Serum and plasma are aliquoted for respository storage and stored in labeled cryovials in an ultra low temperature (-86C) freezer. Specimens in the LSB are available for use in EDRN biomarker development and validation studies.  &lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Novel Surveillance HNPCC&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;201&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;201&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;150                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep  1 1999 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Barrett&amp;#39;s -Associated Carcinogenesis&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;proteins, peptides, &lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 65, 87, 92, 151, 188, 200, 232, 249, 250, 281, 289, 290&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;151&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Specific Aims are identified by each assay laboratory.&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;The primary analysis for this study is to identify proteins/peptides that have potential as colon cancer early detection or risk prediction markers for subsequent validation. The secondary aim is to see if some proteins/peptides are complementary in their early detection abilities so their combinations will improve their sensitivity and specificity. Since thousands of protein/peptides will be identified and/or quantified, one important issue is to quantify and control the False Discovery Rate (# of false positive finding / # of selected markers as differentially expressed) and maintain reasonable power to detect truly differentially expressed markers. Another important feature of the data analysis is that the derived data from mass spectrometry critically depends on the algorithms of identifying the peptides, assigning protein identities and intensities. Coordinating center biostatisticians need work closely with proteomics bioinformaticians and computational biologists with expected iterations between data processing and data analyses.&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;The investigators will be blinded to disease status. For laboratories that use two-color system, the disease status group label will be A and B. After the raw data has been generated and sent to DMCC (or CPAS), the sites will be un-blinded to facilitate their investigations using disease status information.
 A set of split duplicate specimens from 10 additional controls will be sent to each lab. These specimens will be integrated, as if 10 additional matched pairs, with the 100 matched case-control pairs, in a blinded fashion.
&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Data used in a publication will be made publicly available upon publication to allow other investigators access to the data.

&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Jan 17 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jan 17 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan 17 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3, 4&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;EDRN/WHI COLON&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Specifically, it is proposed to assess plasma proteins from postmenopausal women diagnosed with colon cancer within a span of 18 months after year-3 OS blood draw and from appropriate matched controls enrolled in the WHI OS study. The range of case-control differences sought in plasma include:

1   Detection and identification of proteins that may be derived from tumor cells through the classical secreted protein pathway and through non-classical pathways (eg protein cleavage and release) or through cell turnover.
2   Detection and identification of protein changes associated with the host response that occur during tumor development and that may be related to inflammation, angiogenesis, infiltration of tumor with host cells and other processes.
3   Identification of tumor derived proteins that induce a humoral immune response in the form of autoantibodies that are detectable at the preclinical stage.
&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Project continuing&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;100 cases and 100 controls&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;100 colon cancer cases from WHI and an equal number of pair matched controls from the Observational Study (OS)&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;hk2, hk4, hk11, TSP-1, %fPSA, -2ProPSA&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 83, 87, 88, 158, 161, 167, 200, 203&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;203&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Test candidate prostate markers at various labs using specimens collected and processed in a similar manner.&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Specimen shipped to Dan Chan reference lab for aliquoting, re-labeling (blinding done by NCI), and shipping to four labs. &lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Data to be shared with collaborative group members in order to decide which markers move forward.&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Feb  7 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb 10 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb  1 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;PROS-RAPID&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Determine which markers move to validation using the prospectie prostate reference set samples.&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;hK2, hK4 and hK11 do not distinguish cases from controls. TSP-1 does not seem to distinguish cases from controls. %free PSA has some value: at 0-10% free PSA range for men whose PSA between 4-10 ng/ml, this cutoff point picks up near three folds cases as controls and has since moved on to validation.&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;63 Prostate Cancer Cases0, 60 non-malignant&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50/50&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;193&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;193&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;193&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;4D-ELF for CRC detection&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;3.2 Inclusion Criteria
3.2.1 Cases
Cases will include patients with HCC. Tumor staging will be performed using the modified TNM for HCC
used by UNOS. Early stage HCC is determined by the most recent CT or MRI that has lesion(s) and
maximum diameter. UNOS stage I (a single lesion &amp;#060; 2 cm) or stage II (single lesion between 2-&amp;#060;5 cm or
2-3 lesions each &amp;#060; 3 cm), with no vascular invasion (portal vein thrombosis) or extrahepatic metastasis.
Eligibility criteria for cases are:
&amp;#149; Age &amp;#062; 18 years of age
&amp;#149; Diagnosis HCC based on one of the following:
&amp;#1048707; Histology (required if only one lesion &amp;#060; 2 cm is present) – Must have CT/MRI to calculate
stage
&amp;#1048707; Two imaging tests, with at least one (CT/MRI/Angiography) within the past 3 months or up to
2 weeks after consent showing evidence of arterial hypervascularization, and the other within
the past 6 months (US, CT, MRI/Angiography) indicating a mass in the liver.
&amp;#149; MELD &amp;#060; 15. If MELD &amp;#062;15, but INR is &amp;#060; 1.5, Total Bilirubin is &amp;#060; 1.7 and patient has a history of
intrinsic renal disease, then eligible.
&amp;#149; Lab results (other than AFP) must be within the past 90 days. AFP results are optional.
&amp;#149; Able and willing to provide written informed consent
The diagnostic criteria requiring two imaging tests in absence of a biopsy are based on an HCC Consensus
Conference (8). While it is preferable to use histologic confirmation of HCC to determine eligibility, it is
recognized that biopsies are not commonly done in patients with suspected HCC because of concerns of
complications; histology will only be required for patients with only one lesion present that is less than 2
cm.
3.2.2 Controls
Eligibility criteria for controls are:
&amp;#149; Age &amp;#062; 18 years of age
&amp;#149; Diagnosis of cirrhosis based on liver histology. In the absence of histology, cirrhosis would be
defined by an ultrasound or CT scan showing a cirrhotic-appearing liver with splenomegaly and
platelet count of &amp;#060; 120 mm-3.&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 143, 144, 145, 146, 147, 148, 275&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;143&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Specific Aims
Aim 1: To determine the sensitivity and specificity of des-gamma carboxyprothrombin (DCP) for the
diagnosis of early hepatocellular carcinoma (HCC).
Aim 2: To compare the accuracy of DCP and Alpha-fetoprotein (AFP) for the diagnosis of early HCC.
Aim 3: To determine whether demographic or etiology of underlying liver disease alter the expression of
DCP or AFP.&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;recipients of the specimens will sign a data sharing agreement&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Sep 30 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Apr 15 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb 15 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;LIVER REF&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Utilize the remaining specimens collected under the DCP protocol to develop and validate markers for the early detection of HCC&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;see DCP protocol&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;SMRP and OPN&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 68, 84, 87, 176, 456, 498, 499&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;176&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;2&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Phase I: - Identification and assemblage of representative cohorts of individuals with MM, no malignancies but increased risk for MM due to asbestos exposure, and (optionally) lung malignancies other than MM
Phase II (A) - Determine the sensitivity and specificity of SMRP and OPN in distinguishing individuals with a clinical diagnosis of malignant mesothelioma from individuals who are asbestos-exposed but without a clinical diagnosis of malignant mesothelioma.
Phase II (B) – Determine the comparability of analyte values across contributing centers and determine covariates that influence analyte levels
Phase II (C) – Determine the sensitivity and specificity of SMRP and OPN, alone and in combination, in distinguishing individuals with MM from those without.
Phase III.  Determine the sensitivity and specificity of SMRP and OPN in distinguishing individuals who would subsequently develop malignant mesothelioma from matched individuals who did not subsequently develop malignant mesothelioma.
Phase IV.  Determine the sensitivity and specificity of SMRP and OPN in other populations of interest.&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;The form of the final analysis will not be determined until the end of Phase II (B).  To arrive at an initial estimate of the power for this phase, we analyze the power we would have if the data from all contributing sites can be combined and there are no covariates that will need to be included in the analysis.  With a total of 164 cases and 687 controls, using 80% power and with a 2-sided, 0.05-level test, the following tables show the differences in sensitivity and specificity that are detectable:
Table 1.  Sensitivity detectable with 80% power in a joint analysis of sensitivity and specificity
Null Hypothesis Sensitivity 0.10 0.25 0.50 0.75
Detectable Sensitivity   0.18 0.36 0.62   0.85

Table 2.  Specificity detectable with 80% power in a joint analysis of sensitivity and specificity
Null Hypothesis Specificity 0.50 0.80 0.90 0.95
Detectable Specificity   0.52 0.85 0.94   0.98

&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All specimens will be blinded.&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Data will be sent to DMCC for analysis, and shared with EDRN once analyzed and public once published.&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;May 31 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Mar 16 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Mar 16 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;MESOTHELIOMA&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;652 controls and 165 cases&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;p16, RUNX3, HPP1, qMSP, NELL1, TAC1, AKAP12, CDH13, SST&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;100 cases and 200 controls will be selected based on retrospective chart review of endoscopic
and pathology reports demonstrating BE, defined as salmon-colored mucosa in the tubular esophagus with intestinal metaplasia with goblet cells on biopsy. The endoscopic procedures were done as per routine clinical care at participating Consortia institutions. Cases are those BE patients who initially had either no or low grade
dysplasia, who eventually progressed to have either HGD or EAC (progressors). Controls will include patients with BE who have not progressed beyond low grade dysplasia (non-progressors).
&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 82, 87, 343, 344, 345, 346, 347, 348&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;82&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Our specific aims include:
1. Utilizing methylation-specific PCR and FISH, to identify DNA methylation abnormalities and
chromosomal aberrancies which represent biomarkers of risk for progression to EAC in the setting of BE.
2. To perform multivariate analysis of the risk of progression to HGD or esophageal denocarcinoma in patients with methylation and FISH abnormalities after controlling for other known risk factors for EAC&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;The first step in evaluating a candidate marker is to show that there is a significant difference in the marker between cases and controls. If a marker is positive in only 5% of controls (i.e., 95% specificity), then this Project PI: Richard Sampliner, MD Principal Investigator/Program Director (Last, First, Middle): Gerner, Eugene W
sample size (100 cases and 200 controls) will provide over 90% power to detect a positivity rate in cases of 18% or greater, based on a two-group Fisher&amp;#39;s exact test at a two-sided 0.05 significance level. If a marker is positive in 10% of controls, then this sample size will provide over 90% power to detect a positivity rate in cases of 26% or greater. If a marker is positive in 25% of controls, then this sample size will provide over 90% power to detect a positivity rate in cases of 45% or greater. Looked at another way, if a marker is positive in
90% of cases (i.e., 90% sensitivity), then this sample size will provide over 90% power to detect a positivity rate in controls of 74% or lower. Given the exploratory nature of this study, a formal adjustment for multiple statistical comparisons is not planned; however, significance levels will be interpreted cautiously.&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All samples were analyzed in a blinded fashion&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;150                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Data to be shared via EDRN&amp;#39;s Data and Archive Service (EDRN) and made publicly available upon review and approval.&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Mar  2 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Aug 15 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul 15 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;9&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BARRETT&amp;#39;S ESOPHAGUS&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus (&amp;quot;progressors&amp;quot;), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC (&amp;quot;non-progressors&amp;quot;). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful  application for a prospective study of markers identified in this case-control study.&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;A methylation biomarker-based panel to predict neoplastic progression in BE has potential clinical value in improving both the efficiency of surveillance endoscopy and the early detection of neoplasia.&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;A methylation biomarker-based panel to predict neoplastic progression in BE has potential clinical value in improving both the efficiency of surveillance endoscopy and the early detection of neoplasia.&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;145 nonprogressors and 50 progressors&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;145 nonprogressors and 50 progressors&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Annexin, LAMR1, PGP&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 151, 492&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;151&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;2&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim 1:  To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis.
Aim 2:  To identify additional antigens and antibodies in sera from CARET participants, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, and histologic type.
Aim 3:  To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Natural Array technique&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Disease status was blinded for batch 1, but was unblinded after analysis was done to determine if the findings are sufficiently promising to proceed with the rest of the CARET sera&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;shared after publication completed&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Aug  7 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep  5 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep  5 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Lung CARET&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;1.1    To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status.

1.2   To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody.

1.3   To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.
&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;1436&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Annexin was significantly elevated in lung cancer patients in serum 0-12 months prior to diagnosis (p-value = 0.001) and the area under ROC curve 0.71 with 95% confidence interval from 0.63 to 0.78.  The direct clinical utility for Annexin in pre-clinical high risk (heavy smoker) population is unclear as the sensitivity at 90% specificity is 25%, or sensitivity 55% at 80% specificity.  However, this validated marker could serve as a member in a panel, yet to be formed, to reach clinical utility for early detection of lung cancer.

Lung cancer reference set A specified a PPV of 2.5% would be clinically significant assuming lung cancer incidence among heavy smokers is 1% per year. If we apply 25% sensitivity at 90% specificity in this study, PPV is 2.5%. Note that CARET specimens used in this study were collected within 12 month prior to diagnosis, not at diagnosis. This indicates potential use of Annexin to enrich the high risk smokers for further screening (e.g. CT), though the enrichment is a moderate 2.5 folds. Given Hanash Lab using specimens at diagnosis observed 40-50% sensitivity with near 100% specificity, it seems that the diagnostic performance of Annexin improves as time near diagnosis. Therefore, it is recommended that Annexin should also be validated for it’s potential clinical use for aiding diagnosis among patients having suspicious lesions in lung (lung cancer reference set B).

PGP was not significantly associated with lung cancer in pre-clinical serum.

Our findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens
&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;100 blood samples from lung cancer patients and 100 matching controls were randomly chosen in pairs from CARET. Each case and control pair was matched on age at enrollment (5-year intervals), sex, intervention arm (active vitamins or placebo), exposure population (asbestos or heavy smoker), baseline smoking status (active or former), year of enrollment, and year of blood draw.&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;100 blood samples from lung cancer patients and 100 matching controls&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;                                                                                                    &lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt; &lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Familial MM&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;3.1 Cases (Pancreatic Cancer)
Patients will be consented prior to surgery.
A. No prior history of any other malignancy except nonmelanoma skin cancers for ten years.
B. Must have undergone complete surgical resection of the tumor with curative intent including the
presence of negative margins and a pathologic staging of I or IIA.
C. Must have histological verification of a pancreatic adenocarcinoma
D. Must not have received preoperative chemoradiation (neoadjuvant) therapy due to our inability to
adequately stage these patients.
E. Able to give informed consent.
F. Blood sample must be obtained within the past 2 weeks prior to surgery/anesthesia according to
procedure described in Appendix D.
Post-Enrollment Criteria: Inclusion of the patient in the proposed validation set is dependent on the results
of the surgery. The patient must have undergone complete surgical resection of the tumor with curative
intent including the presence of negative margins and a pathologic staging of I or IIA. Samples from any
patients not meeting these criteria will be used in a discovery set.
3.2 Controls
Three different control groups are proposed for this reference set: chronic pancreatitis patients, acute
benign biliary obstruction patients and healthy controls. The cases and controls are required to have a
similar age distribution. Although we will attempt to keep the same number of cases and controls within
each site (1 to 3 ratio), age distribution does not have to be similar for cases and controls within each site.
An algorithm developed by Feng and colleagues will be used to recruit cases and controls across multicenters
to ensure that the cases and controls are frequency matched by age. Eligibility criteria for each of
Page 4 of 7
the controls groups are described below. Control specimens will not be collected until 10 post-operative
PC cases have been successfully enrolled in the study.&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 75, 87, 131, 156, 341, 412, 416, 417, 418, 419&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;156&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;157                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Recipients of the reference set will sign a data sharing agreement&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;May 31 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Nov 26 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Nov 26 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;PANCREATIC-REF&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The primary objective of the EDRN Pancreatic Cancer Working Group Proposal is to create a reference set
consisting of well-characterized serum/plasma specimens to use as a resource for the development of
biomarkers for the early detection of pancreatic adenocarcinoma. The testing of biomarkers on the same
sample set permits direct comparison among them; thereby, allowing the development of a biomarker panel
that can be evaluated in a future validation study. Additionally, the establishment of an infrastructure with
core data elements and standardized operating procedures for specimen collection, processing and storage,
will provide the necessary preparatory platform for larger validation studies when the appropriate
marker/panel for pancreatic adenocarcinoma has been identified.&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;60 Pancreatic Cases, 60 chronic pancreatitis controls, 60 biliary obstruction controls, 60 healthy controls&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Broad based screen of possible biomarkers.  p53 is included here.&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;70, 203, 230&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;230&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;1.B. Project Objectives
Aim 1:  Generation of NAPPA protein microarrays expressing the fifty most common p53 point mutations for solid tumors as well as deletion constructs of p53.

Aim 2:  Identify p53 mutation-specific antibodies in a test set of breast, prostate, and ovarian cancer patient sera.
a.   Using test sera from patients with prostate, ovarian, and breast cancers, identify patient sera that contain anti-p53 antibodies.
b.   Using p53-antibody-positive sera from patients, screen the p53 mutation microarray to identify mutation-specific and domain-specific antibodies
c.   Using p53-antibody-negative sera from patients, screen the p53 mutation microarray to identify mutation-specific antibodies
d.   Determine the sensitivity and specificity of individual antibodies that distinguish patient sera from normal sera.
e.   Determine if mutation-specific antibodies can distinguish tumor types.
&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Various including quantile regression, Fishers exact, binomial proportion and others.  The methods are not yet fixed because we are still in discovery.&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174, 183, 185                                                                                       &lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research, Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Dec 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan  2 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The overall goal of this project application for the EDRN set-aside funds is to focus our collaborative efforts to identify p53 mutation-specific antibody biomarkers in breast, prostate, and ovarian cancer. P53-specific gene mutations are frequent in multiple cancer types.  Of the common solid tumors, p53 mutations have been identified in 50% of lung and ovarian cancers, 45% of colon cancers, 20% of breast cancers, and 10-30% of prostate cancers (The p53 Mutation Handbook, T. Soussi, http://p53/free/fr). The most common mutations vary from cancer to cancer, with 50 point mutations covering the 10 most common mutations for all major solid tumors&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;1365&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;Not yet determined.  Still open.&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;100 early-stage breast cases, 100 early-stage prostate cases, 15 early-stage ovarian cases,
250 breast cases, 250 matched controls&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;231&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 231&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;231&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Our specific aims are to:

1)&amp;nbsp;&amp;nbsp;&amp;nbsp;Perform two comprehensive proteomic profiling experiments.
a.&amp;nbsp;&amp;nbsp;&amp;nbsp;Diagnosed between two years and four months before diagnosis.
b.&amp;nbsp;&amp;nbsp;&amp;nbsp;Diagnosed between four years and two years before diagnosis.
2)&amp;nbsp;&amp;nbsp;&amp;nbsp;Analyze and disseminate the raw and processed data.
a.&amp;nbsp;&amp;nbsp;&amp;nbsp;Search data from pre-clinical specimens and combine with results from clinical specimens.
b.&amp;nbsp;&amp;nbsp;&amp;nbsp;Stage and disseminate data on queryable system and make available to EDRN.
3)&amp;nbsp;&amp;nbsp;&amp;nbsp;Provide MS/MS data analysis and interpretation support to the EDRN, and cooperation with the DMCC.
a.&amp;nbsp;&amp;nbsp;&amp;nbsp;Provide consulting with researchers who wish to interpret the resulting ovarian data.
b.&amp;nbsp;&amp;nbsp;&amp;nbsp;Process and stage other MS/MS proteomic data identified by the EDRN for dissemination through the network and under the supervision of the DMCC. 
&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;183                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;These data may be used as a valuable source for evaluating biomarker candidates within EDRN.  Our vision is to make the protein lists, and their quantitative information, available to the EDRN researchers (prior to publication by our group) so that researchers may interrogate the data for information supporting specific biomarkers of interest to them. All resulting data will be deposited on a secure site with permissions given to EDRN ovarian cancer researchers, or any other researcher involved in EDRN, under the direction of the DMCC.  Data will be housed on the FHCRC (McIntosh laboratory) CPAS installation (Rauch et al 2006).  Details of the specific use of the system for data mining can be found at the site, but the figure below provides an example of what the resource will look like to those who make use of it.  In this screen-shot, the results of a protein query for APOA4 is displayed.  The display shows whether or not the protein was found, provides gene and protein aliases (which accomodate the non-standard manner in which genes and proteins are named), the overall sequence coverage found in the experiment, and specific protein and peptide ratio information for that protein. &lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan  2 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Proteomic Data Resources for EDRN Ovary Cancer Researchers within the EDRN&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;This project will generate a highly valuable data resource and make it available to all EDRN ovarian cancer researchers.  The resource will include comprehensive proteomic (tandem mass spectrometry, MS/MS) data generated from plasma samples that have been collected between four months and four years prior to clinical detection of ovarian cancer.  These pre-clinical samples, provided from the Beta Carotene and Retinol Efficacy Trial (CARET) prospective study, will be interrogated using IPAS, the proteomic profiling method developed by the Hanash Laboratory and with the quantitative methods developed by the McIntosh laboratory.  In addition, we will combine these pre-clinical data with already completed IPAS interrogations of plasma collected at the time of ovarian cancer diagnosis.  Thus together we will provide information on both pre-clinical and clinical behavior of a large number of proteins.  Based on our preliminary work we are able to quantify over 500 plasma proteins in each of these experiments, many of which are putative ovarian cancer biomarkers, showing the platform is capable of providing useful information regarding biomarker candidates.  
This project intends to perform in-depth interrogation of these samples and also to stage these findings as part of a queryable database, which may be used by EDRN researchers.  The results will also be provided to the DMCC.  We also propose to provide consulting resources for the EDRN community who may wish to interrogate and interpret the data we are providing.
&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;17 cases (specimen collected between four months and four years prior to clinical diagnosis), 17 matched controls&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;1) Secreted prostate specific markers.
2) Glycans specific to PCa versus benign.&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92, 192, 407&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;92&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim 1.  Application of MRM to Quantitation of Urine Secretome Protein Biomarkers

Aim 2.  Application of MRM to Quantitation of EPS Protein Biomarkers

Aim 3.  Application of MRM to Glycoprotein Biomarker Analysis
&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;LC-MS/MS via QqQ hybrid TRAP&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Primary data is shared between the two EDRN sites immediately.  The results will be presented at EDRN meetings.  The primary data will be released to EDRN specified sites upon approval by the two EDRN collaborating sites.&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Dec 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan  2 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Early Detection of Cancer by Affinity Mass Spectrometry-Set Aside funds&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;A.   RATIONALE
The recent introduction of multiple reaction monitoring capabilities offers unprecedented capability to the research arsenal available to protein based biomarker discovery.  Specific to the discovery process this technology offers an ability to monitor specific protein changes in concentration and/or post-translational modification.  The ability to accurately confirm specific biomarkers in a sensitive and reproducible manner is critical to the confirmation and pre-validation process.  We are proposing two collaborative studies that promise to develop Multiple Reaction Monitoring (MRM) work flows for the biomarker scientific community and specifically for EDRN. 

B.   GOALS
The overall goal for this proposal is the identification of protein biomarkers that can be associated with prostate cancer detection.  The underlying goal is the application of a novel technological approach aided by MRM toward biomarker discovery.  An additional goal will be the dissemination of knowledge gained from these studies EDRN wide.
&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;[-2]proPSA&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 83, 88, 200, 203&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;200&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;2&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Secondary Objectives – (1) To determine if [-2]proPSA is complementary to other PSA derivatives in a multi-marker model to improve the diagnosis and risk assessment of prostate cancer and reduce unnecessary biopsies, (2) To validate the serum %[-2]proPSA marker for the improvement of diagnosis and risk assessment of prostate cancer and reducing unnecessary biopsies in truncated PSA ranges such as 2-10 ng/mL PSA and 2-4 ng/mL PSA, (3) To determine if the [-2]proPSA marker or a combination of markers studied can aid in the identification of aggressive cancers as determined by Gleason score.&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;The primary outcome analysis is to calculate the sensitivity corresponding to 70% specificity, i.e. ROC(0.30), and performing hypothesis testing against a null hypothesis of sensitivity=40%, i.e. ROC(0.30)=0.40. 95% confidence intervals will be calculated for ROC(0.30) as well as for the threshold corresponding to 70% sensitivity.

The secondary outcome analysis is to calculate the specificity corresponding to 95% sensitivity and its threshold. Hypothesis testing will be conducted against the null hypothesis of specificity 5%. 95% confidence intervals will be calculated for ROC-1(0.95) as well as for the threshold corresponding to 95% sensitivity.

Other exploratory analyses will be performed to examine the complementary properties of %proPSA with other clinical variables (age, race, and family history, DRE) and other PSA derivatives (PSA and fPSA). Logistic regression with forward model selection will be used to combine the markers and clinical variables. The ROC curve of the predicted score will be plotted and compared to that of the model using clinical variables and existing PSA and its derivatives but without %proPSA. These analyses will be performed for the whole group, for the group with PSA 2-10 ng/mL, and for the group with PSA 2-10 ng/mL and without suspicious DRE.&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Specimens are blinded to investigators.&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Clinical information on the reference set samples has already been provided to the DMCC. Laboratory data generated from the PSA isoforms analyses will be transferred directly from the Access analyzers into an excel (or other to be determined data file) file. This file will be forwarded to the DMCC.&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Dec  9 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jul  2 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan  2 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;proPSA&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Primary Objective –  To validate the serum %[-2]proPSA marker for the improvement of diagnosis and risk assessment of prostate cancer and reducing unnecessary biopsies.&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;In the 2.5 – 4 ng/Ml total PSA range:
75% of the cancers can be detected
With only a 41% unnecessary biopsy using %pPSA
Whereas, %fPSA would result in 67% unnecessary biopsies
&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;In the 2.5 – 4 ng/Ml total PSA range:
75% of the cancers can be detected
With only a 41% unnecessary biopsy using %pPSA
Whereas, %fPSA would result in 67% unnecessary biopsies
&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;see rapid reference set&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;200 positive biopsy cases, 300 negative biopsy controls&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;75, 88&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;88&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;189                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan  2 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Release of Set Aside Funds - microRNA Biomarkers for Renal Cell Carcinoma&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;30 normal tissue samples, 30 tumor tissue samples from same patient&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion Criteria

Patients must fulfill all of the following criteria to be eligible:
1.  Histologically confirmed adenocarcinoma of
    the prostate.
2.  Clinically localized prostate cancer: T1-2,
    NX or N0, MX or M0.
3.  No previous treatment for prostate cancer
   (including hormonal therapy, radiation 
    therapy, surgery, or chemotherapy).
4.  ECOG Performance Status 0 or 1.
5.  Patient has elected Active Surveillance as
    preferred management plan for prostate cancer.
6.  Patient consent has been obtained according
    to local Institutional Review Board for
    acquisition of research specimens. 
7.  Patient is accessible and compliant for
    follow-up.
8.  Prostate biopsy requirements:

    a. If diagnosis was within one year of
       baseline visit, participant must have at 
       least one biopsy with at least 10 cores.
    b. If diagnosis was more than 1 year prior to
       baseline visit, participant must have a
       minimum of 2 biopsies, one of which must
       be within 2 years prior to baseline visit.

Exclusion Criteria
Patients who fulfill any of the following criteria are not eligible:

1. Unwillingness or inability to undergo serial
   prostate biopsy.

2. History of other malignancies, except: 
   adequately treated non-melanoma skin cancer or
   adequately treated superficial bladder cancer
  (Ta) or other solid tumors curatively treated
   with no evidence of disease for &amp;#062; 5 years.&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 88, 142, 203, 420, 424, 426, 428, 429, 441, 442, 491, 510, 545&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;142&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Discover and confirm biomarkers that predict aggressive disease as defined by pre-specified histological, PSA, clinical criteria, or outcomes based on these variables.&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;The primary objective of this repository is to discover and validate biomarkers predicting aggressive disease, with emphasis on validation. The sample size and power is based on validation of a biomarker after its initial discovery. Since this cohort of men has already elected AS, a desirable biomarker should have high specificity so that clinicians will minimize the proportion of those men advised for more aggressive treatment, while still identifying the subset of men with high risk for progression. Therefore, we evaluate the sensitivity of a biomarker predicting aggressive disease at 95% specificity. We assume the threshold for 95% specificity needs to be estimated from this study, i.e., there is no pre-fixed threshold. This is more realistic because estimating the threshold usually requires a large study. The proportion of disease progression at 3 and 5 years from diagnosis is estimated at 25% and 33%. We want 90% power to confirm a sensitivity better than 10% (unacceptable) if the true sensitivity is 30% or better, at 95% specificity. Point estimate of sensitivity, specificity, and threshold and their 95% confidence intervals will be calculated. The sample size also depends on the slope of Receiver Operating Characteristic (ROC) curve at 95% specificity, usually quite steep when specificity is near 100%. We used 4 as the slope parameter for power analysis.

Based on above assumptions, for a cohort with at least 3 years follow up, this study requires 100 men with disease progression and 300 men without progression, totally n=400. For a cohort with at least 5 years follow up, this study requires 125 men with progression and 250 men without progression, total n=375. Therefore, the total needed person-years follow up should be 375*5=1,875.

The estimated number of patients elected for AS is about 350 in five sites combined. Given a conventional 25% recruitment rate, we expect 100 patients per year accrual. With 25% loss of follow-up, we estimate that each year’s 100 recruited men will finally contribute 375 person-years by the end of 5 years. It should be noted that we need full 5 years follow up to ensure that the men who had not progressed are indeed non-progressors, not false negatives. By the same reason, men after 5-years follow up will contribute little to the total person-years follow up because their risk of progression is felt to be low. Therefore, the study needs continuing 5 years recruitment and subsequent 5-years follow up with minimum 100 recruitment per year and a minimum 75% follow up rate.&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;All recruiting sites will enter their data into the Validation Studies Information Management System (VSIMS), a secure database maintained by the Early Detection Network (EDRN) Data Management Coordinating Center (DMCC).&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 19 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Dec 19 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;PASS&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Primary Objective:
To discover and confirm biomarkers that predict aggressive disease as defined by pre-specified histological, PSA, clinical criteria, or outcomes based on these variables.

Secondary Objectives:
To determine the proportion of patients on active surveillance who progress based on the above criteria.
To determine the clinical predictors of disease progression.
To measure the recurrence-free, disease-specific, and overall survival of men on active surveillance for clinically localized prostate cancer. 
&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;125 men with prostate cancer progression and 250 men without prostate cancer progression, over 5 years of follow-up.&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;190&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion – Male and female patients must be diagnosed with acute or chronic pancreatitis, biliary obstruction, pancreatic cancer, or other gastrointestinal malignancies. Attempts will be made to recruit minorities. 
Exclusion – Do not expect to enroll children since pancreatic adenocarcinoma is a disease of adults that typically occurs in the 5th, 6th and 7th decades of life.
&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;161, 190&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;190&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Specific Aim 1) Utilize newly developed and to be developed antibodies against the mucin core proteins MUC1, MUC4, and MUC17 to develop an improved serum assay for pancreatic adenocarcinoma. 
Specific Aim 2) Develop and utilize a set of monoclonal antibodies that recognize serum forms of distinct mucin core proteins, utilize these to improve the diagnostic capability of the CA 19-9 type tests for nonmalignant, premalignant and malignant lesions of the pancreas, and evaluate the capability of the test to discriminate pancreatic cancer from other adenocarcinomas.
&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;157                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Jul 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jul 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Determining and quantifying the types of mucin core proteins to which CA19-9 is attached will result in assays with improved performance characteristics compared to CA19-9 alone.&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;188&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Adult males (ages 18-999) with a diagnosis of prostate cancer &lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;75, 83, 88, 92, 188, 203&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;188&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;To establish an EDRN “pre-validation” trial of a multiplex set of transcripts, including the ETS gene fusions, in post-DRE urine sediments. &lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2015 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug  1 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;EDRN Pre-Validation of Multiplex Biomarker in Urine&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The goal of this proposal is to begin to establish an EDRN “pre-validation” trial of a multiplex set of transcripts, including the ETS gene fusions, in post-DRE urine sediments.  As can be evidenced by our preliminary data, we have established the utility of this multiplex urine test (which includes TMPRSS-ERG, SPINK1, PCA3 and GOLPH2) in a cohort of prospectively collected urine sediments from the University of Michigan EDRN CEVC site (collected by co-I, Dr. John Wei).  In this proposal, we will run this multiplex assay on prospectively collected post-DRE urines collected from other EDRN sites.  The idea is to couple this “pre-validation” study with an EDRN validation trial under consideration for the Gen-Probe PCA3 urine test (directed by Drs. John Wei and Harry Rittenhouse).  &lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;CD90&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;192&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;192, 200&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;192&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;2&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;To develop multiple reaction monitoring (MRM) proteomics to measure CD90 in urine samples of pre-op(erative) prostate cancer, biopsy negative, post-op, pre-op bladder cancer, and non-cancer. MRM uses triple quadrupole mass spectrometer and synthetic isotopically labeled CD90 signature peptides for detection at the fmol level.&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Genomic (Affymetrix GeneChip) analysis of sorted cancer cells and their normal counterpart (CD26+ prostate cancer vs. CD26+ luminal; CD90+ tumor-associated stromal vs. CD49a+ stromal; CD9+ bladder cancer vs. CD9+ superficial urothelial) to identify up-regulated genes encoding secreted or extracellular proteins.

Proteomic analysis based on mass spectrometry to measure urinary levels of the protein candidates identified. &lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;n/a&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;Since CD90 is expressed by many other cell types (e.g., T cells), its prostate cancer specificity as a urinary marker needs to be rigorously tested. &lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;All high dimensional data (genomics and proteomics)are available for query and download from our NIDDK-sponsored public database UESC, which is also linked to the EDRN site.&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;1, 3&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;CD90/THY1 is overexpressed by tumor-associated stromal cells as scored by immunohistochemistry, RT-PCR analysis of laser-capture microdissected cells. CD90 protein is detected by quantitative glycopeptide-capture proteomics in tissue digestion media preparations, and also by Western blotting. CD90 protein is detected in urine. The goal is to determine if urinary CD90 level can be used to detect cancer.&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;518&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Our first MRM proteomics found differences in CD90 levels among pre-op, biopsy negative, post-op and non-cancer urine samples. The measured amounts ranged from 0.01173 fmol in non-cancer to 1.987284 fmol in pre-op.

Overexpression of CD90 is characteristic of all tumors, including those in the transition zone, and regardless of Gleason grades.&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;N=20-30&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;No specified sample size for this protocol.  Study will use urine specimens.&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Eligible subjects will be patients who have been referred for cystoscopy to evaluate microhematuria, voiding dysfunction or others concerns.
A) Inclusion criteria include:
1. Patient who is schedule to undergo cystoscopy as indicated in the evaluation of a specific urological condition (eg hematuria or voiding dysfunction)
2. Patient who is willing and able to provide a voided urine specimen for the study.
3. Patient who has signed informed consent
a. allowing processing/evaluation of urine for biomarker evaluation including DNA studies
b. allowing access of the research staff to the patient&amp;#39;s medical record e.g. to determine if bladder cancer diagnosed at cystoscopy or thereafter
B. Exclusion criteria include:
1. Patient not willing to sign informed consent
2. Patient unable to provide a voided urine sample
3. Previously treated malignancy
4. Previous recontructive genitourinary surgery (for example prior prostatectomy in men or augmentation cystoplasty in women would confound urinary methylation marker analysis)
5. Previous pelvic irradiation
6. Previous intravesical pharmacotherapy (eg BCG or DMSO)
7. Presence of urinary infection
8. Indwelling urinary catheter or stent

A. Cases are subjects whose cystoscopry or related clinical testing (eg biopsy pathology or urine cytology) indicates presence of transitional cell carcinoma.
B. Controls are subjects who are not found to have urothelial cancer after cystoscopy, biopsy pathology or urine cystology.
C. Participating subjects found to have non-transitional cell carcinoma (eg squamous cell carcinoma or adenocarcinoma) will be evaluated separately for the cases and controls, eg methylation will be studied for descriptive purposes but excluded from case-controls comparison.
&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 71, 86, 87, 88, 111, 119, 121, 125, 136, 187, 203, 510, 587&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;187&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;This study will test the sensitivity of gene methylation in the presence of clinically evident, pathologically confirmed bladder cancer.

This study will test the specificity of gene methylation in two groups of participants without bladder cancer - requiring cystoscopy for hematuria and for foreign body (urinary stones, stents, and catheters) or infection.&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Quantitative real time methylation specific PCR (qMSP) of urine sediment DNA using a panel of several methylated gene markers.&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;The contract laboratory responsible for urine sediment DNA isolation and the investigators performing qMSP will be blinded to all participant urinalysis, cytology, cystoscopic and pathology results to minimize bias.&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;188                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;At the end of the study, each site is responsible for reporting the status of all cases to the DMCC and NCI.&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;May  1 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb  1 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;7&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BLADDER-PRE-VAL&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;To determine sensitivity and specificity of quantitative real-time methylation specific PCR (qMSP) of urine sediment DNA, using a panel of several methylated gene markers, in detecting bladder cancer in participants pathologically confirmed to have this disease.

Secondary objective: to test the sensitivity and specificity of an Aurora A FISH probe for the detection of clinically evident bladder cancer.&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Study never conducted.  Protocol Closed.&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;Study never conducted.  Protocol Closed.&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50 bladder tumor cases; 75 cystoscopy for hematuria controls; 75 cystoscopy for foreign body or infection controls&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;124&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;88, 124&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;124&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;189                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Oct  1 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Mar  1 2004 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Biomarker Discovery for Renal Cell Carcinoma Through Serum, Urine and Tissue Protein Profiles&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Tissue, serum, and urine from 200 patients undergoing partial or radical nephrectomy for renal cell carcinoma&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;188&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;188&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug  1 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Pre-Validation of Metabolomic Biomarkers of Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;n/a&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;234&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;234&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Stage I: A feasibility study – comparing a limited number (5) of available scFv library derived antibodies (in a number of antibody formats such as scFv, Fab and IgG) and commercially available monoclonal antibodies directed at the same cancer-associated antigens on the same slide with appropriate controls.   This will involve identification, development, and production, of 20 monoclonal antibody pairs specific for 5 antigens with subsequent utilization demonstrated in a micro ELISA assay.  The antibody pairs are represented by one detection antibody and 4 capture antibodies derived as affinity matured subclones directed against the same epitope. The capture antibodies will have affinities ranging from 100 nM to 100 pM.

Stage II: Extension of the phase I study to ~50 antigens and controls chosen on the basis of potential as cancer biomarkers.

In this stage PNNL will: (a) train selected EDRN investigators in the use of the microarray platform, and (b) print a large number of microarrays (1500 slides) for analytical and clinical validation studies.&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;                                                                                                    &lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt; &lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep 14 2015 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep 15 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;9&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BRL: PNNL&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The purpose of this project is to develop antibody microarrays incorporating three major improvements compared to previous antibody microarray platforms, and to produce and disseminate these antibody microarray technologies for the Early Detection Research Network (EDRN) and the research community focusing on early detection, and risk assessment of cancer.&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;71&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 71, 74, 201&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;71&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;188                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Mar 31 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Apr  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;100 healthy individuals
100 participants with benign urinary tract pathology
100 participants with cystoscopically and pathologically verified TCC of the bladder
300 participants with a history of non-muscle invasive TCC bladder cancer&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Post-translation modification for nitro-tyrosine and lipid peroxidation adducts on proteins secreted by the breast.&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;233&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;81, 233&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;233&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim 1)  Develop antibody microarray chips that can be used to measure PTMs associated with glycosylation state or nTyr- or HNE-adducts.  This chip will target abundant proteins we have identified in NAF that are also found in the circulation.  

Aim 2)  Evaluate two sets of human plasma samples from women with and without breast cancer using the chips developed in Aim 1.  The first set of samples is from the Clinical Breast Care Program (CBCP, samples collected at Walter Reed Army Medical Center) and contains 80 samples from control women or women with DCIS or stage 1 or 2 breast cancer.  This set of samples will determine if these assays can detect early disease.  The second set of samples will be from Dr. Jeff Marks (Duke University) and will contain 60 samples evenly split between three study groups: control women and women with Her2+/ER- tumor, and women with ER+/Her2- breast cancer.  This set of samples will determine if these assays can detect both early- and late-stage disease as well as differentiate between different subtypes of cancer.
&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;ELISA microarray&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;The samples used for discovery will not be blinded.  Subsequent validation studies will use blinded samples.&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Dec 30 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 30 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Dec 31 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;PTM Microarray&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;We hypothesize that PTMs on proteins that are secreted by the breast will provide a more sensitive method for detecting breast cancer than analysis of the parent protein.  We will antibody microarrays to have examine 9 circulating proteins, each of which is known to be actively secreted by the breast, for several structurally and functionally distinct PTMs.  We will  determine if these modified proteins have the potential to used in the early detection of breast cancer.&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;80 control samples (healthy, DCIS, or women with stage 1 or 2 breast cancer)
20 controls
20 samples from women with Her2+/ER- cancer
20 samples from women with ER+/Her2- cancer&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;167&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;167, 191&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;167&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;157                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Pancreatic Cancer Early Detection Stem Cell Biomarkers&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Autoantibodies&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;232&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;65, 86, 232&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;232&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim 1:  Assess the sensitivity of the current diagnostic assay using some additional informative biomarkers added to the current diagnostic panel.  
Aim 2:  Confirm the validity of this diagnostic strategy for early HNSCC detection based on pattern of serum immunoreactivity against a biomarker panel in collaboration with 2 other EDRN sites.
&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;We are using IgG molecules specific to cancer patients as a bait to clone antigens derived from phage T7 display cDNA libraries of mRNA from tumor tissue that we use as biomarkers for the early detection of cancer. In a sense we are using the immune system as a biosensor. The immune system elaborates antibodies which we detect as they react with the antigens we clone. The antigens are expressed and then robotically spotted on microarrays. The microarrays are treated with sera from other patients and the binding of IgGs in those sera is used to find the most commonly reactive antigens. We print replicates of thousands of antigens on the microarrays and analyze them with a two-color detection system. The patients&amp;#39; IgGs bound to the spotted antigens are detected using a secondary antibody against human IgG labeled with Alexa-647, a red dye. The second color provides a control for each spot. We use a monoclonal antibody to the N-terminal 11 amino acids of phage backbone protein onto which each antigen is cloned as a fusion protein.  That monoclonal antibody is detected with an Alexa-532 (green dye) labeled antibody against murine IgG. The dye ratios provide a control for variations in spotting so as to quantitate the IgG binding to each clone using sera of each patient. We also have a negative control clone that contains no additional amino acids in the cloning vector. The dye ratios on the chips are normalized and those data used in a t-test using sera from patients and healthy controls. Those clones significant in a t-test are used on a validation set of patients and controls not including the previous training samples. The antibody binding data of those subjects in the validation set are tested using machine learning techniques such as neural networks and n-fold cross validation to determine the accuracy of the classifiers.&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;N/A&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;144, 143, 148, 140, 160, 147, 146, 149, 145, 141                                                    &lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;As cDNA clones of diagnostic antigens are identified, they will be published and added to the EDRN website.&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Feb 28 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb 28 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Mar  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;9&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Autoantibody Approach for Serum-Based Detection of Head and Neck Cancer&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Our long term goal is to improve survival of patients with head and neck squamous cell carcinoma (HNSCC) through early detection using simple noninvasive serum assays in an ELISA-like platform.  The objective of this proposal is to improve and confirm the validity of a diagnostic serum assay based on a panel of cancer-specific biomarkers for early cancer detection in patients with HNSCC.  Our central hypothesis is that the detection of antibody responses to HNSCC-specific antigens, using a panel of biomarkers, can provide sufficient sensitivity and specificity suitable for clinical testing in the primary setting to screen and diagnose HNSCC in high risk populations to improve early detection.&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;We have previously demonstrated the feasibility of head and neck cancer detection based on analysis of patterns of serum immunoreactivity against a panel of 130 cancer biomarkers.  The performance of this panel of 130 markers in discriminating cancer from noncancer serum samples was excellent with an accuracy of 84.9%, sensitivity of 79.8% and specificity of 90.1% and represented a significant improvement over current diagnostic accuracy in the primary care setting.  We are currently in the process of improving the accuracy of this current diagnostic panel by incorporating additional biomarkers identified by biopanning against those cancer sera which were most frequently misclassified.  
Diagnostic accuracy of this new diagnostic panel will then be assessed using serum samples from the other 2 EDRN sites.
&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;500 HNSCC patients (250 early and 250 late stage) and 500 control non-cancer patients&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Sera from 500 HNSCC patients (250 early and 250 late stage)
Sera from 500 control patients&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;amphiregulin, CA15-3, CD14, epidermal growth factor (EGF), EGF receptor, E-selectin, basic fibroblast growth factor, heparin-binding EGF, Her2, hepatocyte growth factor, intracellular adhesion molecule, insulin-like growth factor 1, interleukins 1alpha and 18, matrix metalloproteases 1, 2 and 9, platelet-derived growth factor, prostate-selective antigen, RANTES, transforming growth factor alpha, tissue necrosis factor alpha, urokinase plasminogen activator, vascular endothelial growth factor&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;233&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;233&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;233&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim #1.  Identify new candidate biomarkers of breast cancer by using a semi-quantitative proteomic analysis of plasma.  This analysis will employ capillary liquid chromatography (cLC) interfaced with Fourier transform ion cyclotron resonance (FTICR) mass spectrometry (MS), which is an exceptionally sensitive method for measuring peptides.  We are independently developing a database of proteins secreted into nipple aspirate fluid (NAF) from women with or without breast cancer.  This database will allow us to identify proteins in plasma that are produced by the breast, thereby allowing selection of proteins that are more likely to be specific markers for breast disease.  Because some proteins may only be useful for detecting a single breast cancer subtype, we will analyze 20 samples/group from four groups of women: 1) healthy women, 2) women with ductal carcinoma in situ (DCIS; stage 0), 3) early ductal cancer (stages 1+2), and 4) early lobular cancer (stages 1+2).

Aim #2.  Develop an enzyme-linked immunosorbent assay (ELISA) microarray chip that can simultaneously assay ~50 proteins that are potential markers for non-invasive breast cancer.  These proteins will be selected based on the results of Aim #1, guidance from the EDRN Steering Committee, published reports and other defined criteria.  Where possible, commercial antigen and antibody reagents will be used for these analyses.  However, it is anticipated that a major effort will be required for the development and validation of reagents for many of the ELISA assays.  

Aim #3.  Determine whether the quantitative analysis of 25 proteins by ELISA microarray can distinguish between plasma samples from women with or without breast cancer.  A set of 1000 plasma samples, approximately equally divided between women with and without breast cancer, will be obtained from the Army’s CBCP.  This is an exceptionally high-quality set of samples that was collected under well-defined clinical protocols with an extensive set of epidemiological data.  The epidemiological information will be used to evaluate the influence of factors other than breast cancer on individual protein levels, with the goal of accounting for predictable variability in marker levels.  Profile analysis of the potential cancer markers will then be undertaken.  For this analysis, the samples will be evenly split into a “training” set and a “validation” set of samples, with each set having equal numbers of samples from the control and cancer groups.
&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;High mass accuracy LC-MS proteomics and ELISA microarrays.&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Jul 31 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep 30 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct  1 2005 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;High-Throughput Evaluation of Breast Cancer Markers&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The objective of this study is to use a combination of AMT proteomics and ELISA microarray testing to discover and validate novel biomarkers for breast cancer.&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;1289, 1290, 1294, 1292, 1293, 1287, 1288, 848, 849, 1286&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;1000 plasma samples, approximately equally divided between women with and without breast cancer&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;amphiregulin, CA15-3, CD14, epidermal growth factor (EGF), EGF receptor, E-selectin, basic fibroblast growth factor, heparin-binding EGF, Her2, hepatocyte growth factor, intracellular adhesion molecule, insulin-like growth factor 1, interleukins 1&amp;#61537; and 18, matrix metalloproteases 1, 2 and 9, platelet-derived growth factor, prostate-selective antigen, RANTES, transforming growth factor &amp;#61537;, tissue necrosis factor &amp;#61537;, urokinase plasminogen activator, vascular endothelial growth factor&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;233&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;81, 189, 233&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;233&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;To analyze plasma levels of 24 proteins in 60 samples from women with either benign breast disease, or Her+ or ER+ cancers.&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;ELISA microarray&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Dec 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan  1 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Year 2 Collaborative Project - UCSF and Battelle PNWD&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;To evaluate the effects of receptor status on circulating biomarker levels.&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;188&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 75, 83, 92, 188, 203&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;188&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;We propose that the EDRN U of M Biomarker development lab provide detailed protocols for
urine collection to each of the participating EDRN sites. The preserved sediments and whole urine will be sent to the U of M site in a blinded fashion. The U of M EDRN site will then run the multiplex urine test on the urines from each site and provide the coded data to the central EDRN DMCC site for statistical analyses (Dr. Zideng).&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Apr 30 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;May  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;6&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The goal of this EDRN set-asides proposal is to carry out pre-validation studies on
sarcosine as a metabolomic biomarker of prostate cancer in urine. Not only does sarcosine have potential as a marker for the early detection of prostate cancer in post-DRE urine specimens-- but since its highest levels are in metastatic disease it might have utility in predicting aggressiveness of clinically localized disease. We will also use these funds to determine if we can add additional metabolites to sarcosine in
order to develop a multiplex metabolomic biomarker panel in prostate cancer. In addition to sarcosine, we have 10-12 additional candidate metabolomic biomarkers that could be developed (as seen from our preliminary global metabolite studies).&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;86&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;71, 86&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;86&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;188                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jan 31 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb  1 2005 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Molecular Progression of Methylation in Bladder Cancer&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;86&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;86&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;86&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;188, 162                                                                                            &lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group, Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep 29 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep 30 2004 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Integrated Development of Novel Molecular Markers&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Autoantibodies&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;232&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;81, 232, 238&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;232&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;The aims are organized in 4 subgroups: Aims 1-4 will identify the more informative antigen biomarkers for use on our microarrays. Aim 5 will identify the protein sequences in these informative cDNA clones. Aims 6-8 will provide validation on larger serum sample sets. Aims 9-10 will establish a format of the diagnostic suitable for collaboration with other EDRN components.
Aim 1. Employ high throughput antigen cloning and identification of a suitable number of biomarkers to accurately identify invasive breast cancer.
Aim 2. Use machine-learning techniques such as classification trees and neural networks to develop classifiers able to distinguish women with breast cancer from healthy subjects.
Aim 3. Estimate the test characteristics (sensitivity, specificity, accuracy) of the antigen markers for distinguishing sera of breast cancer patients from control sera.
Aim 4. Eliminate those antigen markers that cross-react with patients with nonmalignant breast diseases and autoimmune diseases.
Aim 5. Determine the DNA sequence of the cDNA clones of validated markers.
Aim 6. Validate the markers on larger sample sets. We will use antigen clones to detect serum antibodies in the BCPS serum set. We will perform a secondary analysis of the reaction of antibodies in the patients’ sera to identify whether there are antigen reactions indicative of a high likelihood of recurrence.
Aim 7. Determine the accuracy of the test in sera prospectively derived from women who later developed breast cancer.
Aim 8. Eliminate antigen clones that react with sera from people with other cancers.
Aim 9. Prepare of purified antigen-containing proteins for the penultimate antigen diagnostic array.
Aim 10. Perform internal and external validation tests with EDRN partners.
&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;We are using IgG molecules specific to cancer patients as a bait to clone antigens derived from phage T7 display cDNA libraries of mRNA from tumor tissue that we use as biomarkers for the early detection of cancer. In a sense we are using the immune system as a biosensor. The immune system elaborates antibodies which we detect as they react with the antigens we clone. The antigens are expressed and then robotically spotted on microarrays. The microarrays are treated with sera from other patients and the binding of IgGs in those sera is used to find the most commonly reactive antigens. We print replicates of thousands of antigens on the microarrays and analyze them with a two-color detection system. The patients&amp;#39; IgGs bound to the spotted antigens are detected using a secondary antibody against human IgG labeled with Alexa-647, a red dye. The second color provides a control for each spot. We use a monoclonal antibody to the N-terminal 11 amino acids of phage backbone protein onto which each antigen is cloned as a fusion protein.  That monoclonal antibody is detected with an Alexa-532 (green dye) labeled antibody against murine IgG. The dye ratios provide a control for variations in spotting so as to quantitate the IgG binding to each clone using sera of each patient. We also have a negative control clone that contains no additional amino acids in the cloning vector. The dye ratios on the chips are normalized and those data used in a t-test using sera from patients and healthy controls. Those clones significant in a t-test are used on a validation set of patients and controls not including the previous training samples. The antibody binding data of those subjects in the validation set are tested using machine learning techniques such as neural networks and n-fold cross validation to determine the accuracy of the classifiers.&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;N/A&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;As cDNA clones of diagnostic antigens are identified, they will be published and added to the EDRN website.&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jul 31 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug  2 2005 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;9&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Early Detection of Breast Cancer Using Autoantibody Markers&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;To identify large numbers of antigens that can be used to recognize the presence of cancer by detecting antibodies to tumor proteins in the serum of the test subjects.  Our technology will provide an early detection test for breast cancer in asymptomatic women. We will use bioinformatics techniques to analyze these protein microarray-immunoassays to discriminate between cancer patients and healthy subjects so as to detect disease prior to standard diagnoses as well as discriminate patients with benign conditions or other cancers that might be a false positive in less specific assays.&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;To date, we have devised an approach to cloning biomarkers that focuses on the goal of identifying breast cancer at Stage I. We have applied this approach to early stage breast cancer and have some preliminary data to indicate the technology is feasible. The goal of this application is to apply this technology to develop: 1) an early detection assay for breast cancer in asymptomatic women and           2) a novel prognostic approach for women with early stage breast cancer, a disease from which 25-30% of women will relapse in 5 years post diagnosis.&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;300 breast cancer Stage I/II patients with no recurrence; 200 breast cancer Stage I/II patients with recurrence; 200 late stage breast cancer patients; 200 patients with non-malignant breast disease; 200 patients with autoimmune disease; 400 healthy control serum donors with no history of cancer; 300 other cancers, 30 each from 10 different tumor sites.&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;30 breast cancer Stage I patients with recurrence
30 breast cancer Stage I patients with no recurrence
120 healthy control serum donors with no history of cancer&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Autoantibodies&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;232&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;65, 86, 232&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;232&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;AIM 1:  Eliminate nonspecific antigen biomarkers that cross-react with sera from patients with nonmalignant head and neck diseases, autoimmune diseases and other types of cancers.
AIM 2:  Validate this diagnostic strategy for early HNSCC detection based on pattern of serum immunoreactivity against the biomarker panel.
AIM 3:  Assess the use of this diagnostic strategy for early detection of HNSCC in collaboration with other EDRN and non-EDRN sites.
&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;We are using IgG molecules specific to cancer patients as a bait to clone antigens derived from phage T7 display cDNA libraries of mRNA from tumor tissue that we use as biomarkers for the early detection of cancer. In a sense we are using the immune system as a biosensor. The immune system elaborates antibodies which we detect as they react with the antigens we clone. The antigens are expressed and then robotically spotted on microarrays. The microarrays are treated with sera from other patients and the binding of IgGs in those sera is used to find the most commonly reactive antigens. We print replicates of thousands of antigens on the microarrays and analyze them with a two-color detection system. The patients&amp;#39; IgGs bound to the spotted antigens are detected using a secondary antibody against human IgG labeled with Alexa-647, a red dye. The second color provides a control for each spot. We use a monoclonal antibody to the N-terminal 11 amino acids of phage backbone protein onto which each antigen is cloned as a fusion protein.  That monoclonal antibody is detected with an Alexa-532 (green dye) labeled antibody against murine IgG. The dye ratios provide a control for variations in spotting so as to quantitate the IgG binding to each clone using sera of each patient. We also have a negative control clone that contains no additional amino acids in the cloning vector. The dye ratios on the chips are normalized and those data used in a t-test using sera from patients and healthy controls. Those clones significant in a t-test are used on a validation set of patients and controls not including the previous training samples. The antibody binding data of those subjects in the validation set are tested using machine learning techniques such as neural networks and n-fold cross validation to determine the accuracy of the classifiers.&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;N/A&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;144, 143, 148, 140, 160, 147, 146, 149, 145, 141                                                    &lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;As cDNA clones of diagnostic antigens are identified, they will be published and added to the EDRN website.&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Mar 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Mar 31 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Apr  1 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;9&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Proteomic Approach for Diagnostic Applications in Head and Neck Cancer&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;To evaluate the test characteristics of a panel of biomarkers for identifying patients with early stage head and neck squamous cell carcinoma (HNSCC). The primary endpoints are sensitivity, specificity and accuracy of the marker panel. This study of the test characteristics of a modeling strategy for diagnosing HNSCC uses a case-control design, with several types of cases and several types of controls.&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;We have demonstrated the feasibility of cancer detection based on analysis of patterns of serum immunoreactivity against a panel of cancer biomarkers selected using microarray-based serological profiling and specialized bioinformatics.  Combining phage display technology with protein microarray, we screened 5,133 selectively cloned tumor antigens and ranked them using a feature selection method based on receiver-operator characteristic curves for neural network classifiers.  A model, built using the top-ranked 40 biomarkers, was validated by bootstrapping on an independent set of 80 cancer and 78 control sera.  Estimated accuracy of this modeling strategy was 83% (95% CI 77-88) with sensitivity of 83% (95% CI 74-92) and specificity of 83% (95% CI 75-94).&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;Sera from 200 patients with nonmalignant head and neck diseases; Sera from 200 patients with autoimmune diseases; Sera from 500 HNSCC patients (200 early stage and 300 late stage); Sera from 500 control patients&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Sera from 200 patients with nonmalignant head and neck diseases
Sera from 200 patients with autoimmune diseases
Sera from 300 patients with other types of cancer
Sera from 500 HNSCC patients (200 early stage and 300 late stage)
Sera from 500 control patients&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Prolactin, Leptin, IGF-11, OPN MIF, CA-125&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Ovarian Cancer (350)(Sensitivity Trial) : The disease group includes women having newly diagnosed ovarian cancer (pelvic mass). The study will be done using archived specimens if they meet the specimen collection protocol  The diagnosis of ovarian cancer is done according to clinical, surgical, histological and pathologic diagnosis. The major histology groups (serous [borderline and invasive], mucinous, endometrioid, clear cell, and undifferentiated) will be represented proportional to their incidences.  Preliminary communication with PLCO investigators indicates that the histological distribution seen in PLCO matches ours expected design.  Within each histology, we will oversample early-stage disease where possible, with a goal of one-half early stage and one-half late stage. Control Group (1000)(Specificity Trial) a) Normal: The healthy control group includes age-matched healthy individuals, that come into the clinic for a regular gynecologic examination, who do not have a diagnosis of any type of cancer, or who are not genetically predisposed to develop ovarian cancer.  This group is available from the PLCO and will represent the majority (80%) of the samples evaluated. Similar criteria will be used for samples collected from all the sites.  b) High-Ris (50 samples): degree of risk is determined by formal genetic evaluation and categorized as mild (only one affected first-degree relative or a personal history of breast cancer), moderate (&amp;#8805; 2 affected first degree relatives), or high (BRCA1 or BRCA2 mutation inherited from an affected relative). It is estimated that over 50% of women with BRCA1 mutations that develop ovarian cancer are less than age 50.  Women with a BRCA1 mutation have approximately a 30-40% risk of developing ovarian cancer by age 70. Also included in this group are women with non-gynecologic malignancies, gynecological malignancies other than ovarian, and benign gynecologic conditions(50samples). In addition we will include 50 samples from pati&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 167, 238, 266, 449, 450, 452, 453, 457&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;266&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;2&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim 1. To validate the Yale Early Detection Assay (YEDA) in a Phase II Validation Trial consisting of a case control study for patients with ovarian cancer.
Aim 2. To determine whether the Luminex platform and the inclusion of three additional markers will increase the sensitivity and specificity of the test.
&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;The concentration of the four markers will be measured in the serum using a sandwich ELISA.  For the Phase II validation study all the tests will be performed by LabCorp, which has completed the process of validation and standardization of the four analytes.  The Luminex platform will be evaluated at Yale. The specimen will be blinded to all labs on disease status. The blinded labels will be provided by EDRN/DMCC. The assay data will be sent to EDRN/DMCC.     &lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;yes&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;183                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;follow NCI guidelnes&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Jun 11 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Nov  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;May  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Ovarian Validation Study - Mor&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;While all cancer patients could potentially benefit from earlier detection and prevention, the development of new screening technologies and chemoprevention for epithelial ovarian cancer (EOC) is unique in this regard. EOC is characterized by few early symptoms, presentation at an advanced stage, and poor survival. Presently there is no commercially available test that is diagnostic for either early or advanced stage epithelial ovarian cancer. The most commonly used marker, CA125, identifies a group of cell surface glycoproteins, which have uncertain biological behavior and very limited clinical utility for the detection of early stage disease. In recent years, several approaches have been used in order to develop a test for early detection, including the analysis of serum samples by SELDI-TOF and MALDI-TOF to find proteins or protein fragments of unknown identity that detect the presence/absence of cancer. Unfortunately, at the present time, none of these techniques have been shown to be adequate. Therefore, the development of a test that can detect early stages of the disease could dramatically improve treatment success and long-term survival. We have developed a new blood test based on a different approach:  1) we used known proteins related to cancer biology, 2) we characterized these proteins with several different screening steps using samples obtained from both healthy and cancer patient populations, and 3) validated the results with different techniques. 
Using split point analysis with four markers, 96 out of 100 EOC patients (96%) were correctly diagnosed with ovarian cancer (including 23 of 24 patients with Stage I/II EOC).  In the healthy group, 6 out of 106 individuals were diagnosed incorrectly (5.6%).  Working in collaboration with the Early Detection Network (EDRN/NCI/NIH), we performed Phase I discovery study confirming the potential application of this test for early detection of ovarian cancer (Preliminary results).
The main objective of this prop&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;1613&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Sera from 500 participants with confirmed ovarian cancer
Sera from 200 normal, healthy participants
Sera from 200 participants with benign disease or who are high risk&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80, 193&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153, 154                                                                                            &lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Light Scattering Spectroscopy for the Detection of Colorectal Neoplasia&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;500 training set specimens, 750 test set speciments from patients deemed to be “average risk” who are undergoing colonoscopy for colorectal cancer (CRC) screening or symptomatic indications.&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;448&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;448&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;448&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Prostate-Specific Glycoproteins for Early Detection of Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;A pooled serum sample from at least 20 individuals that are biopsy-positive and a pooled serum sample from at least 20 patients that are biopsy-negative.&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;162&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;162&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;162&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Oct 21 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb  6 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct  6 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Colon Cancer Specimen Reference Set Application: Jendoubi - Milagen (2006)&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;No Data Received at DMCC&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;See description for Colon Cancer Reference set&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;283&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;283&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;283&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb  6 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct  6 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Colon Cancer Specimen Reference Set Application: Kim - DiaDexus (2008)&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;see description of colon cancer reference set&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Topo2, Cathepsin D, Cyclin B, CEA, IGFBP2, NY-ESO-1, Her-2/neu, p53&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;454&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see description of colon cancer reference set&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 454&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;454&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;To validate the diagnostic value of a panel of serum antibodies (cathepsin D, p53, cyclin B1, topoisomerase IIalpha, IGFBP2, CEA) for the early detection of colorectal cancer.&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;We will run ELISA blinded to case status, data along with our prediction of disease status for each sample, will be sent to EDRN-DMCC at Fred Hutchinson Cancer Research Center for statistical analysis. DMCC already has the combination role from our preliminary study. Our preliminary data suggested that at high specificity 90%, sensitivity is 57%. With n=50 in each group, we have more than 80% power to confirm this level of sensitivity against an inferior sensitivity of 37% at 90% specificity comparing CRC versus normal controls. We understand that the reference set is not powered for definitive validation but to help prioritization. We did not have the data on patients with adenoma but the performance on early-stage CRC suggests that it is possible our marker panel could detection early lesions like adenoma,&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;Goodell V, Lu H, Delong J, Disis ML.  Antibody Immunity to a Panel of Oncogenic Proteins May Predict Presence of Colorectal Cancer and Stage of Disease.  Manuscript in preparation.&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Follow guidelines set by NCI&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Aug 28 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb  6 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct  6 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Colon Cancer Specimen Reference Set Application: Disis - University of Washington (2008)&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The proposed study aims to validate the diagnostic value of a panel of serum antibodies for the early detection of colorectal cancer (CRC). We have developed a serum antibody based assay that shows promise in discriminating sera from CRC patients from healthy donors. We have evaluated two separate sample sets of sera that were available either commercially or were comprised of left over samples from previous studies by our group. Both sample sets showed concordance in discriminatory power. We have not been able to identify investigators with a larger, well defined sample set of early stage colon cancer sera and request assistance from the EDRN in obtaining such samples to help assess the potential diagnostic value of our autoantibody panel&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;1. Assess the Classification Error of their prediction: 

The data set they used for prediction of case/control contains 130 subjects and 30 of them are cases. According to their predicted probability, we classify a subject as a case if his/her predicted risk &amp;#8805; 0.5 and a control vice versa. 

Classification Error= # of false prediction / total # of subjects=0.12.

2. When assessing individual marker’s performance, among 6 tumor markers, only catD showed some potential of discriminating cancers from polyps, and cancer from controls. None of the rest seems to be good. 

3. When using their algorithm (2 methods), the single score calculated based on the Ag weights is significant at discriminating polyps from cancers and polyps from control (but in the reverse direction with polyps has lower score than controls).

4. We also did logistic regression with all 6 tumor markers. The risk models are doing well in terms of classification accuracy (cancer vs. control, polyps vs. control, and polyps vs. cancer). But after correcting for model Overfitting, none of them is significant. 

The results are not as promising as that observed in your preliminary study but catD and p53 do identify a small subset of patients with high specificity. However this set is quite small, about 20-30% of cancer cases. Your prediction model picked about a bit more than 50% of cancers with about 70-76% specificity (see the tables in the file if we combined polyps and controls as non-cancer controls to calculate specificity). Your markers seem to be cancer specific and are not related to polyps.  The marker panel is still premature for a large validation study. catD and p53 definitely are elevated for some cancer cases but their sensitivites are not high enough&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;1. Assess the Classification Error of their prediction: 

The data set they used for prediction of case/control contains 130 subjects and 30 of them are cases. According to their predicted probability, we classify a subject as a case if his/her predicted risk &amp;#8805; 0.5 and a control vice versa. 

Classification Error= # of false prediction / total # of subjects=0.12.

2. When assessing individual marker’s performance, among 6 tumor markers, only catD showed some potential of discriminating cancers from polyps, and cancer from controls. None of the rest seems to be good. 

3. When using their algorithm (2 methods), the single score calculated based on the Ag weights is significant at discriminating polyps from cancers and polyps from control (but in the reverse direction with polyps has lower score than controls).

4. We also did logistic regression with all 6 tumor markers. The risk models are doing well in terms of classification accuracy (cancer vs. control, polyps vs. control, and polyps vs. cancer). But after correcting for model Overfitting, none of them is significant. 

The results are not as promising as that observed in your preliminary study but catD and p53 do identify a small subset of patients with high specificity. However this set is quite small, about 20-30% of cancer cases. Your prediction model picked about a bit more than 50% of cancers with about 70-76% specificity (see the tables in the file if we combined polyps and controls as non-cancer controls to calculate specificity). Your markers seem to be cancer specific and are not related to polyps. The marker panel is still premature for a large validation study. catD and p53 definitely are elevated for some cancer cases but their sensitivites are not high enough&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;see description of colon cancer reference set.&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Serum from 50 participants with colon adenocarcinoma; 50 with colonic adenomas; and 50 with an endoscopically normal colon.&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;CCSA-3, CCSA-4,&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;455&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See summary of Colon Reference Set&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;455&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;455&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim 1:  Characterize the distribution of  CCSA-3 and CCSA-4 values in a blinded set of serum samples obtained from patients with colorectal adenocarcinoma, colorectal adenomas, , hyperplastic polyps, inflammatory bowel disease and normal colons.

Aim 2: Estimate the ROC curves for discrimination between:  patients with colorectal cancer versus others; colorectal cancer or adenoma versus others; colorectal cancer, adenoma, or hyperplastic polyps versus IBD; colorectal cancer, adenoma, or hyperplastic polyps versus IBD or normal. 
&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;1.1&amp;nbsp;&amp;nbsp;&amp;nbsp;Characterize the distribution of CCSA-3 and CCSA-4 values in a blinded set of serum samples obtained from patients with colorectal adenocarcinoma, colorectal adenomas, hyperplastic polyps, inflammatory bowel disease and normal colons.  Both CCSA-3 and CCSA-4 are reported as concentrations on continuous scales.  Graphical displays and descriptive statistics will be presented by disease category.  If the graphical displays indicate the with-population distributions are significantly, non-Gaussian, the values will be appropriately transformed.  Analysis of variance will be used to test the null hypothesis (at a 5% significance level) that the means of the populations are equal.

1.2&amp;nbsp;&amp;nbsp;&amp;nbsp;Estimate the sensitivity and specificity for discrimination between:  1) patients with colorectal cancer versus adenoma, hyperplastic polyps or IBD; 2) colorectal cancer or adenoma versus hyperplastic polyps or IBD; 3) colorectal cancer, adenoma, or hyperplastic polyps versus IBD; 4) colorectal cancer, adenoma, or hyperplastic polyps versus IBD or normal.  For each of the four tests, the sensitivity and specificity will be estimated assuming prevalence of 0.50 and equal false negative and false positive costs.  The null hypotheses that sensitivity &amp;#060; 0.75 and specificity &amp;#060; 0.75 will be tested using a one-side exact binomial test at a 5% significance level; rejection of the null hypotheses constitutes an argument for advancing the markers to a full validation study.

1.3&amp;nbsp;&amp;nbsp;&amp;nbsp;Empirical ROC curves will be plotted for Tests 1-4.  Optimal sensitivity and specificity will be estimated depending on assumptions about prevalence and the costs of false positives and negatives.  Tests 1, 2 and 3 are of particular interest for clinical management, while Test 4 is more relevant for population screening.

&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Follow guidelines set in place by NCI&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Feb 25 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb  6 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct  6 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Colon Cancer Specimen Reference Set Application: Getzenberg - Johns Hopkins (2008)&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The goal of this project is to confirm the early validation of CCSA-3 and CCSA-4 as biomarkers for the early detection of adenocarcinoma of the colon and rectum.  &lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;Serum samples from 60 subjects with colorectal adenocarcinoma, 60 subjects with colorectal adenomas, 60 subjects with hyperplastic polyps, 30 subjects with inflammatory bowel conditions and 60 subjects with endoscopically normal colons &lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Serum samples from 60 participants with colorectal adenocarcinoma, 60 with colorectal adenomas, 60 with hyperplastic polyps, 30 with inflammatory bowel conditions, and 60 with endoscopically normal colons.&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 67, 87&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;67&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Two prospective studies were used to collect samples to make this
reference set. GLNE 001, (Preliminary Clinical Characterization of Serum, Plasma, and
Urine Biomarkers for Colorectal Neoplasms) was a prospective, cross-sectional clinical
trial to collect serum, plasma, urine, and common data elements on subjects undergoing
routine screening colonoscopy or subjects undergoing surgery or endoscopy for colon
cancer. GLNE 007 (Evaluation of Stool Based Markers for the Early Detection of
Colorectal Cancers and Adenomas) is an on-going prospective, cross-sectional clinical to
collect serum, plasma, urine, stool, and common data elements. In both protocols,
subjects were undergoing routine colonoscopy (or being seen in surgery clinic for
colorectal cancer) when the samples were collected. Samples were collected while the
target lesions were still in place in the colon. Subjects were either normal (without
adenomas or cancer), with pathologically confirmed adenomas or pathologically
confirmed colorectal adenocarcinoma. Exclusion criteria for both protocols included
known hepatitis C or HIV, ulcerative colitis, Crohns’s Disease or IBD, history of cancer
within 3 years, or genetic colon diseases including FAP or HNPCC. Samples were
collected from 4 sites around North America.&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;recipients of the specimens will sign a data sharing agreement&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Jun  4 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb  1 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;COLON CANCER REF&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The Early Detection Research Network, Great Lakes-New England Clinical,
Epidemiological and Validation Center (GLNE CVC) announces the availability of
serum, plasma and urine samples for the early detection for colon cancer and validation
studies.&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;The reference set consists of replicate aliquots from 50 subjects with colorectal
adenocarcinoma, 50 subjects with adenomas confirmed by pathology, and 50 subject with
normal colons after colonoscopy. Normals selected for the reference set did not have
polyps of any kind found on colonoscopy.&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Serum from 50 normal, 50 adenoma, and 50 CRC.
Plasma from 50 normal, 50 adenoma, and 50 CRC.
Urine from 50 normal, 50 adenoma, and 50 CRC.&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;70, 190, 230&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;70&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;183                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Jun 30 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Antibodies Against Tumor Antigens or Mucin Epitopes in Ovarian Cancer&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;60 cases, 60 controls + 50 (pre-op cases), 200 controls&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;83&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 75, 83, 200, 446&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;83&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Development and Clinical Validation of Biomarkers for Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;200&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 67, 200&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;200&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153, 154                                                                                            &lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;May 31 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jun  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;75, 80&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;80&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153, 154                                                                                            &lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Prognostic Markers in Lynch Syndrome Colorectal Cancers&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;74&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 71, 74, 86, 88, 187, 203&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;74&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;1                                                                                                   &lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;A Methylation Panel for Bladder Cancer&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;68&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;68, 81, 89, 158, 234&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;68&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;4, 12, 16                                                                                           &lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research, Lung and Upper Aerodigestive Cancers Research Group, Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Aug 31 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;The Early Detection Research Network: Biomarker Reference Laboratories&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;GP73, AFP, SCCA, SCCA-IC, AFP-IC and PIVKA-II&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 509&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;509&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;To evaluate biomarker performanceof SCCA, SCCA-IC, AFP-IC and PIVKA-II versus AFP  in an out-side cohort of LC and HCC patients. Our hypothesis is that the performance of the investigated biomarkers is affected by the accuracy of patient criteria inclusion, and  potential inaccuracy of serum storage. Therefore, the study  we have already reported in the literature is not yet clear cut and conclusive, nevertheless, the data seem promising to be further investigated. Our goals is to clinically validate proposed biomarkers in an external sample population, with more stringent criteria of selection and of data analysis.
The performance of each marker will be evaluate through a ROC (Receiving Operating Charachteristic) analysis determining the area under the ROC curve, sensitivity and specificity. A multivariate logistic model will be also carried out to evaluate the performance of combination of marker.
&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;So far the general attitude to investigating a biomarker has been to search for an ideal molecule with a high specificity and sensitivity. However, the reality has been very different and all the investigators have taken this as a negative result of the potential biomarker investigated. Nevertheless, there is growing evidence that HCC is a very heterogeneous type of cancer, in terms of epidemiology, etiology and clinical outcome. Therefore, we hypothesise that several biomarkers need to be investigated in order to properly address these differences. This hypothesis is based on a number of findings: 
1) in different studies there was a high variability in terms of sensitivity and specificity of the biomarkers investigated, even in the case of AFP. 
2) Other biomarkers such as DCP have been proposed by oriental authors, but poorly accepted in the west.
3) Some biomarkers may predict a particular clinical outcome of HCC, as in the case of DCP associated with vascular invasion.
4) Recently, we have reported that SCCA significantly improves the diagnostic accuracy of AFP, but only in viral-related disease. Some new data recently submitted show that in alcohol-related non virus related disease, SCCA does not play any role, while DCP has a better performance.
5) Recently, it has been suggested that tissue expression of SCCA represents an early event in the onset of HCC, being more expressed in dysplastic compared to regenerative nodules.
6) Consistently with these data, our preliminary data recently submitted, show that SCCA is more strongly expressed in smaller than in larger HCC nodules.

&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All samples were blinded as collected through the DCP validation study&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Follow the guidelines on the application for receiving the set&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Oct 12 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 13 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct 13 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Liver Reference Set (Rapid) Giannelli&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt; To evaluate biomarker performance in an out-side cohort of LC and HCC patients &lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;50 HCC Liver Cancer Cases and 50 Cirrhotic Controls&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50 liver cancers and 50 cirrhotic controls&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;PCA3&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion
&amp;#149;   Males greater than or equal to age 18
&amp;#149;   Patient scheduled for prostate biopsy for any of the following reasons:
o   PSA &amp;#062;2.0 ng/ml
o   Elevated PSA velocity (&amp;#062;0.4 ng/ml/yr)
o   Lower PSA value with other risk factors for PCa (e.g.; family history)
o   Prior ASAP or HGPIN
o   Abnormal DRE
o   % free PSA &amp;#060;15%
&amp;#149;   Finasteride/dutasteride and other medications for BPH and ED are allowable but will be recorded 
Exclusion
&amp;#149;   History of PCa
&amp;#149;   Urine not collected post DRE prior to index prostate biopsy
o   Blood can be collected up to 1 month before urine
o   Urine can be collected up to 1 month before index biopsy
&amp;#149;   Index prostate biopsy with &amp;#060;10 cores and without extended template
&amp;#149;   Index prostate biopsy pathology report unavailable
&amp;#149;   Participating in an intervention trial for prostate disease
&amp;#149;   Prior surgical (open or endoscopic) or minimally invasive treatment (TUNA/TUMT) for BPH
&amp;#149;   Prior saturation biopsy defined as at least 30 cores
&amp;#149;   Prior prostate biopsy within 6 months
&amp;#149;   Prior PCA3 test performed for clinical purpose
&amp;#149;   Consented more than 3 months before index biopsy
&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 83, 87, 88, 125, 131, 142, 200, 203, 491, 510, 525, 526, 527, 528, 529, 546&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;510&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Primary Specific Aims

Aim 1:   To evaluate the PPV of PCA3 for initial biopsy population and NPV of PCA3 for repeat biopsy population in a multi-center prostate biopsy cohort of men without prior history of prostate cancer

Aim 2:   To develop a novel urinary reference set consisting of whole urine /urine sediment as well as plasma/serum necessary for future pre-validation studies of urinary biomarkers.

Secondary Aims

Aim 1:   To evaluate the sensitivity, specificity, PPV, NPV, and absolute risk prediction by PCA3 alone and multiplexed with other biomarkers and clinical variables in the detection of prostate cancer overall, and in the detection of high grade cancer

Aim 2:   To evaluate the correlation between PCA3 and prostate biopsy tumor grade

&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;PCA3 testing of processed urine specimens will take place at John Hopkins University (Dr Sokoll) and Gen-Probe (Dr. Groskopf) (see Appendix 5). Testing will be performed and analyzed according to the method described by Groskopf(8). The Hopkins EDRN Biomarker Reference Laboratory will assay 100% of the samples and the Gen-Probe laboratory will assay 10% as quality control.  

Processed urine specimens will be tested in duplicate at both laboratories with the PCA3 Assay on the Gen-Probe Systems. The calibration curve will be tested in triplicate and the controls will be tested in duplicate. The mRNA results for PCA3 and PSA for each subject must be generated from the same processed urine specimen tube.
&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All samples are blinded by the DMCC&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Upon publication analysis will be shared&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Mar 31 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jan 15 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan 16 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;PCA3&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Independent of serum PSA level, PCA3 score will refine the risk of having cancer detected on an extended template prostate biopsy.&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;850 men having initial or repeat biopsy&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See Lung Reference Set A&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 239, 515&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;515&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim 1. To pre-validate assay performance in a high-risk clinical population from an alternate demographic. We intend to validate the predictive accuracy of our markers for clinically diagnosed lung cancer, identify the limits of the assay in individuals with benign lung disease, and determine marker specificity for lung vs. other cancers. Pre-validation will define performance in samples from an alternate demographic and generate classifiers with which to construct optimalperformance criteria that can be applied to class prediction for subsequent blinded analysis of a larger EDRN clinical reference set.&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Samples were blinded at NCI-Frederick&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Lab Data will be analyzed by the DMCC and shared according the LCBG/NCI guidelines&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Mar 25 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Mar 26 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Lung Cancer Specimen Reference Set A (Full) Application:  Hirschowitz - University of Kentucky (2009&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;We are continuing validation with two advanced objectives: 1) To evaluate assay performance for established lung cancer diagnosed in a clinical population 2) to confirm results that indicate this marker set may detect cancer and predict the onset of NSCLC prior to radiographic detection in a screened population.&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;150 cases and 150 high risk controls w/lesions - Lung Set A pre-validation&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;KLK8, 11, 12, 13, and 14 &lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See Lung Reference Set A&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 68, 87, 158, 239&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;68&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim 1. We will coordinate with the Lung Cancer Biomarker Committee to obtain aliquots of serum reference set A (i.e., Phase II validation set: 180 cases and 180 controls, 75 other cancer controls). The characteristics of these sample sets have been described on the EDRN website.
Aim 2. Two independent sites (UCLA and University of Toronto) will conduct ELISA tests on blinded serum samples for KLK8, 11, 12, 13, and 14. These assays have been well described previously, so we anticipate no technical hurdles. All samples will be run in duplicate. 
Aim 3. Data will be analyzed by the DMCC for both single KLK expression as well as for the entire panel (KLK8, 11, 12, 13, and 14) as previously described (1). 
&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Briefly, the nonparametric Kruskal-Wallis test will be used to examine the relationship between KLK levels, pathology, and clinical information. To evaluate the KLK for disease screening and diagnosis, the classification accuracy will be assessed using receiver operating characteristic (ROC) curves. The ROC curve will plot the true positive fraction (TPF) versus the false positive fraction (FPF) for the set of rules that classify a subject as “test-positive” i.e., if the marker value exceeds a threshold value, where threshold varies over all possible values. It quantifies how well a marker discriminates between diseased and non-diseased individuals. We will perform the ROC analysis first on individual KLK and then in combination. We will use an algorithm that renders a single composite score using the linear predictor, fitted from a binary regression model. A stepwise regression procedure will be used to select markers in the panel with or without additional clinical variables.&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Samples were blinded at NCI-Frederick&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Lab Data will be sent to DMCC, analyzed and shared according to LCBG/NCI guidelines.&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Mar 25 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Mar 25 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Mar 26 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Lung Cancer Specimen Reference Set A (Full) Application:  Goodglick/Diamandis (2009)&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;To study of the utility of KLK8, 11, 12, 13, and 14 profiles in diagnosing lung cancer.&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;180 cases, 180 high risk controls with lesions and 75 other cancer controls&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 88, 142, 420, 424, 426, 428, 429, 446&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;429&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Follow EDRN guidelines&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Mar 23 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb 24 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Canary TMA&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;This study will retrospectively sample tissue from patients who have undergone
radical prostatectomy at the participating institutions. Each site will construct a
set of “validation” TMAs containing tissue from a total of 105 cases of recurrent
prostate cancer and 105 cases of non-recurrent prostate cancer. If resources
allow, sites will construct a second set of “discovery” TMAs containing tissue
from an additional 105 cases of recurrent prostate cancer and 105 cases of nonrecurrent
prostate cancer.&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;EGFR, KRAS, CpG, TITF1 &lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Ever smokers: person who has smoked &amp;#062;100 cigarettes during lifetime; Never Smokers: person who has smoked less than 100 cigarettes during lifetime; Current Smokers: person currently smoking who has quit for &amp;#062; one year; former smokers: smoker who has quit smoking for &amp;#062; one year; long-term former smokers: smoker who has quit smoking for &amp;#062; 10 years;
light smokers: smoker with total exposure of &amp;#062; 10 years.&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 74, 86, 87, 151, 420, 516, 517, 518, 519&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;74&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Specific aim 1: Identify biomarkers of potential use for early detection/risk assessment of lung cancers arising in never smokers.  Multiple platforms will be utilized by a team of highly experienced and competent investigators to compare and contrast the global and individual genetic alterations in lung cancers arising in current, former and never smokers. Appropriate samples or reagents from a set of already collected tumor and paired adjacent non-malignant lung tissues (or blood plasma) will be distributed to the investigators (Drs. Hanash, Gazdar, Lam and Sidransky). About 30 sets of samples from each group will be utilized.  Platforms to be studied will include serum proteomics (Hanash), global messenger gene expression (Gazdar), mutations and copy number analyses for a selected set of genes (Gazdar), global copy number alterations using both SNP and aCGH platforms (Lam) and mitochondrial mutations (Sidransky). Data will be collected and analyzed at the DMCC (Mark Thornquist) and at the Vancouver site (Wan Lam) which has developed software for integration and analysis of cross-platform data. Specific aim 2: Confirmation studies on biomarkers identified in Specific Aim 1. Promising markers identified in Specific Aim 1 will be verified in preclinical studies by other platforms such as FISH and immunostaining using tissue and cell line microarrays, Western blots and qPCR gene expression studies, functional assays etc. After completion of the phase one of the validation process, phase two studies will be initiated. Specific aim 3: Perform phase three validation studies. Markers identified by the DMCC as showing promise after completion of phase 2 studies will be proposed as candidates for EDRN supported phase 3 validation studies.&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;FISH, qPCR, mass spectrometry, gene expression, ACGH, SNPS, methylation, microRNA&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All specimens are blinded at the DMCC.&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Make data available for all EDRN investigators. After publication, make data publicly available to scientific community.&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep 15 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep 15 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;1, 3&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Canary Never Smokers&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The overall goal of this project is to identify, verify and apply biomarkers for the early diagnosis or risk assessment of lung cancer in never smokers. The first year will be regarded as a year of discovery. After successful demonstration of the feasibility of the approach for novel marker discovery, funding will be applied for to perform confirmation and preclinical studies on
the biomarkers and validation studies (specific aims 2 and 3, to be performed in years two and three). Year two can be regarded as the year of confirmation and year three as the year of validation. &lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;28 lifetime never smokers cases; 30 former smokers cases, 30 heavy current smokers cases, 30 smoker controls, 30 never smokers controls&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;KLKs 5,6,7,8,10,11&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see description of Cancer in Women Reference Set&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 158&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;158&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Determine sensitivity and specificity of a panel of kallikreins for early ovarian cancer diagnosis&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;ELISA assays&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;samples were blinded&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;183                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;An oral presentation by Dan Cramer was given at the 2009 AACR annual  meeting&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Follow the application guidelines for data sharing&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Dec 12 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Apr  1 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Apr  2 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BRSCW Applicant: Diamandis (2006)&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Examine kallikreins as ovarian cancer biomarkers&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;One KLK,(KLK6) ranked 6th among all tested biomarkers(approx.50)&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;One KLK,(KLK6) ranked 6th among all tested biomarkers(approx.50)&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;see description of Cancer in Women Reference Set&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;see &amp;quot;cancer in women&amp;#39; reference set description&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;PSA, free PSA, [-2]proPSA, BPSA and testosterone&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;At least a 10 core biopsy with blood collected prior and serum stored at -70C for up to six years prior to analysis.&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 200&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;200&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Specimens were analyzed in a blinded fashion at Beckman Coulter, Inc. on the Beckman Coulter ACCESS 2 immunoassay system for PSA, free PSA, [-2]proPSA, BPSA and testosterone.  The PSA assays are all dual monoclonoal sandwich assays using Hybritech antibodies and chemiluminescent detection system.  The assays for PSA, free PSA and testosterone are commercially available which the assays for [-2]proPSA and BPSA are for research use only.&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;yes&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;follow NCI guidelines&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Sep 15 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb  1 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb  1 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Prostate Rapid Reference Set: Chan/Beckman (2007)&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Evaluate performance of [-2]proPSA as an early detection marker for prostate cancer&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;1360&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;There was no difference in total PSA concentrations (non-cancer: 6.80+/-5.20 ng/mL, cancer: 6.94=/-5.12 ng/mL) between the groups.  Overall %[-2]proPSA had the greatest area under the curve (AUC=0.69) followed by %fPSA (AUC=0.61).  For %[-2]proPSA, maximal sensitivity was 60% and specificity was 70%.  A logistic regression model combining PSA, BPSA, %fPSA, %[-2]proPSA, %[-2]proPSA/BPSA, and tesosterone had an AUC of 0.73.  In the 2-10ng/mL PSA range %[-2]proPSA and the model had the largest AUC (0.73).  The AUC for %fPSA was 0.53. Specificities for %[-2]proPSA, the logistic regression model and %fPSA at 90% sensitivity were 41%, 32% and 18% and at 95% sensitivity were 31%, 26% and 16% respectively.&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;There was no difference in total PSA concentrations (non-cancer: 6.80+/-5.20 ng/mL, cancer: 6.94=/-5.12 ng/mL) between the groups.  Overall %[-2]proPSA had the greatest area under the curve (AUC=0.69) followed by %fPSA (AUC=0.61).  For %[-2]proPSA, maximal sensitivity was 60% and specificity was 70%.  A logistic regression model combining PSA, BPSA, %fPSA, %[-2]proPSA, %[-2]proPSA/BPSA, and tesosterone had an AUC of 0.73.  In the 2-10ng/mL PSA range %[-2]proPSA and the model had the largest AUC (0.73).  The AUC for %fPSA was 0.53. Specificities for %[-2]proPSA, the logistic regression model and %fPSA at 90% sensitivity were 41%, 32% and 18% and at 95% sensitivity were 31%, 26% and 16% respectively.&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;123 men without a prior biopsy or prostate cancer history.  51% cases and 49% controls.&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50/50&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Sample Eligibility defined in DCP Protocol&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 66, 87&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;66&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;For data analysis, Receiver Operating Curves (ROC) should be generated for the Gp73 and fucosylated kininogen either alone and in combination with AFP, AFP-L3 and DCP and the area under the curve determined (AUROC). No training sets will be required. Markers will be directly compared by their AUROC values and ranked accordingly.  The following will be criteria for advancement of a biomarker status and further testing: Statistically significant with alpha = 10% AUROC improvement in the distinction of cirrhosis from HCC with the addition of marker(s) to AFP alone for the full set of samples OR in defined subsets, e.g. AFP negatives, early tumor stage.  The ultimate target is to find a combination of markers that will improve on current AFP-alone sensitivity and specificity, such that we will be able to achieve &amp;#062; 90% sensitivity and &amp;#062; 85% specificity for the distinction of cirrhosis from HCC.  &lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All samples were blinded as part of the DCP protocol and then blinded during the sub-aliquot process at CLASS Lab&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;According to EDRN guidelines data will be shared through public portal.&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Mar 16 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Mar 17 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Apr 15 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Liver Reference Set: Block (2008) (Rapid)&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The goal of this application is to determine if the levels of serum GP73 and fucosylated kininogen/acute phase proteins can be used to detect hepatocellular carcinoma (HCC) in the background of liver cirrhosis.  The use of the validation set would allow us to directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;50 HCC/50 Cirrhosis Controls&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50 Liver Cancer and 50 Cirrhosis Controls&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;TSP-1&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Refer to reference set description&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 161&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;161&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;To evaluate TSP-1 as a marker to specifically detect prostate cancer using anitbody microarray technology&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Antibody microarray&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;yes&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;share according to EDRN guidelines&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Aug 25 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb  7 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb  1 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Prostate Rapid Ref Set: Haab (2006)&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;To evaluate TSP-1 as a marker to specifically detect prostate cancer&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;No differences were detected between cases and controls, and therefore the marker was not validated&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;No differences were detected between cases and controls, and therefore the marker was not validated&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;see reference set description&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50/50&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;hK2, hK4 and hK11&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 158&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;158&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Jun  1 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb  7 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb  1 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Prostate Rapid Ref Set: Diamandis (2006)&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50/50&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;TgII, SCC, HSP 70, IGFBP-1,2, GH, sICAM-1, MMP-9, MPO, tPAI-1, CA72-4, CA15-3, EGFR, Osteopontin (OPN), Endostatin (RNDO), Thrombospondin (THBS), Angiostatin (ANGIO), Apolipoproteins (Apo) A1, A2, B, E), Resistin, and PAI-1&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see BRSCW protocol&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 167&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;167&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;1.   Validation of ovarian cancer biomarkers (pre- and post-menopausal women)
2.   Validation of breast cancer biomarkers
&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Luminex&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Samples were blinded&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Follow NCI Guidelines&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Mar 13 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Mar 13 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Mar 14 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BRSCW Applicant: Lokshin (2008)&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Validate biomarkers identified using Luminex bead-based arrays in case/control sets (individual samples) in reference sets&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Overall, differences observed in the pooled references sets paralleled differences observed in appropriate individual case/control sets.&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;Overall, differences observed in the pooled references sets paralleled differences observed in appropriate individual case/control sets.&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;see BRSCW protocol&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;see &amp;quot;cancer in women&amp;#39; reference set description&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 332&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;332&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Feb 20 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 20 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Dec 21 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BRSCW Applicant: Mathew (Meso Scale) (2006)&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;see &amp;quot;cancer in women&amp;#39; reference set description&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;                                                                                                    &lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt; &lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Nov 14 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;MALDI Dilution Data&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Other specify&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 522&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;522&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Oct  9 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Oct  9 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct 10 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BRSCW Applicant: Wilson (EIC Lab)  (2007)&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;see &amp;quot;cancer in women&amp;#39; reference set description&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 455&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;455&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;eCAS through EKE&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Jun  1 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb  1 2007 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb  1 2006 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Convenience&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Prostate Rapid Reference Set: Getzenberg (2006)&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Analyze marker EPCA2 on 123 observations (60 prostate cancers and 63 non-prostate cancers)&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50/50&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Osteopontin, Mesothelin, Periostin, Endoglin, intestinal Fatty Acid Binding Protein, and FAS-Ligand&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see BRSCW description&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 538&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;538&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Several of the proprietary markers were discovered in collaborator programs employing novel discovery platforms. These methods include differential proteomics and differential gene expression measurements in ovarian cancer and normal tissue samples.  At Biosite, novel high throughput technologies are used to raise antibodies against the markers and to develop immunoassays for application in serum and plasma samples. We have preliminary data on our markers from measurements made in individual serum samples from 72 ovarian cancer patients and 37 normal healthy controls.  The ROC AUC numbers exceed 0.70 for five proprietary markers for both serous and non-serous ovarian cancer samples. The ROC AUC numbers exceed 0.75 for two proprietary markers for serous ovarian cancer samples. The ROC AUC numbers exceed 0.75 for four proprietary markers for non-serous ovarian cancer samples. These proprietary markers outperform Osteopontin and Mesothelin with respect to discrimination between ovarian cancer and normal samples.   Additional sample sets are required for further verification of the clinical utility of these proprietary markers and how they perform against the current benchmarks in the field of ovarian cancer diagnosis.&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Antibody libraries for markers are generated from immunized mice and enriched for high affinity and specificity using phage display methods. The libraries are screened to select monoclonal antibodies to construct assays for the markers. 

A multiplexed assay platform employing custom Luminex xMap ™ magnetic beads is used to measure the markers in samples. Different bead types, based on their unique embedded reporter dyes, are assigned to different marker assays. Sandwich ELISAs are used for markers present at picomolar to nanomolar concentrations in samples. The magnetic beads, conjugated to capture antibodies, are incubated with samples. The captured markers are detected with biotinylated antibodies binding to complementary epitopes, using avidinylated phycoerythrin as a secondary label to generate assay signals. Competitive ELISAs are used for markers present at micromolar concentrations in samples. Here, the capture antibodies conjugated to the magnetic beads are incubated with samples that are pre-spiked with biotinylated marker constructs. The markers and their biotinylated counterparts compete for binding to the capture antibodies. The bound biotinylated constructs are labelled with avidinylated phycoerythrin to generate assay signals that are inversely related to the concentrations of the markers in the samples. For both sandwich ELISAs and competitive ELISAs, the final assay signals are read in a Luminex 200 flow cell. One laser measures the assay signals on the beads derived from phycoerythrin and a second laser identifies the unique bead types and hence the corresponding marker assay identities.

The assays described above are conducted in 96-well assay plates. A robotic platform conducts all liquid handling steps and employs a 96-well magnetic separator station to manipulate the beads. Up to 25 marker assays are multiplexed in each 25 µl sample, resulting in nominal sample volume consumption of only 1 µl per marker assay. 
&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;samples were blinded&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;follow EDRN guidelines&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Oct 12 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Oct  1 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct  1 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BRSCW Applicant: Buechler (Biosite) (2009)&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Over 40 marker assays are available to run on the samples. These include markers such as Osteopontin, Mesothelin, Periostin, Endoglin, intestinal Fatty Acid Binding Protein, and FAS-Ligand, some of which have been previously described in the literature. Other proprietary markers are derived from internal discovery efforts and from collaborator programs.&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;see BRSCW description&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;see &amp;quot;cancer in women&amp;#39; reference set description&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;AFP_1_1, AFP1_2, and AFP_2&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See DCP Protocol&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 260&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;260&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;In this study, we used the &amp;#967;2 and t test to compare the distribution differences of demographic and clinical variables among the two groups of cases and controls for discrete and continuous values, respectively. Spearman correlation test was applied to determine correlations of the tested values from different markers as well as the processing platforms. To justify performances for HCC early detection, the curves of receiver operating characteristic (ROC) were first plotted for all these markers. The area under the ROC curve (AUC) and the corresponding 95% confidence intervals (CI) were used to judge their overall performances. In addition, the logistic regression models with the forward selection were used to know if and how these biomarkers could be combined together to predictive positive responses. For the purpose to estimate their best performances, the potential cutoff values were proposed as all the empirical factor levels and their combination linear scores. The maximum sum value of sensitivity and specificity crossing different cutoff values was then employed to set up the optimal cutoff value. With the optimal cutoff value, the sensitivity, specificity and their 95% CIs were further calculated to contrast the resulting performances for these tested biomarkers&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Samples blinded as part of DCP study&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Share upon completion&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Apr 20 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Apr 16 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Dec 16 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Liver Ref Set: Lubman (Rapid #1) - Univ of Mich&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;We are requesting the reference set, which includes 50 HCC cases and 50 cirrhotic
controls. In our preliminary study, AFP had a AUROC of 0.66 while the AUROC for the 5
glycoproteins was 0.81. The sensitivity and specificity for the 5 glycoproteins was 79% and
72% at the point that maximizes sensitivity+specificity in the ROC curve, and it was 79%
and 35%, respectively, for AFP at the same point in the ROC curve. The reference set will
allow us to determine the best performance of the 5 glycoproteins by themselves or whether
their combination has a better sensitivity and/or specificity and AUROC. While a direct
comparison with AFP will be made, the reference set will not allow a robust comparison due
to the low sample size. If the glycoproteins are complementary or have better performance
than AFP, then the next step would be to test them in the entire phase 2 hepatocellular
carcinoma set.&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;2.1 the AFP group:  It was found that the three markers of AFP from this study had AUC ranging from 0.74 to 0.84, very similar to that of the AFP tested by standard values from EDRN(figure 1).  With the Spearman correlation test, AFP_1_1 and AFP_1_2  had a correlation coefficient (CC) of 0.96 (P&amp;#060;0.001),  they were also very correlated with AFP_2  with CC of 0.85 (P&amp;#060;0.001) and 0.90 (P&amp;#060;0.001). Please note that all these four ROC curves were for the validation set tested by Dr. Lubman’ group. At the beginning, they were compared with the satndard AFP values from EDRN pool, but his group said comparison only focusing their test values for the samples they received from EDRN, so I took of the ROC of AFP kept for the unblind samples at EDRN.  HGF and CD14 were two potential markers proposed to be validated by his group. The combination HGF and CD14 was driven by a logistic regression model.  Overall, the marker HGF performed better than CD14, but neither was better than AFP.  We used a logistic model to combine AFP with these two markers, but the resluing model parametrs was not significant at all, so they could not combine with AFP effectively to predict positive responses to diagnose the HCC.   However, these two markers could be combined together to improve AUC. 
2.3   The group of C3 and CE.:  To some extent, C3 correlated with the two peers C3_LE and at CC values of 0.24 (P&amp;#060;0.019) but not with C3_M (CC=0.19, P=0.070), the latter two were not correlated too (P=0.11).  However, these three values were all correlated with the AFP values from EDRN, CC were 0.38 (P&amp;#060;0.001), 0.47 (P&amp;#060;0.001), and 0.34 (P=0.001).  For three values of CE, they were not highly correlated with each other.   All AUC of the CE group were higher than C3, but not better than AFP. Note:  figure 3 showed three groups of ROC curves, all these marker values were obtained for the validation sets in Dr. Lubman’group.  The two markers C3 and CE were validated by their different platforms.  They also wanted to know if and how they can be combined with AFP, but right now no combination was found.  Note: (1)  Max, Min and Med. were the maximum, minimum , and median values of the tested biomarkers. 
 (2)  AFP was data set from the EDRN sample pool, bind to all labs.
 (3 ) all the values of AFP_11, AFP_12, AFP_2 . HGF, CD14, C3 , CE, and HGF+CD14 were from Dr. Lubman’ group using the bind samples to validate the potential markers proposed by his group.  



&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;See Rapid Liver Reference Set Protocol Description&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50 Liver Cancer and 50 Cirrhosis Controls&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;  APO  
  B2M  
  B7-H4
  CA125 
  CA15.3
  CA19.9
  CA72.4
  CTAP-III  
  EGFR
  Eotaxin
  HE4
  HEPC  
  IGF2
  IGFBP2
  ITIH4  
  KLK6 
  Leptin
  Mesothelin
  MIF
  MMP3
  MMP7
  OPN
  Prolactin
  SLPI
  Spondin-2
  sV CAM
  Transferrin
  Transthyretin&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;borderline ovarian cancers were excluded
postmenopausal women only&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 70, 87, 167, 231, 235, 236, 531&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;70&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;1). Using 1 ml of sera from the PLCO subjects, apply the panel of markers identified through the phase II study to all prediagnostic  specimens from all PLCO participants who subsequently developed ovarian cancer and from all longitudinal specimens from 10 matched controls who did not develop ovarian cancer for each case.
2). Using any residual sera, apply high end mass spectrometry and other discovery techniques to seek new markers especially in pre-clinical cases who were false negative or controls who were false positive by the panels. 
&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Based upon comprehensive reviews of ovarian cancer biomarkers and preliminary studies in which multiple biomarkers have been compared simultaneously, investigators representing Ovarian Cancer SPORES, EDRN and the PLCO trial are working towards defining a consensus panel of biomarkers appropriate for ovarian cancer screening.  Towards this goal, SPORE and EDRN investigators proposed to assemble a new set of phase II specimens (160 ovarian cancer cases with pre-operative bloods over-sampled for early-stage disease, 160 benign disease controls, 480 general population controls, and serial samples collected one year apart from 40 healthy women).  The top 5 markers identified in preliminary work by Boston-NW and FHCRC investigators, plus an expanded panel of Luminex markers, were evaluated to identify a final consensus panel of 5 to 15 biomarkers.  CA125 and the top 5 new markers were measured by standard ELISA using an automated platform, or kit, at BWH.  CA125 and the top 5 new markers, as well as additional candidate markers unique to each institution, were measured using Luminex at FHCRC and Pittsburgh. Results from ELISA were compared to results obtained from Luminex to evaluate the consistency of CA125 and the top 5 new markers across platforms and institutions.  Markers were selected for inclusion in the panel based on their individual performance, their contribution to a panel, and their stability over time, where the last predicts the improvement in performance expected from their use in a longitudinal algorithm. 
For markers that could be measured adequately on Luminex, to preserve specimen volume, the Luminex platform was used to evaluate the final consensus panel in the requested PLCO specimens; standard ELISA were used only if necessary due to inadequate measurement by Luminex.  The phase III PLCO set included pre-clinical specimens from all women who developed ovarian cancer during PLCO follow up (estimated to be about 100) and 1000 controls who did not develop ovarian cancer matched by age of subject and age of specimen. The analysis of pre-clinical specimens from cases was phased, beginning with the serum sample collected closest to date of diagnosis. If the panel performed well, additional pre-clinical samples were analyzed to assess its use in a longitudinal algorithm and to estimate lead time of the panel and the individual markers. Sensitivity and specificity for detecting pre-clinical disease 1, 2 and 3 years prior to clinical diagnosis were determined and the feasibility of applying the panel for general population screening was estimated.
Characteristics of cases who were and were not able to be detected by the panel were examined.  One ml of serum was requested for each PLCO subject included in the set, which allowed for measurement of the standard ELISAs and Luminex panels as well as any re-testing that may be necessary.  Any residual sera, especially from case subjects who were falsely negative and controls who were falsely &lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;all samples obtained from PLCO are blinded&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;183                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Share within EDRN and public after publication&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Oct 21 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jan  5 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct 21 2008 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;OVAR-VAL-PLCO&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Our preliminary data indicate that the performance of CA 125 as a screening test for ovarian cancer can be improved upon by additional biomarkers. With completion of one additional validation step, we will be ready to test the performance of a consensus marker panel in a phase III validation study.  Given the original aims of the PLCO trial, we believe that the PLCO represents an ideal longitudinal cohort offering specimens for phase III validation of ovarian cancer biomarkers.  &lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Results will be released after publication&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;Results will be released after publication&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;118 cases, 474 controls&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;- Ex vivo sub-cellular imaging of DNA-damage and -repair in circulating leukocytes
- Homocystein level in blood-plasma
- Pathology-specific protein-profiles in circulating leukocytes
&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion criteria:
- benign breast pathologies, 
- all types of breast malignancy, 
- pre/peri/post-menopausal status, 
- familial/genetic predisposition

exclusion criteria:
-   Pregnancy, 
-   Breast-feeding, 
-   alcohol and drug abuse.

&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;579&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;579&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Some recently developed, advanced diagnostic approaches focus on minimally invasive blood analysis as a valuable source of information concerning individual stress reactions under irradiation treatment. The prognostic role of leukocyte activity in breast cancer patients has long been recognised. Although fluctuating considerably among both node- negative and -positive patients, this activity has been demonstrated to be significantly lower in patients with a greater tumour burden. The authors emphasise the necessity for a more comprehensive analysis that would consider late effects of radiotherapy, stress-response and repair kinetics in terms of diagnostic and prognostic purposes in favour of the personalised treatment of breast cancer patients.

In addition to the increased risk of tumour-spreading by invasive biopsies, a serious disadvantage of utilizing biopsy samples for molecular imaging is the mixed cell population obtained, strongly varying from case to case, and resulting in differential gene expression with limited specificity related to the pathology. 

The central concept of our research in favour to non-invasive diagnosis focuses on 
1. blood-tests for the prediction of an individual’s predisposition,
2. highly homogeneous subgroups considering single criteria of  patients grouping such as age, familial/genetic predisposition, benign breast pathologies versus malignancy, pre/peri/post-menopausal status, accompanying diseases (e.g. metabolic disorder), etc.
3. combined biomarkers to increase the predictive power of the diagnostic approach.
&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Measurements of Homocysteine in blood-plasma
Measurements of homocysteine in EDTA-plasma were performed using high performance liquid chromatography (HPLC) as described elsewhere.

Comet Assay analysis
The “Comet assay” provides a simple and effective method for evaluation of DNA damage and DNA-repair capacity in single cells such as leukocytes. The principle of the assay is based upon the ability of DNA fragments to migrate out of the cell under the influence of an electric field. An evaluation of the “comet” tail shape and DNA fragments migration pattern allows for assessment of DNA damage and repair capacity. &lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Patient&amp;#39;s data have been encoded.  Both-lab analysis and clinical correlation analysis-have been performed according to the double-blind principle.&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Dec  1 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec  1 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan  1 2005 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;1, 3, 6&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Breast Cancer: subgroups specific blood-biomarkers for early / predictive diagnosis and personalized&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Breast-conserving lumpectomy followed by radiation therapy has been shown to be an alternative strategy, competitive to mastectomy, in preventing mortality caused by breast cancer. However, besides negative short-term effects (blood flow disturbances, painful erythema, etc.) breast irradiation causes severe long-term side-effects (leucopenia, anemia, breast edema, fibrosis, increase of angiosarcoma, leukemia, myelodysplastic syndromes). Therefore, the identification of individual susceptibility to radiation and improved patient-specific radiotherapy planning are highly desirable for personalised treatment in breast cancer. 
Why early and predictive diagnosis is crucial for long-term outcomes of breast cancer?
 Breast cancer is the most common cause of cancer death among women with an average incidence rate of 10-12 per 100 women. In 2005, breast cancer led to 502,000 deaths worldwide. Advanced stages of breast cancer lead to the development of metastasis predominantly in the lymph nodes, bone, lung, skin, brain, and liver. Although breast-MRI is currently the most sensitive diagnostic tool for breast imaging, its specificity is limited resulting in a negative impact for surgical management in approximately 9 % of cases. Early diagnosis has been demonstrated to be highly beneficial, enabling significantly enhanced therapy efficiency and possibly full recovery.
&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Combined parameter &amp;#060;homocysteine (Hcy) level and comet distribution&amp;#062; is proposed as advanced biomarker for predictive breast cancer diagnosis in peri- and post-menopausal women after 45 years of age&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;Combined parameter &amp;#060;homocysteine (Hcy) level and comet distribution&amp;#062; is proposed as advanced biomarker for predictive breast cancer diagnosis in peri- and post-menopausal women after 45 years of age&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;From the current pool of patients treated at the “Centre of Excellence for Brest Cancer Research”, Friedrich-Wilhelms-University of Bonn, 110 patients were recruited for this multidisciplinary study. According to the diagnosis, the recruited patients were grouped as follows: pre-menopausal women with benign alterations in breast tissue (G1); post-menopausal women with benign alterations in breast tissue (G2); invasive lobular &amp; ductal carcinomas in pre-menopausal women (G3); invasive lobular &amp; ductal carcinomas in post-menopausal women (G4); all of them - equally distributed among 4 subgroups.&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;14 SNPs&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Prostate Reference Set description&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 589&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;589&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;As an initial quality control for the genotyping data, tests for Hardy-Weinberg equilibrium are performed for each SNP among control subjects using Fisher&amp;#39;s exact test. The number of risk alleles of the 14 SNPs, is counted for each subject. Men are classified into eight approximately equal sized groups based on number of risk alleles 8;.7, 8, 9,10,11,12,13, and ~14). Number of risk alleles is modeled as a categorical variable with men who had 11 risk alleles (mode) serving as the
398/2590 (Rev. 06/09) Pags_ Continuation Format Page
Program Director/Principallnvestigator (Last, First, Middle):
baseline group. ORs for positive biopsy of PCa for men with various combinations of number of risk alleles will be estimated from regression coefficients of these variables in the logistic regression model. Absolute risk will be estimated based on the OR, calibrated incidence rate of PCa for men with the most common number of risk alleles, and mortality rate for all causes excluding PCa in the U.S. The calibrated incidence rates will be calculated based on jOint attributable risk of number of risk alleles estimated from the data and population incidence rates in the U.S. (2006 data). The initial set of 100 samples will allow us to assess the feasibility of this analysis in terms of having sufficient DNA, DNA quality and genotyping call rates and reproducibility. Following completion of this analysis for the first 100 samples additional samples will be requested to increase the power of the study to provide stable positive biopsy risk rates.
&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;all samples were blinded&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Follow the guidelines of the application&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep 21 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;May 21 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Prostate Ref Set: Isaacs 2010&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Can SNP genotyping assist in the prediction of biopsy results for prostate cancer.&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50 Cases/50 Controls using Citrate Cellular Component from the Prostate Reference Set&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 67, 87, 131, 143, 144, 145, 146, 147, 148, 275&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;143&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Mar 31 2017 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Mar  1 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;HEDS&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Final algorithm will include proteins from this list:
AMPM2, Apo A-I, b-ECGF, BLC, BMP-1, BTK, C1s, C9, Cadherin E, Cadherin-6, Calpain I, Catalase, CATC, Cathepsin H ,CD30 Ligand, CDK5-p35, CK-MB, CNDP1, Contactin-5, CSK, Cyclophilin A, Endostatin, ERBB1, FGF-17, FYN, GAPDH liver, HMG-1, HSP 90a, HSP 90b, IGFBP-2, IL-15 Ra, IL-17B, IMB1, Kallikrein 7, KPCI, LDH-H 1, LGMN, LRIG3, Macrophage mannose receptor, MEK1, METAP1, Midkine, MIP-5, MK13, MMP-7, NACA, NAGK, PARC, Proteinase-3, Prothrombin, PTN, RAC1, Renin, RGM-C, SCFsR, sL-Selectin, TCTP, UBE2N, Ubiquitin+1, VEGF, YES
&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Cases eligibility:
- All lung cancers discovered on CXR or on CT

- Pathology: confirmation of malignancy, all histological groups, primary lung cancer
- &amp;#8805;50% Stage I (Stage 1A = T1, N0, M0 and Stage 1B = T2, N0, M0)

   - No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last    5 years

   - Blood collected prior to treatment (chemo/radiation)

Controls eligibility
- High risk individuals as defined by &amp;#062;50 YO, &amp;#062; 30 PKYs of smoking (prevalence of cancer ~1% based on (3-7)) with a lung lesions on CXR or on CT suspicious for lung cancer but proven not to be cancer at 1 year follow up.  If at 1 year follow up participant has been diagnosed with a type of cancer other than lung then the participant will be considered an “other cancer” control.

- 75 patients with pathology proven primary cancers from other organ sites (25 breast, 25 colon, 25 prostate) – Set C only 37 other cancers.

- No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last 5 years

Cases and controls will be matched for prevalence according to age, sex, race, smoking status, and PKY history of smoking
&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 131, 580&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;580&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;To use the EDRN lung biomarker serum set C to
1. Validate the biomarkers discovered in the train and verification studies
2. Refine the classifier for detection of lung cancer in individuals with indeterminant pulmonary nodules.

&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;This section describes SomaLogic’s statistical methods for biomarker discovery and classifier construction.  These methods were applied to the data presented above, and similar approaches will be used with the EDRN samples.  If our application is approved, the EDRN samples would be run on the SLaptamer array (approximately 800 analytes) and analysis completed by June 2009.  The samples would then be run on subsequent larger arrays as they are developed. SomaLogic has experienced bioinformatics and statistics experts on staff as well as clinical biostatistics consultants.  SomaLogic would nonetheless welcome an opportunity to collaborate with the extensive network of EDRN biostatisticians to learn new ways to identify and characterize potential biomarkers, and develop and optimize classifier algorithms for specific clinical applications.  

All sample information, including sample receipt, clinical data and assay data will be captured, linked and stored in the SomaLogic laboratory information management LIMS system. Statistical analysis will be conducted using parametric and non-parametric models constructed and implemented in java running in a windows environment. Back-ups of all project data are conducted daily, and all back-up data is stored both locally as well as at a SomaLogic redundant off-site location. 

There are two primary statistical problems to be solved in the proposed study: (i) identification of biomarkers that discriminate among the sample classes, and (ii) the construction of classifiers that allow for a new sample to be evaluated. The identification of statistically significant differential protein expression between the control samples and the disease samples will be performed using both parametric and nonparametric tests.  The Kolmogorov-Smirnov (K-S) test is a non-parametric test that can be applied to marker identification.  Similarly, Student’s t-test and an F-test can be used for marker discovery when data are normally distributed.  Several classification methods will be applied to the datasets, including a parametric Bayesian classification scheme, linear discriminate analysis, and a nearest-neighbor classification scheme.  The sample sets will be divided into train and test sets to assess the quality of the classifiers.  
&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;all samples were blinded by the DMCC&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Per reference set receipt guidelines&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Aug  1 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;May  1 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Lung C Reference Set (Full): SomaLogics (2010): Ostroff&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Analysis of the EDRN lung biomarker samples will enable the next step in development of a clinical diagnostic assay for the differential diagnosis of lung cancer or benign disease in patients with indeterminant pulmonary nodules.  The objective is to develop a blood test with sufficient accuracy to identify lung cancer in these patients, which will aid the treating physician in decisions to recommend invasive procedures or watchful waiting.&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;178 Lung Cancer Cases, 179 High Risk Controls and 37 other cancer controls&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;180 cases, 180 controls and 75 other cancers&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;CXCL5 and  CXCL12&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;578&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;To-date, through the efforts of Co-Investigator Dr. John Wei in the Department of Urology, the University of Michigan EDRN has procured serum, plasma and urine from &amp;#062;1000 men referred to Dr. Wei with an indication for prostate biopsy. Of these, only 37.5% exhibit malignant glands on one or more needle biopsies. This is perhaps not surprising, as the majority (70%) of men referred for needle biopsy exhibit pre-biopsy PSA values of &amp;#060;10ng/ml, which, as described above, are not diagnostic for PCa. Taken together, these studies show that low serum PSA and other recently developed biomarkers cannot reliably distinguish between PCa and BPH or indicate which patients should, or should not, undergo diagnostic needle biopsy. Therefore, it is desirable to develop
and validate suitable biomarkers that could be used alone or in conjunction with PSA to distinguish patients at high risk for PCa who should undergo diagnostic needle biopsy from those
at low risk who could benefit from watchful waiting. &lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;578&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;578&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;SPECIFIC AIMS/DELIVERABLES. In order to test this hypothesis, we will accomplish two Specific Aims:
Specific Aim 1. Assess the robustness of serum, plasma, or urine measures of CXCL5 and CXCL12.
Specific Aim 2. Determine whether serum, plasma, or urine levels of CXCL5 and CXCL12 provide
sufficient predictive value for prostate cancer among men with low (&amp;#060;10ng/ml) total serum PSA.&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;The results of these assays will determine whether
statistically significant associations between disease status in the prostate (no disease, BPH, PCa with or without concomitant BPH) and serum, plasma, or urine protein levels for CXCL5 and/or CXCL12 are observed among patients with low but detectable serum PSA. If so, then ROC analyses will determine whether the sensitivity and specificity of these protein levels to ‘predict’ disease status are superior to those of PSA or other similarly evaluated biomarkers as reported in the literature. If so, a larger, multiinstitutional study to validate these findings across a broader patient population will be pursued through collaborative efforts within the NCI-sponsored Early Detection Research Network (EDRN) to validate these findings. Conversely, if no statistically significant associations between disease status in the
prostate and serum, plasma, or urine protein levels for CXCL5 and/or CXCL12 are observed, then we will conclude that these proteins do not comprise suitable biomarkers for disease status in the prostate, and that further studies are not warranted.&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;Aim 1 is completed, Aim 2 is in prcess&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Data shared through public EDRN database one year after study completion&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Sep 30 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep 30 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct  1 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Chemokine Prostate Cancer Biomarkers&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;CXCL5 is a pro-angiogenic CXC-type chemokine that is robustly secreted by prostate cancer cells. Tissue microarray analyses have demonstrated that CXCL5 protein expression levels are concordant with prostate tumor progression. Biological assays have demonstrated that CXCL5 promotes both the proliferation and invasiveness/metastasis of prostate cancer cells. CXCL12 is also a pro-angiogenic CXC-type chemokine expressed in bone marrow stroma and tumor endothelium that ‘guides’ invasive prostate cancer cells to establish metastatic tumors in bone. Prostate
cancer cells up-regulate protein expression of CXCR4, the CXCL12 receptor, concordantly with prostate tumor progression in response to increasing levels of tumor stromally-secreted CXCL12. Preliminary studies from our laboratory have shown that, among 51 men with low (&amp;#060;10ng/ml) serum PSA values, both serum CXCL5 and serum CXCL12 levels were significantly higher among men who were biopsy-positive compared to those who were biopsy-negative for prostate cancer. These studies also showed that serum CXCL5 levels distinguished cancerous from non-cancerous large volume prostates, whereas CXCL12 accomplished the same for small volume prostates. Based on these preliminary data, we hypothesize that serum, plasma, and urine levels of CXCL5 and CXCL12 can distinguish between men with cancerous or non-cancerous prostates. In order to test this hypothesis, we propose two specific aims intended to assess the robustness and predictive value of these markers.&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;estimated at ~250&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;~400&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Sample Eligibility defined in DCP Protocol&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 66, 87&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;66&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;For data analysis, Receiver Operating Curves (ROC) should be generated for the Gp73 and fucosylated kininogen either alone and in combination with AFP, AFP-L3 and DCP and the area under the curve determined (AUROC). No training sets will be required. Markers will be directly compared by their AUROC values and ranked accordingly.  The following will be criteria for advancement of a biomarker status and further testing: Statistically significant with alpha = 10% AUROC improvement in the distinction of cirrhosis from HCC with the addition of marker(s) to AFP alone for the full set of samples OR in defined subsets, e.g. AFP negatives, early tumor stage.  The ultimate target is to find a combination of markers that will improve on current AFP-alone sensitivity and specificity, such that we will be able to achieve &amp;#062; 90% sensitivity and &amp;#062; 85% specificity for the distinction of cirrhosis from HCC.  &lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All samples were blinded as part of the DCP protocol and then blinded during the sub-aliquot process at NCI-Frederick.&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;According to EDRN guidelines data will be shared through public portal.&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Oct  1 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug  1 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Case/control&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Liver Reference Set: Block (2010) (Full)&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The goal of this application is to determine if the levels of serum GP73 and fucosylated kininogen/acute phase proteins can be used to detect hepatocellular carcinoma (HCC) in the background of liver cirrhosis.  The use of the validation set would allow us to directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;383 HCC Cases/388 Cirrhosis Controls&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;383 liver cancers and 388 cirrhotic controls&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Galectin-3 Ligand, Vimentin methylation (Colosure), FOBT-CHEKOC®, Polymedco, Inc for Fecal Immunochemical Test (FIT) and Exact Sciences DNA Stool Biomarker Panel:  Potential improved Exact Sciences DNA Stool Biomarker Panel.&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;5.2   Eligibility 
5.2.1    Inclusion Criteria
&amp;#149;   Adults 50-80 and undergoing a colonoscopy defined as:
o   First time screening or a surveillance procedure  
o   No complete colon exam (colonoscopy or CT colonography) within 3 years except as noted. (see section 5.4.1)  
&amp;#149;   Willing to sign informed consent 
&amp;#149;   Able to physically tolerate removal of up to 50 ml of blood
&amp;#149;   Willing to collect 2 stool samples 
&amp;#149;   Willing to collect 150 ml of urine

5.2.2   Exclusion Criteria
&amp;#149;   Inability to provide informed consent
&amp;#149;   History of Inflammatory Bowel Disease
&amp;#149;   Overt rectal bleeding within (including due to suspected hemorrhoids).
&amp;#149;   Positive guiaic-based occult blood or fecal immunochemical test (e.g. FOBT, FIT) in the past 12 months.
&amp;#149;   Undergone resection of the colon for any indication
&amp;#149;   Subjects with known HIV or chronic viral hepatitis (Hepatitis B and C)
&amp;#149;   Subjects with known or suspected HNPCC (Lynch Syndrome) or FAP
&amp;#149;   Any cancer  within 5 years of enrollment except any of the following: 
o   Squamous cell carcinoma of the skin or Basal cell carcinoma of the skin
o   Carcinoma in situ of the cervix, Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery only.  (Excluded if had pelvic radiation) 
o   Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery
&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 67, 68, 87, 131, 184, 198, 201, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 676, 677, 703, 704, 705, 706, 707, 708, 710, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;67&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;2&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim 1
a. To estimate the sensitivity and specificity for 1) colorectal adenocarcinoma and high grade dysplasia, or 2) screen relevant neoplasms (colorectal adenocarcinoma, high grade dysplasia, and adenomas&amp;#062;1cm) of the following individual colorectal neoplasia early detection biomarkers using colonoscopy as the gold standard:
&amp;#149;   stool vimentin methylation
&amp;#149;   serum galectin-3 ligand, 
&amp;#149;   fecal immunochemical tests (FIT) 
&amp;#149;   Exact Sciences stool DNA panel
&amp;#149;   Other currently unspecified biomarkers 

b. To test the null hypotheses that the sensitivities are 50% or lower versus the alternative hypotheses that sensitivities are higher than 50% for the early detection of colorectal adenocarcinoma and high grade dysplasia; and the null that sensitivities are 25% or lower versus  the alternative that they are higher than 25% for the detection of screen relevant neoplasia, using colonoscopy as the gold standard and  for both outcomes, to test the null hypotheses that the specificities of the above early detection biomarkers are 70% or lower versus the alternative hypotheses that specificities are higher than 70%.

Aim 2: To determine if the sensitivities of the above early detection biomarkers are greater than that for fecal immunochemical testing (FIT) for the detection of the combined endpoint of colorectal adenocarcinoma or adenomas with high grade dysplasia. 

Aim 3
a. To estimate the sensitivity and specificity of the above individual binary biomarkers, in combination with FIT for 1) colorectal adenocarcinoma and high grade dysplasia, and for 2) screen relevant neoplasms (SRN). The combinatory rule defines a test positive if either individual test is positive.

b. To test the null hypothesis that the sensitivities of the combined tests described Aim 3a are equal or lower than a minimally acceptable value (MAV) versus the alternative that they are higher than the MAV, with the MAV set as 70% for the detection of colorectal adenocarcinoma and high grade dysplasia and 45% or higher for SRN with the assumption that the specificity is maintained at 70% or higher using colonoscopy as the gold standard. 

c. To construct a combined early detection biomarker score using the above individual biomarkers using logistic regression, and describe its performance for 1) colorectal adenocarcinoma and high grade dysplasia, and for 2) SRN.

Aim 4
To establish an archive of appropriately preserved stool, serum, plasma, urine, and DNA human biospecimens to be used by EDRN investigators for future validation and biomarker discovery research.

&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;7.1   Vimentin methylation (Colosure)
This assay will be performed at LabCorp under a sublicense from Exact Sciences according to previously published method described in the background.  Assay qualitatively tests for presence of methylated vimentin gene.  Result is positive or negative.  The vimentin methylation assay will be performed blinded without knowledge of clinical source or results of other assays. 
7.2   Fecal immunochemical Test (FIT)
The FOBT-CHEKOC®, Polymedco, Inc product will be used according to manufacturer’s instructions.  The threshold for a positive test is 100 ng/ml. The Central Biomarker Laboratory will process the samples using equipment provided by Polymedco, Inc.  Technicians will undergo tutorial and quality assessment with Polymedco, Inc support technicians prior to study launch.  A quantitative result will be generated and recorded in the database.  If either stool result is above Polymedco, Inc recommended cut-off, that subject will be called positive. 
7.3   Galectin-3 Ligand
The analytically validated ELISA method described in the preliminary data will be transferred to an EDRN Biomarkers Reference Laboratory.  Serum aliquots will be provided to the analytical sites in a blinded fashion. The Bresalier laboratory will assay 20% of the samples to ensure quality control. All of the samples will be assayed by the Biomarker Reference Laboratory that will be selected by the NCI-EDRN program staff.
7.4   Exact Sciences DNA Stool Biomarker Panel:  Potential improved Exact Sciences DNA Stool Biomarker Panel
The Exact Sciences panel consists of a panel of genetic biomarkers from DNA isolated from human stool.  The panel consists of:
1. qInvader (an automated, multiplexed rtPCR assay) reactions of:
a.  methylated vimentin and MM2 multiplexed
b.  K-Ras multiplex, 1 amplicon, 7 mutations
c. APC panel 1, 3 amplicons, 3 mutations.
d. APC panel 2, 3 amplicons, 3 mutations
2. Immuno-hemoglobin (ELISA based) assay or stool supernatant.
&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;All specimens will be blinded by the DMCC&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Follow EDRN guidelines for public sharing upon completion&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jul 31 2015 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug  1 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Prospective&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3, 9&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;GLNE 010&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;We propose a Phase 2 (large cross-sectional) PRoBE-compliant validation trial of stool-based and serum-based tests for the detection of colorectal neoplasia  (1).  The trial is powered to detect early stage colorectal adenocarcinoma or high grade dysplasia.  This is the most stringent, conservative approach to the early diagnosis of colonic neoplasia and addresses the most important endpoint of identifying individuals with curable, early stage cancer and those with very high risk non-invasive neoplasia (high grade dysplasia).&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;6000 colonoscopy patients&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 614&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;614&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec 24 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug 24 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Lung Reference Set A (Full) Applicant: Takacs - Biosystems (2010)&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;180 cases, 180 controls and 75 other cancers&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;AFP_1_1, AFP1_2, and AFP_2&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See DCP Protocol&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 260&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;260&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;In this study, we used the &amp;#967;2 and t test to compare the distribution differences of demographic and clinical variables among the two groups of cases and controls for discrete and continuous values, respectively. Spearman correlation test was applied to determine correlations of the tested values from different markers as well as the processing platforms. To justify performances for HCC early detection, the curves of receiver operating characteristic (ROC) were first plotted for all these markers. The area under the ROC curve (AUC) and the corresponding 95% confidence intervals (CI) were used to judge their overall performances. In addition, the logistic regression models with the forward selection were used to know if and how these biomarkers could be combined together to predictive positive responses. For the purpose to estimate their best performances, the potential cutoff values were proposed as all the empirical factor levels and their combination linear scores. The maximum sum value of sensitivity and specificity crossing different cutoff values was then employed to set up the optimal cutoff value. With the optimal cutoff value, the sensitivity, specificity and their 95% CIs were further calculated to contrast the resulting performances for these tested biomarkers&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Samples blinded as part of DCP study&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Share upon completion&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Apr 20 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jan 15 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep 15 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Liver Ref Set: Lubman (Rapid #2) - Univ of Mich&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;We are requesting the reference set, which includes 50 HCC cases and 50 cirrhotic
controls. In our preliminary study, AFP had a AUROC of 0.66 while the AUROC for the 5
glycoproteins was 0.81. The sensitivity and specificity for the 5 glycoproteins was 79% and
72% at the point that maximizes sensitivity+specificity in the ROC curve, and it was 79%
and 35%, respectively, for AFP at the same point in the ROC curve. The reference set will
allow us to determine the best performance of the 5 glycoproteins by themselves or whether
their combination has a better sensitivity and/or specificity and AUROC. While a direct
comparison with AFP will be made, the reference set will not allow a robust comparison due
to the low sample size. If the glycoproteins are complementary or have better performance
than AFP, then the next step would be to test them in the entire phase 2 hepatocellular
carcinoma set.&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;2.1 the AFP group:  It was found that the three markers of AFP from this study had AUC ranging from 0.74 to 0.84, very similar to that of the AFP tested by standard values from EDRN(figure 1).  With the Spearman correlation test, AFP_1_1 and AFP_1_2  had a correlation coefficient (CC) of 0.96 (P&amp;#060;0.001),  they were also very correlated with AFP_2  with CC of 0.85 (P&amp;#060;0.001) and 0.90 (P&amp;#060;0.001). Please note that all these four ROC curves were for the validation set tested by Dr. Lubman’ group. At the beginning, they were compared with the satndard AFP values from EDRN pool, but his group said comparison only focusing their test values for the samples they received from EDRN, so I took of the ROC of AFP kept for the unblind samples at EDRN.  HGF and CD14 were two potential markers proposed to be validated by his group. The combination HGF and CD14 was driven by a logistic regression model.  Overall, the marker HGF performed better than CD14, but neither was better than AFP.  We used a logistic model to combine AFP with these two markers, but the resluing model parametrs was not significant at all, so they could not combine with AFP effectively to predict positive responses to diagnose the HCC.   However, these two markers could be combined together to improve AUC. 
2.3   The group of C3 and CE.:  To some extent, C3 correlated with the two peers C3_LE and at CC values of 0.24 (P&amp;#060;0.019) but not with C3_M (CC=0.19, P=0.070), the latter two were not correlated too (P=0.11).  However, these three values were all correlated with the AFP values from EDRN, CC were 0.38 (P&amp;#060;0.001), 0.47 (P&amp;#060;0.001), and 0.34 (P=0.001).  For three values of CE, they were not highly correlated with each other.   All AUC of the CE group were higher than C3, but not better than AFP. Note:  figure 3 showed three groups of ROC curves, all these marker values were obtained for the validation sets in Dr. Lubman’group.  The two markers C3 and CE were validated by their different platforms.  They also wanted to know if and how they can be combined with AFP, but right now no combination was found.  Note: (1)  Max, Min and Med. were the maximum, minimum , and median values of the tested biomarkers. 
 (2)  AFP was data set from the EDRN sample pool, bind to all labs.
 (3 ) all the values of AFP_11, AFP_12, AFP_2 . HGF, CD14, C3 , CE, and HGF+CD14 were from Dr. Lubman’ group using the bind samples to validate the potential markers proposed by his group.  



&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;See Rapid Liver Reference Set Protocol Description&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50 Liver Cancer and 50 Cirrhosis Controls&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;tNOX, ENOX, ENOX2, NXOB826, NX034&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see cancer in women reference set description&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 309&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;309&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;To obtain preliminary indications of utility for serum detection of breast and ovarian cancer.&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;sandwich ELISA&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;samples blinded&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Follow NCI Guidelines&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Aug 31 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Feb 28 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct 29 2009 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;Other&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BRSCW Reference Set: NOX (2009)&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Evaluation using NOX Technologies ECTO-NOX blot diagnostic 2-D gel electrophoretic cancer detection system in combination with a sandwich ELISA of our derivation&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Results were submitted to the EDRN on August 31, 2010.  The samples remain coded to us so we have no information on outcome at present writing.&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;Results were submitted to the EDRN on August 31, 2010.  The samples remain coded to us so we have no information on outcome at present writing.&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;As the samples remain to be decoded to us, no information on outcome is available.&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;see &amp;quot;cancer in women&amp;#39; reference set description&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 176&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;176&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Aug 31 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec  1 2013 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Dec  1 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;US-Turkey&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Study never launched.&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;Study never launched.&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;400 villagers and 400 controls&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;AFP-L3, DCP&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See DCP Protocol&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 647&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;647&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Effectively measure AFP-L3 and DCP for early detection of HCC.&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Sensitivity and specificity of AFP, AFP-L3% and DCP assays on the uTASWako i30 will be calculated for the patients using several cutoff values (5%, 7%, 10% etc).  Sensitivity by tumor characteristics (stage, size and number) will be evaluated.

For three single markers, i.e. AFP_wako (AFP from Wako),  AFP_L3 and DCP),  the data was analyzed by two steps: (1), the Receiver Operating Characteristic (ROC) curve was plotted to show the marker overall performance differences by  the areas under the Curve (AUC)and their 95% confidence intervals (CI),  they were  contrasted with  the AFP values from EDRN; and (2) these markers were compared with the standard AFP on the optimal cutoff values and their associated sensitivity and specificity; the  underlying optimal estimation was basis on the maximum sum of se. and sp. 
To know combination potentials among these three single markers from Wako, the logistic regression model was then applied to judge if and how the two markers AFP_L3 and DCP could be combined with the values of AFP_W and the standard AFP.  The marker values were transformed by their logarithm functions. These logarithm based marker values were regarded as the independent variables to be put into the logit models by the forward selection.  The model based linear scores were then used as the combined marker indicators to do further data analysis for the combined markers in ROC performances. 
&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Samples blinded as part of DCP&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Share upon completion&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;May  4 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 28 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb 28 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;LIver Reference Set (Rapid) Yamada-Wako (2011)&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Measure clinical effectiveness of AFP-L3 and DCP for early detection of HCC in patient samples collected prospectively during surveillance.  However since such samples are not readily available in the USA the reference set samples are well characterized and studied, gaining access to these samples will allow Wako to quickly measure clinical effectiveness of AFP-L3 and DCP in detecting early HCC.&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;1.  unmeasurable ratios:   There are 22 values of AFP_L3 labeled &amp;#060;0.5 (22.22%), 1 labled &amp;#062;99.5 (1%), they were set as 0.5 and 99.5 for further analysis, respectively.  For DCP, there were 3 values labeled with &amp;#060;0.10 (3.03%). Similarly, these 3 values were set as 0.1 for ROC curve analysis

2.  single biomarkers:  Figure 1. The ROC curves for the three tested biomarkers and the standard AFP from EDRN. Note: AFP_W , AFP_L3, and DCP were biomarkers from Wako, respectively. AFP was the marker AFP from EDRN.  From figure 1, it was seen that the three tested markers had relatively lower values of AUC than the standard AFP, but their 95% CI still crossed over.  The table 1 showed us the optimal cutoff values when the biomarkers had the maximum sum of sensitivity with specificity.   The standard AFP from EDRN had the highest sensitivity, but AFP_L3 had the highest specificity.  
3.  combined biomarkers:  With the forward selected logistic regression models, it was found that both AFP_L3 and DCP could combine together with the standard AFP and AFP from Wako, respectively.   The resulting combinations had a little better values of AUC, compared with the AFP from EDRN (figure 2).  At the optimal cutoff points, they also performed better, having higher values of sensitivity and specificity (table 2).Note:  (1) AFP_Wako w/AFP_L3 and DCP was combined AFP_Wako with AFP_L3 and DCP; and
(2) AFP w/AFP_L3 and DCP was combined  the standard AFP from EDRN  with AFP_L3 and DCP


&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;See Rapid Liver Reference Set description&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50 liver cancers and 50 cirrhotic controls&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 153&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;153&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 28 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb 28 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;LIver Reference Set (Rapid) Beretta-FHCRC (2011)&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50 Liver Cancers and 50 cirrhotic controls&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 646&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;646&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;v&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 28 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Feb 28 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;LIver Reference Set(Rapid) Qu-Quest (2011)&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50 liver cancers and 50 cirrhotic controls&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;610&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 81, 87, 158, 234, 235, 238, 593, 610&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;610&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;1. Rank candidates identified through past research using bioinformatic analyses 
(GO, KEGG, Ingenuity), including cancer pathway analyses and gene ontology 
classifications. 
2. Attempt to develop assays for top ranked candidates from step 1 with goal of 
assay development for 50 candidates (using multiplex immunoassays where high 
quality mAb pairs or mAb/pAb pairs exist, and SRM targeted mass spec for all 
other candidates) 
3. “Rule in” at least 10 and at most 25 candidates based on assay performance in 
serum biospecimens obtained at diagnosis, achieving minimal clinical sensitivity 
(&amp;#062; 5%) at 98% specificity. 
4. Measure in pooled samples most proximal to diagnosis of ovarian cancer case in 
screening study, and in matched control samples, minimizing pooling to achieve 
minimum required volume for SRM in depleted serum. 
5. Rank candidates by sensitivity at fixed high specificity 
6. Measure up to top 25 candidates from step 5 in individual longitudinal samples 
from ovarian cancer cases in screening study, and in matched control samples 
7. Candidates validated for early detection of ovarian cancer if clinical sensitivity 
achieved (5% or greater) at 98% specificity at least 1 year prior to clinical 
detection. 
&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;183                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;All data will be shared through EDRN and with the public upon publication.&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jul 31 2014 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug  1 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;OC Team 1&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Early detection of Ovarian Cancer (OC) is one of the key clinical problems in this 
disease. We propose a team EDRN project to address the issue of early detection of 
OC by performing a validation study on candidate protein markers already identified in 
previous EDRN research or in the literature (e.g. protein products of TCGA identified 
mutations specific to ovarian cancer). (See appendix for full listing) Biospecimen 
sources have been identified which include samples obtained at diagnosis and matched 
controls (Urban, Godwin, Marks, Skates), and longitudinal samples obtained prior to 
diagnosis (Urban, Skates, Godwin). Bioinformatic filters will be applied to rank the 
candidates (Diamandis). In order of ranking, candidate proteins for which high quality 
antibodies are available will be measured by development of ELISAs at JHU 
(Chan/Zhang) or through NAPPA at DFCI (Anderson/LaBaer), while for other 
candidates mass spectrometry based selective reaction monitoring (SRM) assays will 
be developed at PNNL (Rodland). Three milestones are defined. The first two 
milestones are to assemble the necessary specimens and to develop the qualifying 
assay(s). The final milestone is to estimate the markers’ sensitivity one year prior to 
diagnosis at a given high specificity. &lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50 serous ovarian cancer cases, 50 serous benign ovarian disease controls, 300 longitudinal samples from 28 ovarian cancer 
cases, and 56 matched control subjects&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;A.   Paul Cairns (DNA Methylation Sensitivity in IBC)
MAL         
RASSF IA      
CTGF         
HIN1         
APC         
RAR&amp;#61538;         
GSTP1      
IGFBP3      
GOS2         
B.   Andrew Godwin (Protein Biomarker)
C.   Indra Poola (Protein Biomarker)
MMP-1
CEA CAM6
HYAL-1
D.   Nicole Urban
CAV-1 (Caveolin 1)
FN-1 (fibronectin)
COL1A1
TIMP4
SPP1 (osteopontin)
S100A7 (Psoriasin)
MMP10
MMP12
&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Identification of eligible subjects:
Each participating CVC will utilize a registry of women who have had breast surgery for benign breast disease at the CVC hospital/cancer center in the time period 1 January 1994 through 31 December 2004.  Cases of atypical ductal hyperplasia (ADH) that meet the inclusion-exclusion criteria will be given a unique EDRN-VSIMS number. 
Study Cohort Inclusion Criteria:
1.Diagnosis of BBD with atypia (ADH).
2.Formalin-fixed archival tissue (preferably excisional biopsy or core biopsy) sufficient for 2 or more tissue sections.
3.Adequate follow-up information to determine subsequent cancer status (IBC yes-no).
4.Clinical information sufficient to determine race, family history of breast cancer, mammography history and breast surgery history, and clinical management and outcome of patients developing IBC.
Study Cohort Exclusion Criteria:
1.Women age &amp;#060; 40 or &amp;#062; 70 at the time of first BBD breast biopsy.
2.Women with diagnosed concurrent invasive breast cancer, DCIS, invasive lobular carcinoma or lobular carcinoma in situ.
3.Women with insufficient clinical information to determine subsequent breast health history including mammography status and invasive breast carcinoma.
4.Women who had only FNA or in whom the pathology bloc contains insufficient material for at least two cut sections.
 
&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 81, 87, 187, 202, 235, 238, 593, 610, 709&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;202&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Biomarkers expressed in benign breast disease tissue of women who progresse to invasive breast cancer are quantitatively and/or qualitatively different from those expressed in tissue of matched women who do not progress to invasive breast cancer.  A nested case-control design will be used to determine if available proteomic and methylation biomarkers predict risk for future invasive cancer (IBC).  Women with ADH who are disease-free will be matched 2:1 to women with ADH who progress to IBC.&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Samples will be analyzed in a blinded fashion&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Follow the EDRN guidelines&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 13 2013 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug 13 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3, 9&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BBD Team Project&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;To identify women diagnosed with atypical ductal hyperplasia (ADH) who are at increased risk of developing invasive breast cancer (IBC) and who might benefit from risk reduction with the use of chemoprevention agents such as Tamoxifen.  (Note:  A companion protocol will study women with DCIS and their risk for invasive breast cancer.)&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;90 incident IBC cases from women with atypia (ADH) and 180 non-IBC control subjects matched 2 controls to 1 case: 1)Atypical ductal hyperplasia (ADH), 2)Age at date of ADH diagnosis (w/in 2yrs), 3)Months to time of IBC diagnosis (w/in 6 mo) and 4)Family history of breast cancer (yes vs no)&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;230&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 230, 233, 523, 593&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;230&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;The overall study design involves the identification of three distinct types of blood-based biomarkers:
1. Autoantibodies (Anderson/LaBaer) 2. Protein antigens (Li/Lampe; Zangar). 3. miRNA
(Huebner/Croce). These biomarkers will be validated in a step-wise fashion using samples provided by the CEVCs and multi-institutional cohorts, with study design and evaluation by the DMCC.
Aim 1. Verification of novel biomarkers for TNBC
Aim 2. Validate the top biomarkers for TNBC using a diagnostic set of plasma.
Aim 3. Determine the sensitivity, specificity, and positive predictive value of the top marker
combinations found in aim 2 to distinguish TNBC from benign breast disease, and for the detection of ER+ and Her2+ breast cancer, using the EDRN Reference Set.
Aim 4. Develop a phase III validation plan for testing the top biomarkers and biomarker combination for TNBC detection using prediagnostic sera from WHI, ROCA, and PLCO.&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;Data will be shared upon publication&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 3013 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;TNBC Team Project&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 647&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;647&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Oct 20 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul 20 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Liver Reference Set (Full) Yamada-Wako (2011)&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;383 liver cancers and 388 cirrhotic controls&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Ongoing&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;592&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Since several different studies are involved, multiple eligibility criteria exist.&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;151, 592&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;592&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Specific Aim 1. To evaluate the expression/activation of proteins important in proliferation, angiogenesis, and inflammation in plasma collected 0-24 months prior to diagnosis of colon cancer.
Approach: For discovery, we will utilize our high density array supplemented with antibodies targeting proteins such as cytokines, chemokines, growth factors, ubiquitination related proteins, insulin-related/resistance proteins, kinases, phosphatases and other regulators of cell signaling (IGF, IGFBP, STAT, TGF-&amp;#946;, AKT, MAPK).  For biomarker candidates discovered during our previous research, we will perform “pre-validation” analyses utilizing smaller format antibody microarrays.
Specific Aim 2. To evaluate changes in the glycosylation status of proteins during colon cancer progression in plasma collected 0-24 months prior to diagnosis.
Approach: We will utilize our large format antibody arrays to fractionate proteins and then probe their glycosylation status through the use of 6 lectins (Aleuria aurentia lectin (AAL), Concanavalin A (ConA), Len culinaris agglutinin (LCA), Phaseolus vulgaris leucoagglutinin (L-PHA), Maackia amurensis lectin II (MAL II), and Sambucus nigra bark lectin (SNA).  Differences will be followed up with immunopurification and glycan characterization (ELLA).
Specific Aim 3.  To develop CRC-specific diagnostic biomarkers using pretreatment cancer tissue and plasma from colorectal cancer patients. 
Approach: We will compare protein expression/activation in tumor vs. normal colon mucosa and in plasma vs. controls via antibody array to discover diagnostic biomarkers. The best markers will then be rescreened on a second array with independent samples. After triage, we will determine whether the surviving biomarkers are tumor or stromal derived by analyzing its expression in fixed tumor tissue.
Specific Aim 4. To validate colon cancer early detection and diagnostic biomarkers on independent sample sets.
Approach: We will utilize sandwich ELISA to judge the sensitivity and specificity of the plasma biomarkers that have survived either the early detection or diagnostic biomarker triage process or both (the latter will be particularly interesting). For the tumor derived diagnostic biomarkers, we will examine their expression in tissue microarrays (TMA) created from cores of tumors from people with known disease status and outcome.  Thus, we will be able to determine if there is a correlation between biomarker expression and disease outcome. 
&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;High-density antibody microarrays
To discover potentially informative biomarkers for CRC early detection and diagnosis, we will utilize a high-density microarray antibody platform, developed by the Lampe laboratory, which has capacity for over 18,000 antibodies (we typically print up to ~4500 in triplicate). We will tailor this microarray specifically for application to the clinical management of CRC. Our current arrays contain ~3000 commercial antibodies from several vendors (~400 Hypromatrix, Inc, ~400 Genway Biotech, Inc., ~1200 cancer related antibodies from SDIX, ~400 from Abnova and ~800 from Aviva).  The antibodies were produced to a wide variety of signaling proteins, cytokines, apoptotic, proteases and cancer related proteins. Where possible, we selected antibodies to secreted proteins. For the recombinant antibodies, sub-libraries specific to CRC plasma have already been selected from 2 master libraries (Tomlinson I and J libraries) and 310 CRC-specific scFv have shown excellent performance on arrays probed with prediagnostic CRC plasma. 
A. Fabrication/printing of arrays
Buffers, protocols, slide surfaces and techniques were modified from DNA array-based technology and existing antibody array-based literature. Triplicate features of each antibody are printed. Previous array experiments confirmed that spatial separation resulted in no loss of reproducibility among the three common features. Coupling of the antibody primary amines on the array surface is essentially complete in 10 min. When required, antibodies will be diluted in PBS (50 mM potassium phosphate, pH 7.2, 150mM NaCl) to a final concentration of 0.20 to 0.25 mg/ml. This mixture is combined with 2x volume (10 µl) of 3x Protein Printing Buffer (3x PBS, 0.03% Tween, 3% glycerol). Arrays are contact printed onto HiSens Hydrogel H glass slides (Nexterion) using a Genetix Q-Array 2 microarray platform. Printed arrays have good shelf life (we saw no deterioration up to one month after printing when stored at 4°C and 1 year at -80°C). Arrays are blocked just prior to usage by placing in a slide rack and washing vigorously in phosphate buffered saline-0.01% Tween 20 (PBST) by dunking 30 times, washing twice in fresh water by dunking 30 times, then blocking with 0.3% ethanolamine in 0.05 M sodium borate pH 8.0 by dunking 30 times. After 2-3 hours incubation (orbital shaker, 80 rpm) in block solution, the slides are dunked 30 times in PBST, twice in fresh water, and then dried immediately by spinning 1000 x g for 5 min. Dried slides are immediately challenged with labeled plasma.
B. Fluorescent labeling of plasma and tissue lysate proteins
The detection of protein on the array requires direct incorporation of a tag or label. For plasma, we first remove the two most abundant proteins (Albumin and IgG) using a Sigma Prot I/A column.  The protein solution is then reconcentrated to about half of its original volume.  Protein (100 µg) from each sample is then labeled with the fluoropho&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Data on subject demographics, risk factors, and tumor characteristics will be kept separately from the laboratory data and laboratory scientists blinded to all but the most basic of information, such as the case:control pair designation (not assignment of case and control status). &lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;ongoing&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;As part of our participation in the EDRN, we will share both data and resources. We affirm our support for the concept of data sharing.  We agree that data sharing is essential for expedited translation of research results into knowledge, products, and procedures to improve human health.  We will share our final research data via manuscript publication and through the DMCC. We will follow data sharing guidelines as established by NIH in its Final Statement on Sharing Research Data.&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jul  1 2015 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;3&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Affinity-Colon Cancer Biomarkers&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Our goal is to discover plasma and tissue-based tumor biomarkers that work well enough together to identity colon cancer at early stages, lead to accurate diagnosis and could ultimately allow for individualized treatment.&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;Ongoing&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;Ongoing&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;Since this is a biomarker discovery lab, there isn&amp;#39;t a final sample size&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;None&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 260&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;260&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Dec  3 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug  3 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Liver Reference Set Applicant (Full): Lubman (2011)&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;383 liver cancers and 388 cirrhotic controls&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;610&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;1. Ovarian serous disease (benign or malignant) with cyst for cyst fluid extraction, age &amp;#062; 21
2 &amp; 3. ovarian serous cancer tissue, or normal fallopian tube tissue, age &amp;#062; 21
&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;452, 610, 613&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;610&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;1.   Candidate discovery via 
         a.   LC/MS in ovarian cyst fluid
         b.   LC/MS in vibratome sliced fresh tissue (fallopian tube vs ovarian cancer)
         c.   LC/MS in conditioned media from phenocopy model fallopian tube system 
         d.   Affy arrays in fallopian/ovarian tissue filtered by secretome

2.   Integrated prioritization of candidates for verification by systems biology/pathway analysis 

3.   Verification of 50 candidates in plasma from 50 cases  &amp; 50 benign adnexal masses, and in longitudinal plasma from ovarian cancer screening trial

4.   Longitudinal change-point analysis to determine candidates with earliest significant rise above baseline   
&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Phase 1 will consist of the proteomic analysis of proximal fluids (ovarian cyst fluid, conditioned media from FTE or ex-vivo phenocopy system if needed) and genomic analysis of ovarian/fallopian tube tissue and will occur during years 0-2.5, and produce a list of candidate discovery biomarkers. The ovarian cyst fluid follows the PRoBE design since at time the fluid is obtained the pathological diagnosis has not been made, and
therefore the design will be a nested case-control one. However, the conditioned media will be from known cases and control subjects, so will not be PRoBE compliant – as there is no feasible way to achieve this goal in this setting. Quantitative criteria for phase 1 genomic and proteomic over-expression are that the ratio exceeds 5 with a p-value &amp;#060; 0.001 assessed by the permutation test (false discovery rate FDR &amp;#060; 10%).

Phase 2 will consist of the AIMS experiments to determine which discovery candidates are detectable in multiple pools of plasma, and SISCAPA-MRM experiments in plasma biospecimens obtained prior to surgery in patients with pelvic masses, to determine which candidates differentiate malignant from benign disease.

The pools of plasma will be from the same set of patients as from which the cyst fluid was obtained, while the plasma samples will be from the same patients and patients with a pelvic mass but without a cyst, which is the case for the majority of patients with a pelvic mass. Therefore the plasma specimens will
be from a patient set which is a super-set of the cyst fluid patients. SISCAPA-MRM over-expression are that the 95% probability intervals for sensitivity at 98% specificity exceed 5%, that is, there is evidence that there is at least 5% sensitivity
contributed to ovarian cancer detection by a candidate biomarker before going on to phase 3.

Phase 3 will consist of SISCAPA-MRM experiments to measure the best 50 candidates in longitudinal samples from a pilot screening trial, and will occur from years 3-5. Screening samples automatically comply with the PRoBE design as they are collected prospectively before diagnosis is known and will be evaluated without knowledge of their case/control status. The quantitative criterion for the next phase is that the longitudinal algorithm for a given candidate provides a sensitivity of at least 10% at 1-2 years prior to detection at 98% specificity.&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;Specimens undergoing mass spectrometry analyses will be blinded until after the MS analyses have been performed, at which point they will be unblinded.&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;183                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;1. We will collaborate and share data freely with other EDRN components, participate in planning and attending workshops and symposia, to serve on the SC and be bound by its decisions. We will participate in collaborative studies conducted by their respective EDRN collaborative group focusing on ovarian cancers. 

2. We will be able and willing to share data and research resources with other successful applicants and the NCI. We will submit (on-line) information on specimen collections per the Network’s Common Data Elements (CDEs) and register their protocols with the Network’s DMCC.&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;Yes&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2015 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;1, 3&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Ovarian Cancer Biomarker Discovery&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Discovery and verification of early detection ovarian cancer plasma/serum biomarkers.&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Discovery Stage: 12 samples of ovarian cyst fluid from malignant tumors; 12 samples from patients with benign ovarian disease
Verification Stage: blood specimens from 50 cases and 50 controls; 2nd part of verification: 200 longitudinal specimens from women who have developed cancer during the study and those who did not develop ovarian cancer during study.
Another pathway for biomarker discovery/verification will be 20 cases/20 controls of ovca tissue for transcriptional profiling; also will perform mass spec on tissue interstitial fluid on 8 cases/8 controls&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;151, 160, 169, 455, 592, 597, 609&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;609&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2015 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep 11 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Colorectal Neoplasia Biomarkers&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Aim 1: 20 retrospective specimens: 15 negative for adenoma, 5 with adenomas; 30 prospectively collected normal-appearing mucosa. 
Aim 2: specimens from 25 people without adenomas and 25 people with adenomas
Aim 3: not determined yet&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 680&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;680&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep 27 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep 28 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Lung A Reference Set (Full) Applicant:  Coverley-York (2011)&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;See Full Lung Reference Set A description&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 131, 156, 181, 416, 681, 682, 683, 684, 693&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;156&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;157                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Oct  1 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct  1 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Panc Cyst&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;191&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;156, 161, 190, 191, 341, 608&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;191&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;157                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Biomarkers for Pancreatic Cancer&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 153&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;153&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Oct 20 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Oct 21 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Liver Reference Set (Rapid #2) Beretta-FHCRC (2011)&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;EVL, ITGA4 MGMT, EVL, ITGA4, and CDKN2A, 2) genes that are not subject to methylation in colon cancer: GSTP1, BRCA1, and CDH1, and 3) genes that undergo aging related methylation in the colon: ESR1, MYOD1, and N33
Getzenberg CCSA-2 &lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;67&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;All study participants must be 18 years of age or older, able to physically tolerate removal of 30 – 60 ml of blood and willing to sign informed consent.  
   The criteria to be a healthy control are 1) no prior history of any other malignancy except non-melanoma skin cancers for the past ten years, 2) no personal history of colonic polyps, ulcerative colitis or crohn’s disease, and 3)    Normal colonoscopy with excellent or good colonic preparation within 2 years. 
   Adenomatous polyps patients will be defined as a colorectal polyp meeting histological criteria for adenomatous polyp that does not meet criteria for an advanced adenoma.
   Advanced adenomatous polyps will be defined as adenoma with significant villous features (&amp;#062;25%), size of 1.0 cm or more, high-grade dysplasia, or early invasive cancer
   Stage A/B colorectal cancer patients will be defined as any T, N0, and M0.  The patient must not have started any form of cancer treatment at the time of sample collection.
   Stage C/D colorectal cancer patients will be defined any T, N &amp;#062; 1, and any M.  The patient must not have started any form of cancer treatment at the time of sample collection.
&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;67, 87, 151, 169, 455, 592, 609, 676&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;67&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;We propose a GI Collaborative biomarker validation project with the goal of identifying those biomarkers developed by the GI collaborative that will predict the presence of advanced colorectal adenomas.  Biomarkers from the diverse colon focused and pancreatic focused BDLs of the GI Collaborative will assay their biomarkers on sets of identical reference set samples.  The GI Collaborative will also assess markers of tissue/serum-plasma and/or urine from other EDRN collaborative groups, i.e. urologic, breast, lung, in this reference set.  The most promising biomarkers that meet required adenoma detection bars will be assayed in a second, blinded test set of biosamples from a separate group of subjects before being considered for inclusion in large, cross sectional biomarker validation project for the early detection of both colorectal adenocarcinomas and advanced adenomas. 

Aim 1
To define preliminary sensitivity, specificity, and their variance of biomarkers for the detection of advanced adenomas in a standardized, open labeled training biosample reference set.

Aim 2
To select those biomarkers for the detection of advanced adenomas in the training set for additional validation in a standardized biosample reference test set using pre-set performance characteristics.

Aim 3
To verify sensitivity, specificity, and their variance of biomarkers for the detection of advanced adenomas in a standardized, blinded test biosample reference set.

Aim 4
To select biomarkers for the detection of advanced adenomas from the test set for inclusion in a large, cross sectional validation trial of biomarkers for the early detection of advanced adenomas.
&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Markowitz
Approach: Candidate aberrant methylated loci will be identified from RRBS analysis of tissues in the archive of the Case Medical Center.  Real-time MS-PCR assays will be developed to quantitatively assay for these aberrant methylation events. Validation of these methylation events, their timing, and their selectivity for neoplasia, will be examined in tissue samples from the GLNE archive including normal mucosal biopsy from individuals with clean colonoscopies, normal mucosal biopsies from individuals with colon neoplasia (advanced adenomas or cancers), biopsies of non-advanced adenomas, biopsies of advanced adenomas, biopsies of early stage colon cancers, and biopsies of late stage colon cancers.  Marker loci that show sensitivity and specificity for colon neoplasia at the independent tissue collections of the GLNE will be tested for their sensitivity and specificity for early and late neoplasia detection in body fluids including in fecal DNAs and in plasma samples. 
Grady Approach:  Quantitative CpG methylation assessment with quantitative methylation specific PCR (qMSP or MethyLight).  
Lampe compare protein expression/activation in adenoma vs. normal colon mucosa via antibody array to discover diagnostic/prognostic biomarkers. The best diagnostic and prognostic markers will then be rescreened on a tissue microarrays. After triage, we will determine whether the surviving biomarkers are adenoma or stromal derived by analyzing its expression pattern. 
Getzenberg evaluate the potential of CKB IHC staining within the colon to serve as a marker for the development of colon cancer and perhaps  at the onset of adenomas.  The laboratory is now developing a sandwich ELISA to detect CCSA-2 in the serum and would propose to evaluate this marker&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;Sep  1 2014 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep  1 2014 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep  1 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Colon Team Project #1&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;the goal of identifying those biomarkers developed by the GI collaborative that will predict the presence of advanced colorectal adenomas.  &lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Phase 1 - 300 plasma samples

Phase 2 - 475 plasma samples&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;609&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;All patients will have, at baseline, one or more non-advanced or advanced adenoma.  Because the number and histology of the baseline adenomas will influence the scheduling of subsequent colonoscopies, the number and histology of adenomas (and, potentially, their interaction) and the time to subsequent screen will be used as covariates in all modeling.  &lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;87, 151, 160, 169, 455, 592, 597, 609&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;609&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;
1.&amp;nbsp;&amp;nbsp;&amp;nbsp;Characterization of intra-subject reproducibility and variability: To assess the reproducibility and variability of marker expression within individuals, we will evaluate marker expression in duplicate samples from the same region of the colon and in 4 different sites around the colon, the rectum, left, transverse and right colon.
2.&amp;nbsp;&amp;nbsp;&amp;nbsp;Characterization of inter-subject variability in marker expression by disease phenotype: To characterize the inter-subject variability in marker expression by disease phenotype, we will compare marker expression in normal colonic mucosa between subjects with and without adenomatous polyps. 
3.&amp;nbsp;&amp;nbsp;&amp;nbsp;Characterization of the relationship of marker expression and long-term adenoma recurrence: To examine the relationship between marker expression and long-term adenoma recurrence, we will compare marker expression among subjects with baseline adenomas who have a recurrence of adenomatous polyps compared to those who do not.
&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Analysis Plan:  A mixed effects linear model will be used to estimate means and between-patient and within-segment variance parameters; location of biopsy will be considered a fixed effect, and patient a random effect. The within-segment variance is an estimator of assay reliability, while the difference in means between segments indicates how well rectal or distal colon values agree with transverse and proximal colon values.  The between-patient variances can be used to calculate effect sizes used in the design of subsequent trials.  The biopsy location effect is an indicator of the consistency of the biomarkers throughout the colon; because these are normal tissue, not adenoma, biopsies, significant variation between biopsy sites would have implications for sampling strategies, and could indicate non-specificity of the marker for adenoma.  Using Monte Carlo simulation of the proposed design, we determined that, in 90% of the simulated trials, the estimated between-patient variance was within 70% of the true value, and the estimated within-segment variance was within 28% of its true value.  The power to test the null hypothesis of no difference in means between segments was in excess of 80% if the effect size (difference between segment means divided by within-segment standard deviation) was 0.8 or greater.  &lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep  1 2014 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Sep  1 2011 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Colon Team Project #2&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;The goal of this project is to evaluate biomarkers in normal colonic mucosa to determine their relationship to the occurrence of short- and long-term colorectal neoplasia. Candidate markers have been proposed by participating investigators based on promising preliminary data. The purpose of this team project is to evaluate these markers in a common, tissue-based reference set, under a uniform, structured protocol. &lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;200 Samples&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 711&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;BRSCW Applicant: Tuszynski - Temple University (2012)&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;See &amp;quot;Cancer in Women&amp;quot; reference set description&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 81, 87, 332&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;332&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;May 29 2013 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;May 30 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Breast Ref Applicant: Anu Mathew-Meso Scale&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;506 Subjects:  Two 200ul of Plasma&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 81, 87, 187, 202, 235, 238, 593, 610, 709&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;593&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 13 2013 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Aug 13 2010 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;DCIS Team Project&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;250 women with DCIS who progress to IBC and a control group of 500 women with DCIS who do not progress to IBC&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 161&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;161&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;157                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Pancreatic Reference Set Applicant-Haab (2012)&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Please see description of Pancreatic Cancer Specimen Reference Set&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 88, 142, 203, 424, 426, 510, 545, 596, 605&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;88&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;185                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Prostate and Urologic Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jan 20 2013 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jan 20 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;PROS-Upgrading&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 84, 86, 87, 176, 201, 240, 241, 600, 601&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;601&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Mar  7 2015 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Mar  8 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Lung Team Project #2&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;200 current and former smokers with indeterminate-pulmonary nodules (5mm-20mm)&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 233&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;May 31 2013 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jun  1 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Breast Reference Set Applicant:- Zangar-Pacific NW Nat&amp;#39;l Laboratory&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;See &amp;quot;Breast Cancer Reference Set&amp;quot; description&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5, 87, 713&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;5&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;155                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Sep 12 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul 12 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Liver Reference Set  (Rapid) Norman (2012)&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Reference Set&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;50 Liver Cancer and 50 Cirrhosis Controls&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;Discovery for mutations of TP53.&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;190&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;190&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Specific Aim 1. Deep sequencing of DNA samples from surgically resected primary pancreatic
tumors, and correlation of TP53 mutation status with clinical outcomes data. The surgical
oncologists at the University of NE Medical Center currently perform approximately 25 Whipple
procedures annually. Each sample is fixed in formalin, embedded in paraffin (FFPE) and catalogued
for future use. Presently there are at least 200 FFPE samples available. Representative sections from
each tumor block will be examined by our pathologist Dr Lazenby and selected for having cellular
content of tumor greater than 20% (well above the minimum needed for detecting mutations using
greater than 80x coverage in deep sequencing). An appropriate number of sections (8-20 depending on
cellular content) will be prepared from each block by the UNMC Tissue Sciences Facility. The tissue on
those sections will be used as the source material for DNA isolation. DNA isolation will be performed
utilizing commercially-available reagents (Qiagen, Inc) according to the manufacturer’s instructions.
The TP53 gene encompassing all exons will be amplified by PCR, the products purified and subjected
to library generation (Illumina Inc.) for next generation sequencing (NGS) utilizing the Illumina Hi-Seq
2000 instrument in the UNMC Next Generation Sequencing Core Facility. NGS platforms enable the
identification of mutant sequences from heterogeneous samples containing both tumor cells and normal
cells, even when the mutant sequence only comprises ~5% of the total sequence (19). This is due to
the extensive coverage of NGS methods and the independent sequence data output for each molecule
sequenced.
De-identified clinical outcome data for all samples will be used for correlative studies of outcome. For
each sample, tumor recurrence status and overall survival will be determined. The results will allow us
to ascertain if TP53 mutation status in the primary tumor can be used as an accurate predictor of tumor
aggressiveness. Data from this analysis will be provided to and analyzed by the DMCC for
performance characteristics in predicting tumor recurrence among surgically resected patients.
Although we do not currently know the potential power of this analysis, this represents the largest set of
clinical samples that are currently available to us to undertake this analysis and the study should be
adequately powered to address the simple hypothesis that is under investigation.
Specific Aim 2. Development of ICE COLD-PCR reagents and protocols for detecting TP53
mutations in human samples. While NGS methods provide high quality data, the cost per sample
makes them unsuitable for general large-scale patient screening purposes. An alternative and cheaper
method to identify mutant sequences in a pool of normal sequence is ICE COLD-PCR (ICP; Improved
and Complete Enrichment Co-amplification at Lower Denaturation Temperature-PCR). COLD-PCR is a
novel form of PCR that allows&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Together with the experts at Transgenomic, Inc., we will design primary and nested amplification
primers for each of the p53 mutation hotspots that are detected in our analysis of pancreatic cancer
samples, as well as RS-oligos for each that are complementary to the wild type sequence. Plasmids
containing wild type and mutant sequences will be used to empirically determine the appropriate
reaction conditions for each site. Mixtures of wild type and mutant plasmids will be prepared (eg-10:1,
100:1 and 1000:1, wild type:mutant) and used to test the limits of detection for each. Finally, clinical
samples will be tested independently on FFPE samples and the data compared to the deep sequencing
data obtained in Specific Aim 1.&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;                                                                                                    &lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2013 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Hollingsworth 2012&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;We will examine DNA extracted from FFPE sections from approximately 200 different
surgically resected primary pancreatic tumors from the UNMC Department of Pathology and
Microbiology. DNA will be purified from those sections and subjected to deep sequencing for the entire
TP53 locus.&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;0-9 mos
Sequence/analyze ~ 50 selected clinical samples 12-18 mos
Develop ICP reagents for identified predictive mutations from 1st 100 samples
Sequence/analyze ~ 100 selected clinical samples12-15&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Because lung cancer occurs in both males and females and members of all ethnic groups, clinical specimens
from both sexes and a variety of ethnic groups will be utilized in the proposed studies. Human clinical
specimens of normal, premalignant, and malignant lung tissue utilized in Aim 1 are available through the UCLA
Lung Cancer SPORE Tissue Repository. The specimen bank includes males, females, and members of
ethnically/racially diverse groups. Research in this proposal will utilize existing specimens in the tissue
repository, so it will not be necessary to recruit new subjects for the research in this proposal. The approximate
composition of the tissue repository is described in the Table 2.
African Americans 5
Hispanic/Latino 1
Asian Americans 5
Native Americans0
Pacific Islanders 0
White 29
Other 0
Total 40
&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;241&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;241&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;1. Use targeted massively parallel DNA sequencing to assess the presence of mutations in specific genomic
regions in matched sets of primary lung adenocarcinomas, premalignant lesions, and adjacent,
histologically normal lung tissues obtained from the same patient.
What is the prevalence of common lung-cancer-associated mutations in a panel of adenocarcinomas or
premalignant lesions from the same patient? What is their baseline prevalence in lung tissue with no histologic
indication of disease?
2. To identify mutations whose prevalence is significantly higher in tumors and premalignant lesions than in
histologically normal lung tissue from the same patient, assess the variability of this prevalence among
independent specimens within each patient, and examine the biological relationship between mutations
whose prevalence is covariant across patients.
Which mutations may be useful as early markers of lung cancer in patients with subclinical disease and which
may be clinically actionable? How much does the spectrum of known cancer-associated mutations vary
between independent premalignant lesions or different samples of the same primary tumor? Are there
mutations that are frequently associated with each other or mutually exclusive, and if so, does this covariance
reflect the biological relationship of the genes in which they occur?&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2013 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Dubinett - 2012&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;we propose to use targeted massively parallel DNA sequencing to identify somatic alterations within mutational hotspots in matched sets of primary lung tumors, premalignant lesions, and adjacent,histologically normal lung tissue.&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Protocol&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;10 FFPE or fresh frozen samples
LCM of the remaining 30 samples&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;190&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;190&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;190&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;157                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2014 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Hollingsworth 2012&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Sequence/analyze ~ 50 selected clinical samples (6-9 months). Grunkemeyer/Grandgenett

Analyze sequence data against clinical outcomes data (9-10 months). DMCC/surgical oncologists

Sequence/analyze ~ 50 selected clinical samples (9-12 months). Grunkemeyer/Grandgenett

Analyze sequence data against clinical outcomes data (12-13 months). DMCC/surgical oncologists/Lazenby

Develop ICP reagents for identified predictive mutations from 1st 100 samples (12-18 months). Wu/Grunkemeyer/Grandgenett

Sequence/analyze ~ 100 selected clinical samples (12-15 months). Grunkemeyer/Grandgenett&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;67&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Create repository with DNA samples extracted from normal tissue, BE, BE+LGD, BE+HGD,
and EAC&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;160&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;160&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Aim 1: To characterize the genome-wide methylation status of various histological subtypes of
esophageal tissues:
Aim 1a: To determine the methylome of BE, BE+LGD, BE+HGD, and EAC.
Aim 1b: To determine if a panel of methylated genes can be used to distinguish BE,
BE+LGD, BE+HGD, and EAC.
1) 1st quarter
1. Request tissue samples from EDRN biorepository
2. Obtain tissues from biorepository and assess quality
3. Extract DNA from tissue samples and treat with sodium bisulfite
2) 2nd quarter
1. Run HumanMethylation450 arrays using tissue samples
2. Analyze data and identify methylated genes that are specific for BE, BE+LGD, BE+HGD, and
EAC
3) 3rd quarter
1. Develop pyrosequencing assays and/or MethyLight assays for candidate genes identified
from array studies
2. Organize DNA samples in Grady lab tissue collection and bisulfite treat DNA samples
3. Assess methylation state of candidate genes in independent tissue set available in Grady lab
4. Identify methylated genes that show highest specificity for BE, BE+LGD, BE+HGD, and EAC
4) 4th quarter
1. Continue to assess methylation state of candidate genes in independent tissue set available
in Grady lab
2. Continue to identify methylated genes that show highest specificity for BE, BE+LGD,
BE+HGD, and EAC
3. Determine best methylated gene(s) to be used to identify aggressive BE vs. indolent BE
Aim 2: To conduct a pilot study to determine if methylated genes can be used to identify
aggressive BE vs. indolent BE.
1) 1st quarter
1. Arrange to obtain tissue samples from EDRN for initial analysis of methylated gene
biomarkers. This will be run on samples from 33 patients
2. Begin enrollment of study subjects and collection of tissues from these additional study
subjects enrolled in EDRN GLNE study
2) 2nd quarter
1. Continue enrollment and tissue collection of samples from EDRN GLNE study
2. Perform histologic quality assessment of tissues obtained from the initial patient cohort
(N=33)
2
3. Begin DNA extraction and bisulfite treatment of DNA samples
3) 3rd quarter
1. Run HumanMethylation450 arrays using tissue samples from initial patient cohort
2. Analyze data and identify methylated genes that are specific for aggressive BE vs. indolent
BE
3. Develop pyrosequencing assays and/or MethyLight assays for candidate genes identified
from array studies
4. Run pyrosequencing assays and/or Methylight assays on DNA samples from array studies to
validate array results
5. Identify methylated genes that have the highest specificity for aggressive BE vs. indolent BE
4) 4th quarter
1. Analyze samples from initial patient cohort using best candidate genes for identifying
aggressive BE vs. indolent BE
2. Obtain tissue samples from additional patients in EDRN GLNE study, assess quality of
samples, and extract DNA
3. Bisulfite treatment of DNA from tissue samples from 2nd patient cohort.
4. Assess best candidate genes in 2nd patient cohort to determine if results can be valid&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Statistical Analysis: Dr. Chao-Jen Wong will direct the statistical analysis. We will assess genomewide
methylation patterns using HumanMethylation450 arrays in matched aggressive BE and indolent
BE cases. We will subsequently identify methylated gene profiles that are significantly methylated (ß
value &amp;#062;0.5) in tissues from both these groups using the selection criteria as described in Aim 1.
Next, we will compare candidate methylated genes identified in Aim 1 between the aggressive BE
and indolent BE groups using two-sided two sample t-test to identify transcripts deregulated specifically
in the aggressive BE population. Methylated genes will then be prioritized based on their consistent
methylation pattern in BE, HGD or EAC lesions in Aim 1. Finally, those methylated genes will be
considered as candidate biomarkers associated with aggressive BE, and will be subsequently validated
in an independent cohort of patients in future studies.
3) Power Analysis: Given the small initial sample size, we will initially assess for trends indicating a
methylated gene is a potential aggressive BE biomarker. In year 2, Dr Wong will conduct a power
analysis when we know how many people with aggressive vs. indolent BE have been collected.&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;150                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2014 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;7&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;William Grady Supplement 2012&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;OVERALL STRATEGY: Our strategy will consist of using HumanMethylation450 arrays to identify
methylation profiles and/or candidate methylated genes that distinguish BE from BE+LGD, BE+HGD
and EAC (Aim 1). We will then assess whether these genes are predictive markers for aggressive BE
(Aim 2)&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Arrange to obtain tissue samples from EDRN for initial analysis of methylated gene
biomarkers. This will be run on samples from 33 patients

Molecular classification of BE, LGD, HGD and EAC (Aim 1):
I. Illumina HumanMethylation450 Array:
1) Barrett’s esophagus (N=24)
2) Barrett’s esophagus/LGD (N=24)
3) Barrett’s esophagus/HGD (N=24)
4) Esophageal adenocarcinoma (N=24)
5) Normal esophageal squamous epithelium and proximal gastric epithelium (N=12 each)

Based upon a moderated twosample
t-test, at least 24 samples for both control (SQ) group and treatment (EAC) group are needed to
achieve 80% statistical power with 0.05 significant level.&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;BiomarkerName&lt;/slot&gt;&lt;value&gt;We will obtain cDNAs of the up-regulated proteins previously published: CD30 ligand, endostatin, HSP90alpha, MIP-4, pleiotrophin, PFKCI, and YES (a tyrosine kinase oncogene).
Based on our previous studies, a panel consisting of thirteen protein biomarkers will be used for determining presence or absence of autoantibodies in serum specimen. The 13-protein marker panel consisting of purified full-length recombinant proteins are c-myc, cyclin A, cyclin B1, cyclin D1, CDK2, survivin, CD30 ligand, endostatin, HSP90alpha, MIP-4, pleiotrophin, PRKCI, and YES.&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;cases stratified by no recurrence within three years “indolent” and recurrent within three years “aggressive.”&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;84, 180&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;84&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;Specific Aim 1. Develop a novel biomarker panel based on our auto-antibody publication and our development of an Immunoruler using auto-antibodies to glycosylated proteins using synthetic glycans printed on glass microarray technology. Specific Aim 2. Test the autoantibody panels on CT-scan screen-detected lung cancers including both indolent and aggressive cancers, and validate with thoracic surgery lung cancer cases stratified by no recurrence within three years “indolent” and recurrent within three years “aggressive.” Each lung cancer case will be matched to a control with normal CT scans by smoking, gender, and age.&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;development of an Immunoruler using auto-antibodies to glycosylated proteins using synthetic glycans printed on glass microarray technology.
Each sample will be assessed in triplicates, and the average value at 490 nm will be used for data analysis. During the 02 year we will be focusing our efforts at completing the assays and data analysis.&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;162                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Lung and Upper Aerodigestive Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2013 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;4&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;William Rom Supplement 2012&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;We hypothesize that our novel Biomarker Panel of Auto-antibodies can distinguish aggressive, symptom diagnosed lung cancer from non-aggressive, screen-detected lung cancer.&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Validation&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;We have 32 patients with CT screen-detected cancer, who have provided us with multiple pre-diagnostic blood samples, which we have banked and are ready to use for this study. There are 12 individuals who we followed for &amp;#062;3 years before surgery who we classify as “indolent” and were all stage 1 adenocarcinomas; we have 20 that were “aggressive” lung cancers and were immediately referred to surgery or had a three-month follow-up CT-scan and were then referred to surgery.&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Coordinating_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;593&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;The first enrolled 1,907 breast cancer patients diagnosed between 55-74 years of age from 2000-2008,
and the other enrolled 1,028 younger women 20-44 years of age diagnosed from 2004-2010. Details regarding
the methods of both studies have been published.21,22 For this pilot study we propose to limit eligible cases to
the 321 Group Health Cooperative (GHC, a large integrated health organization serving western Washington
state) patients who underwent mammographic screening and were diagnosed between 40-74 years of age (so
that it is restricted to women for whom screening mammography may be recommended) with stage I or II
breast cancer. The study is restricted to women with stage I or II disease in order to make the patients uniform
with respect to stage, and because an appreciable majority of screen detected tumors diagnosed among
women in this age range are early stage.&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;593&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;593&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;screen detected breast cancer focusing on early stage invasive disease. We will compare gene
expression profiles using the whole genome-cDNA-mediated Annealing, Selection, extension and Ligation
(DASL) assay of 50 screen detected cancers to those of 50 interval detected cancers. Through this approach
we will advance our understanding of the molecular characteristics of interval vs. screen detected breast
cancers and discover novel biomarkers that distinguish between them.
Aim 2: To identify biomarkers in tumor tissue related to risk of cancer recurrence among patients with
screen detected early stage invasive breast cancer. Using the DASL assay we will compare gene
expression profiles from screen detected early stage breast cancer that either recurred within five years or
never recurred within five years. These two groups of patients will be matched on multiple factors including
tumor stage and treatments received. Our goal with this comparison is to identify novel biomarkers that
discriminate between tumors that recur and are more aggressive compared to those that are less aggressive
and do not recur.&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;Gene expression data will be pre-processed, normalized and cleaned as described in our protocol
(Appendix 1). We will perform two levels of analysis: gene-set level and gene level, to identify gene sets and
genes that are associated with interval vs. screen detected disease and those that are associated with
recurrent vs. non-recurrent disease. In general, we will account for multiple testing by controlling the false
discovery rate (FDR).23 We will use a 5% FDR when assessing statistical significance across all samples, and
a 1% FDR (or lower) when performing subgroup analyses. For our gene-level analysis, we will use linear
regression for each gene to identify genes showing differential expression in our comparisons of interest.
Matching variables are adjusted as covariates in the linear regression models. For gene set-level analyses, we
will first rank genes from high to low based on their association in each comparison, then for each gene set we
will calculate an enrichment score that reflects how much the gene set is represented with genes that
differentiate between our comparison groups (http://www.broad.mit.edu/GSEA).24,25 The statistical significance
of enrichment scores will be evaluated by calculating enrichment scores relative to each of the null distributions
formed by: 1) permuting exposure status within each matched set and 2) permuting genes. Using both types of
null distributions gives us gene sets associated with a given comparison as well as those particularly enriched
with associated genes. Performing the analysis in two tiers will help us to identify not only the genes that are
individually most likely to differentiate our comparison groups, but also those that may have only moderate
effect individually but collectively as a gene set may strongly discriminate between our comparison groups.
This will enhance the power to detect all the associated genes or gene sets.
We will construct a panel of genes that discriminate between our comparison groups based on
significantly associated genes or gene sets using regularization techniques, which have been shown to
improve prediction and interpretation considerably compared to ordinary regression models without
regularization. Specifically, we will use the elastic net26 regularization method as it has a desirable feature well
suited to our data, i.e., encouraging genes in the same pathway to be selected as a group in the model.27 10-
fold cross validation will be used to determine the appropriate amount of regularization, and hence the panel of
the biomarkers that are associated with the outcome.
While microarray technology allows simultaneous evaluation of expression levels of thousands of
genes, only a fraction is expected to be associated with the exposures of interest. With respect to statistical
power, the minimum detectable effect size (MDES) is determined by the number (m) of truly altered genes out
of the total p (here 25,000) genes studied, in additio&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;174                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;Breast and Gynecologic Cancers Research&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;
&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2014 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Christopher Li Supplement 2012&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Distinguishing aggressive cancers from non-aggressive or non-progressing cancers is an issue of both clinical
and public health importance particularly for those cancers with an available screening test. With respect to
breast cancer, mammographic screening has been shown in randomized trials to reduce breast cancer
mortality, but given the limitations of its sensitivity and specificity some breast cancers are missed by
screening. These so called interval detected breast cancers diagnosed between regular screenings are known
to have a more aggressive clinical profile. In addition, of those cancers detected by mammography some are
indolent while others are more likely to recur despite treatment.&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Collaboration&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Identification of 50 interval detected breast cancer patients and 50 matched screening detected breast cancer patients
• Identification of 50 screening detected breast cancer patients whose disease recurred within 5 years of diagnosis and 50 matched screening detected patients whose disease did not recur within 5 years&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;this proposal will provide for comprehensive profiling of DNA methylation across the promoter
associated CpG islands of 20 matched pairs (40 samples) of colon cancer hepatic metastasis and matched colon cancer primary tumors.&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Involved_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;169&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Lead_Investigator_Site_ID&lt;/slot&gt;&lt;value&gt;169&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_5_Phase_Status&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Aims&lt;/slot&gt;&lt;value&gt;The specific aims of this study are to determine whether in human colon cancer epigenetic gene silencing by
aberrant DNA methylation provides the basis for intra-tumor heterogeneity and generation of lethal metastasis.
We will answer this question by:
2.1. Comprehensive NextGeneration sequencing based analysis of DNA methylation across promoter
associated CpG islands will be used to compare the DNA methylome of 20 colon cancer hepatic metastases
versus 20 matched primary colon cancer tumors.
2.2. Sequence comparisons of the DNA methylome between matched colon cancer hepatic metastases and
colon cancer primary tumors will be analyzed to identify presence or absence of metastases specific DNA
methylation signatures, and to determine whether metastases are clonally identical to colon cancer primaries,
are generated from subclones within colon cancer primaries, or are generated from subclones that arise in
blood or distant sites outside of colon cancer primaries. Methyl-BEAMing based assays will be used to confirm
the presence or absence within colon cancer primaries of subclones bearing DNA methylation signatures that
typify the metastatic lesions, but are divergent from the dominant signature of tumor primaries.
2.3. The predictive potential of metastases associated methylation marks will be tested by determining the
frequency of these aberrant methylation marks in a validation cohort of over 700 colon cancer tissue
specimens from early stage colon cancer primaries, late stage colon cancer primaries, and colon cancer
hepatic metastases.&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Analytic_Method&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Blinding&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Cancer_Type&lt;/slot&gt;&lt;value&gt;153                                                                                                 &lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Collaborative_Group&lt;/slot&gt;&lt;value&gt;G.I. and Other Associated Cancers Research Group&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Comments&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Data_Sharing_Plan_In_Place&lt;/slot&gt;&lt;value&gt;No&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Finish_Estimate&lt;/slot&gt;&lt;value&gt;Jun 30 2013 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Date_Start&lt;/slot&gt;&lt;value&gt;Jul  1 2012 12:00AM&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Design&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Field_of_Research&lt;/slot&gt;&lt;value&gt;1&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Name_Abbrev&lt;/slot&gt;&lt;value&gt;Markowitz Supplement 2012&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Objective&lt;/slot&gt;&lt;value&gt;Colon cancer is the second leading cause of cancer death in the United States. A key issue in treating colon cancer patients is inability to accurately predict tumors that have metastatic potential and require adjuvant chemotherapy. This project will test the model that tumor metastases arise from intra-tumor heterogeneity generated by DNA methylation events, and that detecting these events can provide a predictve signature of tumors with poor outcome
&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_or_Project_Flag&lt;/slot&gt;&lt;value&gt;Project&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Publications&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Results_Outcome_Secure_Site&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Type&lt;/slot&gt;&lt;value&gt;Single&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Final&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Sample_Size_Planned&lt;/slot&gt;&lt;value&gt;Month 6: Prepare reduced representation sequencing libraries from the first set of 10 matched pairs of colon cancer primary and metastasis paired samples, and run these samples on the Illumina Sequencer.
Month 12: Complete sequencing runs and data analysis for 20 matched pairs of colon cancer primary tumors and hepatic metastasis.  Complete data reduction and data analysis, and identify the statistically most significant top 100 metastasis associated differential methylation event.
&lt;/value&gt;</EDRN_ProtocolResult></EDRN_ProtocolResponse></soap:Body></soap:Envelope>